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Abstract 
Over the last few years stimulant substances, such as amphetamine-type 
stimulants (ATS) and synthetic cathinones (SC), have dramatically increased the 
frequency of lethal intoxications. The spread of these stimulant drugs has caused 
a complex challenge to the forensic toxicology community. Most analytical 
methods focus on detection and quantification of a specific class of drugs instead 
of an extensive variety of compounds. A method for the detection and 
quantification of 29 ATS and SC drugs in a single procedure was carried out using 
solid-phase extraction (SPE), pentafluoropropionic anhydride (PFPA) agent and gas 
chromatography—mass spectrometry (GC−MS). The method was validated in 
accordance with SWGTOX guidelines using human urine samples. The limits of 
detection (LOD) and lower limits of quantification (LLOQ) were between (0.5 and 
10) ng mL−1, and (5 and 50) ng mL−1, respectively. The linearity range was between 
50 and 2000 ng mL−1 with a R2 >0.990 for 20 compounds. The bias and RSD were 
≤20%, and no interferences or carryover were observed. The recovery was 80 to 
120% for the majority of analytes.  
Prior to testing the substances, the GC−MS was initially optimised in terms of the 
oven and injector port temperatures. The sensitivity and selectivity of the GC−MS 
were then improved using acidified methanol and derivatisation agents. Six 
acylation reagents were compared and investigated using PFPA, trifluoroacetic 
anhydride (TFA), chlorodifluoroacetic anhydride (CLF2AA), heptafluorobutyric 
anhydride (HFBA), acetic anhydride (AA) and propionic anhydride (PA). The 
derivatisation method was optimised by modifying incubation time and 
temperature during the reaction and evaporation stages. Several parameters were 
used to evaluate the performance of the reagents, including the number of ions, 
relative ion ratio, peak area values, number of unique ions with some validation 
parameters. The reagents were further inspected using recovery through SPE in 
whole blood. The results of the comparison study showed that PFPA was the 
favoured reagent. All the derivatisation reagents were suitable for use on 
cathinones.  
Long term stability was investigated for the 29 stimulant compounds in human 
urine specimens over a period of 381 days at room temperature (RT), refrigerator 
(4°C) and freezer (−20°C) conditions. ATS were stable under all conditions, and all 
ii 
tested substances were stable at freezer conditions. Most SC at RT had lost more 
than 20% of the compound after two days, and had completely disappeared after 
a month. Most SC’s at refrigerator temperatures were unstable after day 21, and 
gradually decreased until undetected between days 77 and 349. The substances 
were stable on the autosampler for three days. No concentration-dependent 
variations were observed. Half-lives of selected drugs were briefly discussed. 
A sample preparation method that meets green analytic chemistry (GAC) 
requirements is desirable. Therefore, a method using solid phase microextraction 
(SPME) tips were initially developed via 13 processing steps and then validated 
using GC−MS in urine for eight ATS and SC substances. LOD and LLOQ were (5−25) 
ng mL-1, and (25−100) ng mL-1, respectively. The bias and RSD were <15% error 
with R2 ≥0.992 for all analytes. Applying green analytical chemistry (GAC) 
parameters, the procedure had minor effects on health, waste and safety 
proportionate to LLE and SPE by adding the only microscale amounts of 
methanol and salt. 
Attention to the prevalence of new psychoactive substances (NPS) such as SC, is 
significant to the justice system and the forensic toxicology community. The 
prevalence of SC was studied using 273 urine specimens collected from Riyadh City 
in Saudi Arabia. The cathinone compound estimation prevalence rate was 1.01%. 
No other cathinones were identified. Further prevalence studies should be 
conducted in the future using a larger sample size and incorporating more drug 
substances and metabolites.  
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Chapter 1—1 
1. Introduction  
1.1 Statement of the problem 
Drugs such as amphetamine-type stimulants (ATS) and synthetic cathinones (SC) 
have caused many intoxications and fatalities. These new stimulants drugs, for 
instance SC’s, have become a significant class of new psychoactive substances 
(NPS) within European countries. The propagation of the NPS and the effects on 
abusers present a complex challenge to the forensic toxicology community. Not 
all laboratories have the ability to confirm these new stimulant drugs, even though 
use may cause significant problems in the health and security sectors. The 
detection of these drugs is difficult because routine immunoassay screening 
methods cannot fully detect them. This partly due to cost-effectiveness or 
unavailability of reagents and partly because it is difficult to confirm in 
spectrometry instruments (for example GC−MS), due to either the lack of 
reference standards or the fact that some substances have isomers with similar 
masses. The Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), 
Zuba and Joshi et al. have all discussed the above problem based on mass 
spectrometry reporting the structural classes of related compounds and 
correspondent determination [1-3].  
SC are a subgroup of NPS that are used as recreational drugs, due to amphetamine-
like effects. These drugs are derived from the cathinone compound. The active 
ingredients of cathinones were originally found in the khat plant (leaves of Catha 
edulis). Khat was traditionally used for several hundreds of years, and when 
chewed it increased energy, made users more talkative and increased sexual drive 
[4, 5]. The SC made up 23% of the global usage of individual NPS, as reported in 
the Early Warning Advisory (EWA) from 2008 to 2015 [6]. Internationally, ATS are 
the second most commonly abused drugs, and often exceed heroin and cocaine 
use [7, 8].  
Although the market has more sensitive instrumentation available, the most 
popular technique used in forensic laboratories is GC−MS. SC are well known to 
have relatively poor sensitivity and detection in electron ionisation (El) and yield 
very few fragmentation ions and/or the quality of the mass spectra is relatively 
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weak. More specifically, the general rule for interpreting results in GC−MS is that 
at least three mass-to-ion ratio (m/z) must be selected and evaluated; the higher 
the ratio, the higher the sensitivity and specificity [3]. Therefore, the relative ion 
ratio intensities play an essential role in proper interpretation. However, 
cathinones have either poor detection as a result of the thermal decomposition of 
products in the injector port or having low ion ratios with sometimes only one ion. 
Consequently, the poor quality fragmentation patterns for derivative or 
underivative cathinones present a challenge; especially the pyrrolidine classes. 
MDVP, as an example, has only one ion (126 m/z) as a base peak, hence the 
residual mass spectra ions in the background of the electron ionisation has a very 
low abundance of ions with less than 5% relative intensities of the base peak.  
Derivatisation reagents are normally used to solve the above problem. The 
sensitivity and selectivity of the GC−MS for the detection of SC substances can be 
improved by applying these reagents. Therefore, six acylation reagents were 
studied to improve the quality of fragmentation patterns using GC−MS and applied 
to nine SC for the evaluation. This selection covered a wide variety of SC groups. 
The GC−MS method and incubation time and temperature of each reagent were 
optimised to confirm excellent evaluation of the fragmentation patterns, including 
the quality of ions and the ion number. Besides the derivatisation agents, the 
sensitivity of the instrument can also be improved by using acidified methanol to 
concentrate the SC substance before evaporation. The use of acidified methanol 
was also demonstrated in this study, because of its contribution to the sensitivity 
of GC−MS.  
The GC−MS itself was optimised until excellent responses were obtained with 
adequate separation for all studied compounds. Thermal degradation and 
decomposition of the SC in the injector port was minimised. Chapter 3 describes 
the above in more detail. 
The matrix of the sample causes contamination when directly added to separation 
methods, such as GC−MS. In addition to its contribution to decreasing the 
chromatographic resolution, it also reduces the ionisation efficiency of MS and 
increases detection noise, which limits the detection level. This problem can be 
solved by applying sample preparation techniques that eliminate certain elements 
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in the biological samples, while keeping the target of analytes. Therefore, precise 
sample preparation techniques are fundamental. In this project, two sample 
preparation methods were developed for the detection and quantification of SC 
and ATS using GC−MS in biological matrices within a single procedure (see chapters 
4 and 6).  
Knowledge of the stability of the compounds is also very important. The 
degradation of the analyte is dependent on the time, concentration and storage 
conditions of the biological samples. This can influence the interpretation of the 
results and may provide a false negative. The stability of SC is a concern in the 
forensic toxicology field. In addition, although there are several published papers 
on the stability of SC, no single article has studied the stability of SC for more 
than six months in urine samples. This stability study lasted for 381 days (see 
chapter 5).  
The achievement of long-term stability in urine samples required a sample 
preparation technique for the extraction of 29 selected drugs in a single 
procedure. Accordingly, the solid-phase microextraction (SPME) fibre tip was 
initially chosen over traditional techniques, such as solid-phase extraction (SPE) 
and liquid-liquid extraction (LLE), due to its simplicity and the low volume of 
solvent and chemicals required. Although the SPME and green analytical methods 
were undoubtedly desirable, the SPE extraction method was used for the stability 
work. This was because the SPE successfully provided high recoveries and 
responses for 29 selected drugs that were examined and fully validated. The SPME 
fibre tip was still in the development stage during that period.  
The literature review showed numerous papers on SC and ATS in GC−MS, however 
there was a distinct gap, showing a lack of a method for the determination and 
quantification of a wide range of chemical groups (SC and ATS) in GC−MS in a single 
procedure. Additionally, the speed with which SC appeared on the recreational 
drug market meant that laboratories are much more likely to use a single 
procedure for the screening of any new compound that may appear under the scan 
method.  
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The development of a new method using SPME fibre tip was conducted, not only 
because of the publication gap, but also due to the need for green analytical 
chemistry (GAC). The SMPE and GAC are discussed in more detail in chapter 6. 
Due to the harmful effects of SC products, many countries have announced that 
SC should be controlled using emergency powers. In Saudi Arabia (SA), there is no 
data regarding the use of products containing SC among Saudi people. Therefore, 
the prevalence of SC in SA was examined in this project (see chapter 7).    
Indicators suggesting the presence and use of these products in SA were: 
o SA reported in the UNODC questionnaire on NPS having to use emergency 
scheduling to temporarily ban NPS ‘‘while the legislative process is being 
completed and/or a rigorous assessment of the risks is conducted’’. Khat was 
the most frequently plant-based substance reported by respondents to the 
questionnaire. The highest seizures in 2010 were made in SA at 374 metric tons 
[9]. 
o United Arab Emirates (UAE) Ministry of Health has added 33 synthetic 
cathinones to Schedule V drugs [10]. There are thousands of Saudi people 
travelling to the UAE daily, and this could increase the probability of the 
presence of these products in SA. 
Urine samples were collected for the prevalence assessment of SC in SA. Hence, 
this project will help with identifying the prevalence of these new drugs (SC) and 
lead to developing a better understanding of the issue in SA.  
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1.2 Aims and objectives  
1. To compare six derivatising agents (trifluoroacetic anhydride (TFA), acetic 
anhydride (AA), chlorodifluoroacetic anhydride (CLF2AA), heptafluorobutyric 
anhydride (HFBA), pentafluoropropionic anhydride (PFPA) and propionic 
anhydride (PA)) for the determination of nine synthetic cathinones 
(mephedrone, flephedrone, pentedrone, methylone, ethylone, methedrone, 
MDPV, butylone and pyrovalerone) using gas chromatography-mass 
spectrometry. 
2. To determine and quantify a wide variety of SC and ATS compounds 
(amphetamine, methamphetamine, PMA, MDA, MDMA, MDEA, PMMA, 
cathinone, methcathinone, buphedrine (buphedrone metabolite), 
flephedrone, 4−methylephedrine (mephedrone metabolite), 
4−methyl−N−ethyl−norephedrine (4−MEC metabolite), buphedrone, 
N−ethylcathinone, mephedrone, pentedrone, methedrone, methylone, 
butylone, ethylone, pyrovalerone, 4−EMC, 4-MEC, α−PVP, pentylone, MDPPP, 
naphyrone and MDPV) in urine using SPE and GC−MS in a single procedure.  
3. To address the need for green analytical methods using new SPME fibre tips as 
an alternative to traditional sample preparation techniques, such as SPE and 
LLE. This was after the SPME fibre tip method was developed and validated for 
detection and quantification of eight selected ATS and SC substances 
(amphetamine, methamphetamine, PMA, MDMA, mephedrone, buphedrone 
ephedrine metabolite, 4-methylephedrine (mephedrone metabolite) and 
pentylone) using GC-MS in urine. The green analytical methods were compared 
based on the selection of SPME fibre tip, SPE and LLE procedures.     
4. To evaluate and investigate stability of the 29 SC and ATS and associated 
metabolites (named above) in urine using SPE and GC−MS under different 
concentrations and temperatures over a period of 381 days. 
5. To estimate the prevalence rate of SC in specific population in Riyadh City 
based on 273 urine samples that were collected at Security Forces Hospital 
(SFH) in Saudi Arabia using GC-MS.   
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2. Background and literature review 
As this thesis mainly focuses on the stimulants drugs such as SC and ATS, and 
includes the using some sample preparation techniques, therefore the chapter 
spotlights on the up to the date of the mentioned above topics.  
2.1 New Psychoactive Substances (NPS) 
New psychoactive substances are being introduced to the market and referred to 
as “new synthetic drugs”, “legal highs”, “designer drugs”, “spice”, “club drugs”, 
“bath salts”, “herbal highs”, “research chemicals”, “new drugs”, “plant food”, 
“plant feeders” and “plant-growth fertilizers”; labeled with tag warnings “not for 
human consumption” or “not tested for hazards or toxicity”. These substances 
have emerged to replicate the traditional drugs of abuse, such as amphetamines, 
cocaine and cannabis. These design drugs have similar or more potent effects than 
the traditional predecessors [11-15]. Historically, the “designer drugs” term was 
used for the first time by Dr. Gary Henderson, who worked as a pharmacologist at 
the University of California at Davis. This term was used to introduce the definition 
of NPS to the press in 1988 [16].  
The NPS have been distributed among abusers since mephedrone was reproduced 
in 2003. Manufacturing chemists have designed these compounds to bypass current 
legislation and regulation for profit, while the abusers get similar effects to the 
banned drugs regarding purity, affordability and availability. It is not likely that 
the trend of NPS will diminish in the coming years [4, 5, 17-20]. The NPS are 
defined by the UK Advisory Council on the Misuse of Drugs (ACMD) as “psychoactive 
drugs which are not prohibited by the United Nations Single Convention on 
Narcotic Drugs or by the Misuse of Drugs Act 1971, and which people are seeking 
for intoxicant use” [21]. 
In the last decade, abusers could purchase NPS or related drugs through the deep 
web in darknet markets. This new internet technology applies encrypted 
communication or anonymisation services to facilitate untraceable payments with 
cryptocurrency services. This example of strategies exists in parallel with 
participants in legitimate online marketplaces, such as Amazon and eBay [22]. 
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The synthetic drugs were divided to nine categories based on effects and harm: 
cannabinoids, stimulants, opioids, psychedelics, empathogens, depressants, 
dissociative, others and unknown [23]. These drugs can also be classified in terms 
of chemical structure into the following categories: tryptamines, synthetic 
cathinones, synthetic cannabinoids, plant-based substances, piperazines, 
phenethylamines, phencyclidine-type substances, aminoindanes and other 
substances [24].  
In 2016, the NPS produced at least one substance on a weekly basis internationally 
[25]. The United Nations Office on Drug and Crime (UNODC) reported more than 
644 NPS amongst 102 countries between 2008 and 2015. On the following UNODC 
report between 2009 and 2016, the number of new compounds increased to 739 
NPS, 19% of which were SC. Five-hundred NPS with 80000 seizures were reported 
in 2015 alone. This figure shows a sharp increase in NPS between these years [26]. 
This spread of recreational drugs naturally puts agencies of law and/or 
laboratories behind the constant innovation in the market. Since proposing new 
reference standards or regulations, inventors have created new compounds, 
resulting in a cat-and-mouse chase [19, 22, 26, 27]. Very recently, however, the 
innovations in NPS have been continuous but at a slower pace [22, 24].   
2.2 Synthetic cathinones (SC) 
2.2.1 General view 
Cathinone designer drugs are a subgroup of NPS derived from cathinone. The 
active ingredients of cathinone were originally found in the khat plant (leaves of 
Catha edulis). This plant has been used for several hundreds of years because of 
its central stimulant actions. Khat is mostly found in countries of the Arabian 
Peninsula and the Horn of Africa. Its first description in western literature was in 
1697 when a French scientist was visiting Yemen. The identification of the 
centrally acting agents of cathinone were announced 30 years ago. It was the first 
compound identified as a stimulant phenylalkylamine, beyond its effects on the 
central nervous system [28, 29]. SC substances have monoamine alkaloids and β-
ketophenethylamines that were consumed for recreational purposes at the 
beginning of this century [27].  
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Popular brand names of SC drugs include “Ivory Wave”, “White Lighting”, “Meow-
Meow”, “Blow”, “Cloud 9”, “Bohemian”, “Research Chemicals”, “Columbian 
Odorizer”, “Serenity”, “Explosion” and “Recharge”. These substances are widely 
sold as “bath salts”, “plant nutrients”, “plant feed”, “plant feeders”, “stain 
removers”, “insect repellants”, “glass cleaners” or “room deodorizers” with 
printed warnings stating “not for human consumption” or “licensed by the Ministry 
of Health” to avoid any legal consequences. Currently, the labeling of SC 
compounds have been replaced by “bidet refreshers”, “conquerors of leeches”, 
“additives to sand” or “driver’s charms” [12, 13, 30-35]. 
2.2.2 Chemical structure of synthetic cathinones 
Cathinone is formally named 2-amino-1-phenyl-1-propanone by the International 
Union of Pure and Applied Chemistry (IUPAC), but has also been named β-keto 
amphetamine or 2-aminopropiophenone. The common names of cathinone 
compounds that were studied in this project, along with IUPAC, street and other 
names are shown in Table 2-1. The labile cathinone can be transformed into a di-
phenyl-pyrasine dimer named 3,6-dimethyl-2,5-diphenylpyrasine. Cathinone 
derivatives are very similar to the phenethylamine group. SC differ from the 
phenethylamine group by the presence of the keto functional group, linking to the 
parent substance cathinone that occurs naturally in the khat plant as the S-
enantiomer. SC have the ability to be formed into two isomers, which may change 
the effects. The majority of ring-substituted derivatives of SC consist of racemic 
mixtures that resulted from keto-enol tautomerisation [36, 37]. 
Any SC compound described in this study is related to cathinone (primary amine), 
alkyl-amines (secondary amines) or a nitrogen atom in a pyrrolidine ring (tertiary 
amines). In general, SC must have ketone and amine functional groups. The 
general structure of SC are classified into four groups: N-alkylated, 3,4-
methylenedioxy-N-alkylated, N-pyrrolidinyl and 3,4-methylenedioxy-N-
pyrrolidinyl derivatives [38]. However, nine of new SC were substituted through a 
carbonyl group as illustrated by Smolianitski (these are not protected by law in 
most countries) [39]. The substitution patterns of cathinone derivatives are 
illustrated in Figure 2-1.   
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Abbreviations: 4-MEC (4-methylethcathinone), 4-EMC (4-ethylmethcathinone), MDPV (methylenedioxypyrovalerone), MDPPP (methylenedioxy-α-pyrrolidinopropiophenone), α-PVP (α-pyrrolidinopentiophenone), βk-MDEA (β-
keto-methylenedioxy-N-ethylcathinone).  
 
Table 2-1: Common, chemical, street and other names of SC included in this thesis 
Common name IUPAC name Street name Other name (s) 
CATHINONE 2-amino-1-phenylpropan-1-one Chat, tohai, khat, oat, African salad, qat, 
bushman tea and Abyssinian tea 
β-Keto-amphetamine 
METHCATHINONE 2-methylamino-1-phenylpropan-1-one Intash, cat, catnip or jeff Ephedrone 
BUPHEDRONE 2-methylamino-1-phenylbutan-1-one Mebuphedrone α-Methylamino-butyrophenone (MABP), α-
ethylmethcathinone 
ETHCATHINONE 2-ethylamino-1-phenyl propan-1-one Eth-cat N-Ethylcathinone, ethylpropion 
PENTEDRONE 2-methylamino-1-phenylpentan-1-one Drone α-Methylamino-valerophenone 
4-MEC 2-ethylamino-1-4-methylphenylpropan-1-one Boosting or bumping 4-Methylethcathinone 
MEPHEDRONE 2-methylamino-1-4-methylphenylpropan-1-one M-cat, meow meow or white magic 4-Methyl methcathinone (4-MMC)  
METHEDRONE 1-4-methoxyphenyl-2-methylaminopropan-1-one Bubbles, bristol, meth, dolley Para-methoxymethcathinone, 4-
methoxymethcathinone 
FLEPHEDRONE 1-4-fluorophenyl-2-methylaminopropan-1-one  4-FMC, flephedrone 4-Fluoromethcathinone (4-FMC) 
4-EMC 1-4-ethylphenyl-2-methylaminopropan-1-one  4-EMC 4-Ethylmethcathinone 
ETHYLONE 1-1,3-benzodioxol-5-yl-2-ethylamino propan-1-one βk-MDEA 3,4-Methylenedioxy-N-ethylcathinone  
BUTYLONE 1-1,3-benzodioxol-5-yl-2-methylamino butan-1-one Ease, arlone β-Keto-N-
methylbenzodioxolylbutanamine 
METHYLONE 1-1,3-benzodioxol-5-yl-2-methylamino propan-1-one M1, explosion 3,4-Methylenedioxy-N-methylcathi 
PENTYLONE 1-1,3-benzodioxol-5-yl-2-methylamino pentan-1-one Pentylone β-Keto-methylbenzodioxolylpentanamine 
MDPV 1-1,3-benzodioxol-5-yl-2-pyrrolidin-1-ylpentan-1-one Lunar wave, magic, vanilla, sky, super 
coke  
Methylenedioxypyrovalerone 
NAPHYRONE 1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one Energy-1, NRG-1 Naphthylpyrovalerone 
PYROVALERONE 1-4-methylphenyl-2-pyrrolidin-1-ylpentan-1-one Rave 4-Methyl-β-keto-prolintane 
MDPPP 1-1,3-benzodioxol-5-yl-2-pyrrolidin-1-ylpropan-1-one MDPPP 3,4-Methylenedioxy-α-
pyrrolidinopropiophenone 
α-PVP 1-phenyl-2-pyrrolidin-1-ylpentan-1-one Flakka α-Pyrrolidinopentiophenone 
4-MEC metabolite 2-ethylamino-1-4-methylphenyl propan-1-ol Not applicable 4-Methyl-N-ethyl-norephedrine 
Mephedrone 
metabolite 
2-methylamino-1-4-methylphenyl propan-1-ol  Not applicable 4-Methylephedrine 
BUPHEDRINE 2-methylamino-1-phenylbutan-1-ol Not applicable Buphedrone ephedrine metabolite 
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Figure 2-1: Substitution patterns of cathinone derivatives 
The history of the inherent chemistry of the SC substances is ambiguous and not 
well understood [33, 40]. The structure and the pathways of all SC studied in this 
thesis were conducted by several scientist groups using MS, nuclear magnetic 
resonance (NMR), infrared spectroscopy (IR) instruments  [37, 41-50].  
The fragmentation ions and the isomeric composition of SC tertiary amines were 
evaluated by Abiedalla using GC electron ionisation mass spectrometry (GC-EI-MS) 
and GC−MS-MS [51]. Reviews of chiral separation of SC and the stability study of 
isotopes in SC have been conducted in 2017 [52, 53].  
The chemical structures of cathinones discussed in the thesis are illustrated in 
Table 2-2. These structures were selected based on the most apparent availability 
in the market and trade. In addition, some substances from each group of 
cathinones were chosen to cover a wide range of SC structures.  
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Table 2-2: The chemical structures of SC and their metabolites included in this thesis 
 Non-ring substitute 
CATHINONE METHCATHINONE BUPHEDRONE N-ETHYLCATHINONE PENTEDRONE 
 Ring substituted 
4-MEC MEPHEDRONE METHEDRONE FLEPHEDRONE 4-EMC 
 Methylenedioxy-substituted 
ETHYLONE BUTYLONE METHYLONE PENTYLONE 
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 Pyrrolidine-type (tertiary amines) 
MDPV NAPHYRONE PYROVALERONE MDPPP α-PVP 
 Cathinone metabolites 
4-METHYL-N-ETHYL-NOREPHEDRINE 
(4-MEC metabolite) 
4-METHYLEPHEDRINE  
(Mephedrone metabolite) 
 BUPHEDRINE  
(Buphedrone ephedrine metabolite) 
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2.2.3 Pharmacology and toxicology of synthetic cathinones  
The research history of pharmacology and toxicology of cathinones and 
corresponding metabolites covers more than a century [40]. Many published 
review papers that have reviewed the cathinone derivatives are illustrated in 
Table 2-3. Even though the toxic effects of cathinones were well reported, the 
pharmacological and toxicological studies in humans is quite limited. The action 
of the agents pharmacologically was not equivalent in each cathinone product. 
These agents produce actions via serotonin, dopamine and/or norepinephrine 
transporters to either reuptake and/or release neurotransmitters. To date, no one 
paper has documented the logical relationships between structure activity of the 
mechanism and the behavioural actions in each SC compound. This is because each 
drug must be studied individually, or on a “case-by-case basis” [40].  
The pharmacology, toxicology and treatment of intoxication from SC and 
metabolites have not yet been fully understood and further studies are required 
[40, 54, 55]. However, using these drugs can be very harmful and impair health 
[56]. The mechanism of action of SC and metabolites can be measured through in 
vitro experiments. SC enter the brain barrier through blood, and apply active 
stimulant agents to the central nervous system (CNS). This is due to the presence 
of side amines that are distributed in high concentrations on the synapses in the 
CNS. For that reason, the active stimulant agents of SC are regularly higher than 
ATS [57-59]. Both SC and ATS have somewhat similar effect actions since each 
exists in two stereoisomeric forms, each having a different potency [38, 57, 60-
63].   
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Table 2-3: Review papers published on pharmacology and toxicology of SC   
Title  Year Ref. 
Pharmacological aspects of the chewing of khat leaves 1985 [64] 
Khat consumption: A pharmacological review  1989 [65] 
Use and abuse of khat (Catha edulis): A review of the distribution, pharmacology, side 
effects and a description of psychosis attributed to khat chewing  
1989 [66] 
Amphetamine-like effects in humans of the khat alkaloid cathinone   1990 [67] 
Adverse effects of khat: A review  2003 [68] 
Effects of khat (Catha edulis) consumption on reproductive functions: A review  2003 [69] 
Khat and synthetic cathinones: A review  2004 [60] 
Khat (catha edulis)—An updated review  2005 [70] 
Chronic khat use and psychotic disorders: A review of the literature and future prospects  2007 [71] 
Risk assessment of khat use in the Netherlands: A review based on adverse health effects, 
prevalence, criminal involvement and public order  
2008 [72] 
Chemical composition of catha edulis (khat): A review  2008 [72] 
A review of the neuropharmacological properties of khat  2008 [73] 
Psychopharmacological aspects of catha edulis (Khat) and consequences of long term use: A 
review  
2011 [74] 
Pharmacology and toxicology of mephedrone 2011 [75] 
Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: A review of 
their metabolisms and toxicological analysis  
2011 [76] 
Mephedrone toxicity in a Scottish emergency department  2011 [77] 
Chemistry, pharmacology, and toxicology of khat: a review  2011 [78] 
The chemistry, pharmacology and toxicology, synthetic cathinones  2011 [79] 
The toxicology of bath salts: A review of synthetic cathinones  2012 [80] 
Intoxication delirium following use of synthetic cathinone derivatives  2012 [12] 
A brief review of the emergence of mephedrone use  2012 [81] 
Bath salt use: A case report and review of the literature  2012 [82] 
Resident journal review – synthetic cathinones (“bath salts”) and herbal marijuana 
alternatives  
2012 [83] 
Khat as a risk factor for hypertension: a systematic review  2012 [84] 
Miaow miaow: A review of the new psychoactive drug mephedrone  2012 [85] 
Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: a review of clinical 
and pharmacological aspects of bath salt use: A review of the literature and case reports 
2013 [86] 
Forensic analysis of cathinones  2013 [87] 
Khat: A widely used drug of abuse in the Horn of Africa and the Arabian Peninsula: Review 
of literature  
2013 [28] 
A review on hazards of khat chewing  2013 [88] 
Mephedrone: Public health risk, mechanisms of action, and behavioural effects  2013 [89] 
Methylenedioxypyrovalerone (“bath salts”), related death: Case report and review of the 
literature 
2013 [90] 
Khat: Social habit or cultural burden? A survey and review  2013 [91] 
A review on synthetic cathinone and its derivatives: Prevalence and syntheses  2014 [92] 
Behavioural pharmacology of designer cathinones: A review of the preclinical literature  2014 [93] 
Recently abused synthetic cathinones, α-pyrrolidinophenone derivatives: a review of their 
pharmacology, acute toxicity, and metabolism. Forensic Toxicology 
2014 [94] 
“Not for human consumption”: A review of emerging designer drugs 2014 [95] 
Bath salts and synthetic cathinones: an emerging designer drug phenomenon 2014 [96] 
Comprehensive review of the detection methods for synthetic cannabinoids and cathinones 2015 [97] 
The psychostimulant drug khat (Catha edulis): A mini-review 2015 [98] 
The effects and risks associated to mephedrone and methylone in humans: A review of the 
preliminary evidences  
2016 [99] 
Neurotoxicology of synthetic cathinone analogues  2016 [62] 
Khat (catha edulis) and obesity: A scoping review of animal and human studies  2016 [100] 
Khat use and mental illness: A critical review  2017 [101] 
“Bath salts” the New York City medical examiner experience: A 3-year retrospective review  2017 [102] 
A report of novel psychoactive substances in forensic autopsy cases and a review of fatal 
cases in the literature 
2017 [103] 
Toxic effect of khat (catha edulis) on memory: Systematic review and meta-analysis 2017 [104] 
Neurotoxicity induced by mephedrone: An up-to-date review  2017 [105] 
Chapter 2—15 
In general, pharmacological effects of SC on neurotransmission can be classified 
based on potency into three groups. First, cathinones that act similarly to cocaine 
and MDMA are named the mixed cathinone group. The action mechanism of SC 
related to this group includes non-selective reuptake inhibition of monoamines. 
For example, cocaine has more selectivity to dopamine than serotonin, with 
similar action for mephedrone, butylone, methylone and ethylone, or elevation 
and liberation of serotonin, such as in case of MDMA and naphyrone.  
The second group is the SC that have a similar mechanism to methamphetamines, 
where actions increase liberation of dopamine and the reuptake inhibition of 
monoamines. Cathinones that belong to this group are flephedrone, 
methcathinone and clephedrone. 
The third group is related to pyrovalerone structure compounds, such as MDPV and 
MDPPP. These substances do not have liberation effects on neurotransmission, but 
have very potent effects and selective inhibition of monoamine reuptake [38, 58, 
59, 106-108]. 
The response, strength and extent of the mechanism of action of cathinones on 
the CNS vary depending on several factors, including mode of administration, type 
of drug, number of doses, duration of addiction, health conditions, age, mixture 
of drugs taken, onset action of addiction, alcohol consumption, tolerance, sex, 
medical treatments and body type. However, the desired feelings from taking SC 
are generally similar, including talkativeness, excitement, open mindedness, 
euphoria, concentration, mental awareness, positive feelings and sexual arousal. 
The effects of SC peak between 30 and 45 minutes after taking and last for three 
hours. SC produce a range of peripheral, central and mental effects. Examples 
include increased blood pressure, respiration and heart rate, anorexia, 
psychomotor agitation, hyperthermia and insomnia. Besides to the common 
psychostimulant effects, hallucinogenic effects approaching those of ecstasy can 
also result [38, 60, 109-114].   
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2.2.4 The metabolism of synthetic cathinones  
The metabolism and pathways of most SC are fairly well known. For example, in 
1926, studies found that cathinone was the metabolite of methcathinone [115], 
but cathine and ephedrine were the metabolites of cathinone which were 
pharmacologically identified as active central stimulants of khat in 1975 [40, 116]. 
The majority of SC metabolite and pathway studies  were discussed in the 1960s 
[40]. The metabolism and pathways of SC substances discussed in this thesis have 
been demonstrated in many papers: cathinone [116, 117], methcathinone [116, 
118], mephedrone [108, 119, 120], flephedrone [121], methylone [108, 122], α-
PVP [123, 124], butylone [108, 125], MDPV [49, 126, 127],  16 SC metabolic profiles 
excreted from urine [128], buphedrone [129], 4-MEC [130], naphyrone [131], 
MDPPP [132, 133], methedrone [134] and ethylone [125]. Metabolism of 
mephedrone and its metabolites in urine and blood in vivo was discussed by 
Pedersen, Reitzel [119] using ultra-performance-liquid chromatography-tandem-
mass spectrometry (UPLC-MS-MS) and ultra-performance-liquid chromatography 
quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF). CYP2D6 was 
identified as the main enzyme responsible for mephedrone metabolites and any 
similar structures of NPS. See Figure 2-2 for suggested metabolic pathways for 
mephedrone in rats and humans [108, 119].  
2.2.5 Administration of synthetic cathinones 
SC are commonly administered through nasal insufflation or oral ingestion. The 
compounds are fairly simple to synthesise and are sold as a white, brown or 
yellowish powder that is odourless and occasionally with coloured crystals. It is 
less often sold as tablets or capsules. Most SC were originally produced in China 
and South East Asian countries though less frequently in India, and were later 
distributed to Europe. These products often consist on a mixture of cathinones, 
diluted with caffeine, lidocaine and/or may other adulterants such as benzocaine 
or any synthetic byproduct [7, 31, 33, 38, 40, 60, 79, 134-136]. 
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Figure 2-2: Metabolic pathways of mephedrone 
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2.2.6 Synthetic cathinones and fatal cases 
SC have been related to acute toxicity, and as a consequence, several deaths have 
been documented [90, 130, 137-143]. For example, in the UK, in 2008, 59 deaths 
were reported because of mephedrone use only, and in 2011 that number 
increased to 90 fatal cases. Most users died because of being unaware of the 
mixtures taken [144, 145].  
The determination of SC compounds in biological matrices in fatal cases depended 
on the type of case and the matrix. For examples, the concentrations of SC in 
blood in antemortem cases were reported between 10 and 1000 ng mL-1 and 
frequently higher in postmortem cases. In urine, mephedrone was found to be 
between 186 and 198 ng mL-1 (post mortem) [141, 146] and mephedrone in serum 
(antemortem) was reported as 150 ng mL-1 [147]. 4-MEC was 4.3 ng mg-1 (hair-
antemortem) [148], while other fatal cases were reported related to 4 MEC by [50, 
149].  In blood, methylone was 22 ng mg-1 [150], α-PVP was 654 ng mg-1 [151] and 
MDPV was 440 ng mg-1 [152]. In general, MDPV, mephedrone, 4 MEC, buphedrone, 
methylone, PVP, flephedrone and methedrone respectively were most reported in 
the literature for fatal cases. The variation of concentrations was large because 
of the effect of stability which was still not fully understood.  
In England and Wales, there were 80 deaths between 2012 and 2016 reported by 
the Prisons and Probation Ombudsman, due to suspected NPS use. The number of 
deaths from using amphetamine compounds was 151 deaths in 2014, while MDMA 
was reported in 50 cases the same year, but amphetamine itself was the largest 
proportion of the total. 114 deaths related to NPS were seen in 2014, 49 of which 
were due to using cathinones and 44 of those were mephedrone. Most of the 
deaths were individuals under 40 years old, related to NPS, cocaine and 
amphetamine use. Almost one-third of deaths were because of using 
amphetamines and NPS by individuals under 30 years of age [153-155]. In Scotland, 
deaths related to NPS increased suddenly five years ago, with 123 deaths reported 
in 2016 (8% increase from 2015), and only 31 deaths in 2011 [156]. The reported 
deaths from amphetamine, ecstasy, NPS and mephedrone in Scotland, England and 
Wales in the years 2000, 2005, 2010 and 2015 are illustrated in Figure 2-3.   
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Figure 2-3: Number of deaths from amphetamine, ecstasy, NPS and mephedrone in Scotland, 
England and Wales 
Data was collected from the Office for National Statistics [154, 155] and National Records of Scotland [156]. 
2.2.7 Legal status of synthetic cathinones 
The regulations for the prohibition of NPS are not similar between countries [18]. 
Globally, the legal response has been to implement several approaches in order 
to control NPS, including ‘the individual listing system’ and ‘supplementary 
regulatory frameworks’. The individual listing system has some flexibility in 
controlling NPS, and by now has been used in most countries. This approach 
introduces generic regulation to extend to isomers of substances; for example, to 
include ethers and esters of substances. Several countries, for example Denmark, 
use temporary or emergency bans to restrict NPS for a period of time until final 
decisions are made regarding legislation. Some other countries, for example, 
Sweden, Norway and Poland, use the rapid procedure to ban NPS permanently 
[157]. Currently, most countries, such as the UK, USA and Canada, use the generic, 
analogue systems or blanket ban systems, where the legislation covers a wide 
range or defined group or analogue instead of naming the specific drug. The above 
applied procedures contribute to limiting abuse of NPS (slowing the pace) in the 
recent years [22, 153]. 
0
50
100
150
200
250
2000 2005 2010 2015
N
u
m
b
e
r 
o
f 
d
e
at
h
s
Amphetamine MDMA/ Ecstasy drugs
All NPSs Mephedrone (England and Wales)
Chapter 2—20 
2.2.8 Prevalence and history of synthetic cathinones 
The prevalence of SC across countries has been reviewed in [27, 92, 158-164]. The 
data obtained for NPS prevalence were uncertain since abusers often take the 
drug(s) yet do not recognise which drug(s) have been taken. This is why the trend 
data shows fluctuation; some surveys showing growth while others were 
decreasing or even stable trends [165].  
The prevalence of NPS in the UK was discussed by the Home Office in 2016, 
concluding that the prevalence of SC was low compared to traditional drugs. 2.7% 
of people in England and Wales between the ages of 16 and 59 had taken NPS, 
with only 0.7% taking the drugs in 2015. The prevalence of NPS was lower in 
Scotland (1.6%) and Northern Ireland (2.2%). Prevalence of mephedrone (1.3%) was 
similar to ecstasy in 2010, and in the recent years, the prevalence of mephedrone 
dropped after being controlled, reaching 0.3% in England, Wales and Scotland in 
2016 and 0.6% in Northern Ireland [153]. In Europe, the lifetime prevalence of NPS 
is 8% with 3% confirming use in 2013 alone, between ages of 15 and 24 (from the 
Eurobarometer survey) [165]. In Germany, in 2015, 0.9% of individuals between 18 
and 64 confirmed use [165].   
Historically, the first active components of SC were made in the 1920s for medical 
purposes, to treat depression and obesity [27, 33, 40, 162, 166]. The active 
component of cathinone was synthesised in 1929 [42], methcathinone in 1928 [33, 
166], buphedrone in 1928 [166], mephedrone in 1929 [33], MDPV in 1969 and 
pyrovalerone in 1964 [139]. In 1940, methcathinone and cathinone were used for 
the treatment of depression in Russia. However, between 1970 and 1980, the 
substances were misused in many countries, including the USA, Russia, the 
Republic of South Africa and finally in Japan in 1995. Recently, bupropion has been 
used for cathinone and methcathinone withdrawal treatment [167, 168]. 
Methcathinone has been misused since the 1970s and became widespread in 
Europe, USA and Australia in the 1990s. Mephedrone was primarily used for the 
treatment of depression and for appetite suppression in the USA between the 
1930s and the 1950s. In the 1960s, MDPV was initially synthesised for the treatment 
of chronic fatigue [27, 29, 169]. Pyrovalerone was developed in 1969, and later 
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used illegally in 1975 [170], Methylone was used as an antidepressant and for the 
treatment of Parkinson’s disease in 1996 [14, 171]. After the year 2000, methylone 
and the first generation of SC compounds appeared for recreational users. From 
2000 to 2009, the pioneer SC in Europe was the mephedrone followed by 
methylone, MDPV, butylone, ethylone, buphedrone and flephedrone, and after 
2009, pentedrone and α-PVP were also included. The second generation of SC were 
later seen (from 2015) as the group of α-pyrrolidinopentiophenone [33, 38, 58, 60, 
114, 172].  
The most commonly seized SC in 2015 were α-PVP, 3-MMC, ethylone, and 
pentedrone [29, 31]. Three SC compounds (methylone, mephedrone and MDPV) 
made up 98% of all SC used in the USA in 2014, even when these drugs were 
controlled [20, 173]. In 2005, the European Monitoring Centre on Drugs and Drug 
Addiction (EMCDDA) included methylone as the first SC illegally used. After two 
years, mephedrone had been distributed around the world, in countries such as 
Israel, Australia and the UK [79]. Later, mephedrone increased in Europe and the 
USA [174]. Mephedrone and methylone were the two most misused SC in Europe 
[175]. In 2009, up to 41% of the people who attended dance music clubs (the 
sample size was 2295 participants) in the UK had used mephedrone [176]. MDPV 
was misused by more than 6% of 259 drivers in Finland between August 2009 and 
August 2010 [177]. 
Meanwhile, almost 150 SC have been documented through distribution into the 
market [15, 178]. More than 376 SC have been discovered in the National Forensic 
Laboratory Information System (NFLIS) data [1]. Examples of new SC, recently 
reported in 2016 and 2017 were hexedrone, 4-Cl-α-PPP, 4-Br-α-PVP, 4-
bromoethcathinone [179], 4-methylpentedrone, N-ethylnorpentylone [180], N-
ethylhexedrone, propylone, 4-Cl-EAPP, 6-Methoxy-bk-MDMA, α-PiHP, 4-F-α-PHP, 
4-Cl-α-PHP [181], α-PBT and some other related drugs were reported by [182], as 
well as thiothinone reported by [183].  
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2.3 Amphetamine-type stimulants (ATS) 
2.3.1 General view 
In the last decade, the abuse of ATS compounds, such as amphetamine, 
methamphetamine and MDMA has become a global concern, but especially in East 
Asia and the Middle East. According to a recent UNODC report in 2017, the abuse of 
ATS has globally increased and they are now the second most abused drug in the world 
after cannabis [22]. In 2015, global seizures of methamphetamine increased 21% (132 
tonnes) from 2010. Similarly, amphetamine seizures increased 8% (52 tonnes) and 
ecstasy decreased 35% (6 tonnes). There were nearly 200 tonnes seized and over 37 
million users of ATS compounds in 2015. In 2010, there were 100 tonnes of ATS seized; 
these figures indicate the sharp rise of ATS between 2010 and 2015 [165]. The 
quantities of amphetamine, methamphetamine and MDMA seizures in 2015 in the 
UK were roughly 4.5, 0.1 and 3.5 tonnes, respectively [31].  
Amphetamine was first manufactured in 1887 and from 1935 has been used for the 
treatment of hypertension, obesity, attention-deficit/hyperactivity disorder 
(ADHD) and narcolepsy. Because of potential addiction, it is controlled in almost 
all countries. Amphetamine is a form of a phenethylamine derivative compound 
that has two enantiomers: dextrorotatory or levorotatory, or a mixture of both, 
each one having different plasma half-lives. The dextrorotatory isomer is three to 
four times more potent than the levorotatory isomer [184, 185]. 
Methamphetamine is the methyl derivative of amphetamine and is a strong potent 
stimulant in the CNS. It was synthesised in 1919 for the treatment of ADHD and 
obesity [186]. Methamphetamine has commonly been sold illegally as a racemic 
mixture of dextrorotatory and levorotatory with strong and rapid stimulant effects 
[187].  
2.3.2 Chemical structure of amphetamine-type stimulants  
ATS substances can be classified based on the structural characteristics and the 
substitution patterns on the ring into three sub-groups. The first group has no 
substituents on the benzene ring, such as amphetamine and methamphetamine. 
The second group has methylenedioxyphenol-substitution on the aromatic ring, 
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such as MDMA and MDEA. The third group has other chemical substitution patterns 
with alkyloxy groups, such as PMA and PMMA [188]. The chemical structures of ATS 
discussed in this thesis are illustrated in Figure 2-4. These compounds were 
selected based on apparent availability in the market and trade. Substances were 
also chosen from each group of ATS in order to cover many ATS structures. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 2-4: The chemical structures of ATS included in this thesis 
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2.3.3 Pharmacology of amphetamine-type stimulants  
Stimulant drugs of the CNS, such as ATS and amphetamine-like stimulants (ALS), 
effect the cerebral cortex and produce effects similar to adrenaline. For instance, 
amphetamine crosses the blood-brain barrier into the monoamine 
neurotransmitter system and acts similar to dopamine. ATS substances such as 
amphetamine and methamphetamine can react, bind and act in some processes. 
The substances act as substrates of a monoamine transporter protein with low-
affinity in the dopamine and noradrenaline systems, resulting in high concentrations 
of neurotransmitters. Conversely, MDMA acts more heavily on the serotonin system 
and results in more potent effects than amphetamine substances [188-190]. 
The symptoms related to ATS substances are euphoria, elevated blood pressure 
and heart rate, a weakness in memory, increased body temperature and 
respiration. Hallucinations, tremors, violent behaviour, agitation, memory loss, 
psychosis and paranoid delusions can occur with chronic abuse [191].  
ATS compounds are absorbed rapidly in the abdominal system. They are lipophilic 
substances that pass the blood brain barrier and concentrate in the brain, lungs, 
cerebrospinal fluid and kidneys. The primary active pathway of amphetamine 
includes 4-hydroxyamphetamine and norephedrine. In urine at pH 7, 30–40% of the 
amphetamine is excreted unaffected 24 hours after the oral administration, and 
nearly 50% is excreted as inactive metabolites, including the metabolites of 
hippuric acid and 4-hydroxyphenylacetone. The concentration of amphetamine in 
plasma is at a peak level between one and three hours after taken orally, and full 
absorption occurs after four to six hours. Methamphetamine is 40% excreted in 
urine unchanged along with 5% amphetamine (a metabolite of methamphetamine) 
after 24 hours (orally). The half-life in human plasma is 10 hours and the peak 
occurs after three hours. The active metabolite of methamphetamine is 4-
hydroxymethamphetamine [186, 187, 192-194].  
2.3.4 Administration of amphetamine-type stimulants  
ATS substances are produced in a variety of forms, such as tablets, powder, capsules 
or white crystals that can be administrated orally, smoked, injected or snorted [187].  
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2.3.5 The concentration of ATS in abuse samples  
The cutoff concentration of amphetamine, methamphetamine, MDMA, MDA and 
MDEA for a drug of abuse test in urine samples is 500 ng mL-1 for screening and 250 
ng mL-1 for a confirmatory test; this is based on the Substance Abuse and Mental 
Health Services Administration (SAMHSA) [195]. The amphetamine and 
methamphetamine cutoff in the EU and the USA are 300 ng mL-1 and 500 ng mL-1, 
respectively. According to the World Anti-Doping Agency (WADA), the detection 
of ATS substances initially measures qualitatively the ATS groups rather than on a 
quantitative basis; this is because the trace amount of ATS compounds with 
metabolites are essential for detection. Therefore, the development of an 
instrument for the wide determination of ATS substances with the ability to detect 
small concentrations of ATS even after several days will enable more stringent 
regulations on the abuse of ATS drugs [187, 196].  
2.3.6 Legal Status of amphetamine-type stimulants  
ATS substances are heavily regulated and controlled in most countries, restricting 
access, such that the substances are only used for medical treatment purposes 
[197].  
2.3.7 Prevalence of amphetamine-type stimulants  
In 2015, ATS prevalence rates (excluding MDMA) were 0.5 and 0.6% in Europe and 
North America, respectively [198]. The lifetime prevalence of ATS for young 
populations (15-34) varied from 0.1% to 12.4%, with an average of 5.5% in European 
countries. In the USA, the prevalence of methamphetamine use in people aged 15-
64 increased from 0.5% to 0.8% between 2012 and 2015 [165].  
MDMA prevalence in the UK (England and Wales) decreased from 4% to 3.2% from 
2000 to 2015. In Europe (amongst 15-64 year olds) MDMA was misused by 9.3 
million males and 4.7 million females in a lifetime, and amphetamines were 
misused by 8.4 million males and 4.2 million females [199]. The estimation of 
amphetamine prevalence for young Europeans aged 15–34 was 1.3% (1.7 million) 
in 2012 [200]. The most commonly misused drugs after cannabinoids were MDMA, 
Chapter 2—26 
amphetamine, cocaine, methamphetamine and LSD in European countries by 
students 15-16 years old, with a lifetime prevalence of 5%, excluding cannabis 
[22].  
2.4 Sample preparation methods and matrices 
Sample preparation techniques are used in the first stage, before the samples are 
analysed using chromatographic mass spectrometric methods. These techniques 
eliminate some components of the sample, such as lipids and proteins, and 
maintain the target analyte for detection even in small concentrations. Biological 
matrices frequently contaminate the instruments, particularly when samples are 
directly inserted into the instruments. Therefore, the requirements for 
eliminating contamination using sample preparation methods play an essential 
role in any laboratory [56, 201]. 
Sample preparation techniques can generally be classified into two categories: 
exhaustive or non-exhaustive techniques. Figure 2-5 illustrates the classification 
of sample preparation techniques [202].  
Exhaustive extraction techniques are employed for the extraction of the entire 
analyte from the matrix by applying a large quantity of organic solvent in liquid 
or sorbent. This procedure is used to confirm that the analytes are fully extracted 
from, especially when development parameters are applied. Subsequently, the 
outcome products easily reach the desired recovery. The SPE and LLE are both 
good examples of the exhaustive technique. Non-exhaustive techniques depend 
on reaching the equilibrium between the target analytes and the stationary phase 
[202].  
A review of extraction techniques in the toxicological analysis of drugs was 
reviewed by Maurer [203]. 
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Figure 2-5: General classification of extraction techniques [202]  
2.4.1 Liquid-liquid extraction (LLE) technique applied to SC  
Liquid-liquid extraction (LLE) has been extensively used for the analysis of forensic 
biological samples, and it was the first sample preparation method historically 
used in analytical chemistry [204]. It potentially offers high recovery and 
reproducibility, and covers a large range of drugs in a single procedure for forensic 
toxicology matrices. LLE is a batch extraction technique, which involves the direct 
addition of a large quantity of organic solvent to the matrix. Target analytes are 
distributed among the sample matrix and the organic solvent phases, and because 
the organic solvents have different miscibility, density and solubility, a large 
amount of the analyte is extracted into the organic solvent phase or the aqueous 
phase. Additional steps, including evaporation with sometimes derivatisation 
should be performed before the samples are inserted into the analytical 
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instrumentation for analysis. Even though LLE is a straightforward technique for 
preparing the sample and has been employed in a wide range of matrices, it is 
labour intensive, time-consuming and harmful to the environment and general 
health. The limitations also include emulsion formation, a large sample volume 
and the use of toxic organic solvents. LLE can result in inadequate cleaning and 
increases the interference of components [202, 205].  
LLE has been widely applied for the extraction of cathinone derivatives coupled 
with GC or LC-MS-MS. The selected test procedures applied to SC using LLE 
techniques are illustrated in Table 2-4. 
Li et al. [206] used a 0.5 mL plasma sample and 5 mL of organic solvent methyl-
tert-butyl-ether (MTBE) for the extraction of 11 cathinone derivatives. The top of 
the organic layer was transferred for evaporation and analysis. Ammann et al. 
[207] utilised whole blood samples mixed with 1 mL of 1-chlrobutane and 10% 
isopropanol (v/v), and the sample was analysed using LC-MS-MS for the detection 
and quantification of 25 components of cathinones. 
2.4.2 Solid-phase extraction (SPE) technique applied to SC  
The solid-phase extraction technique was developed with the objective of 
eliminating at least one of the limitations of the LLE technique. In SPE, the organic 
solvent is substituted for a solid phase and the matrix travels through a sorbent 
bed. The analytes in the sample settled completely on the solid sorbent. By using 
solvents and distilled water for washing, the components that are not required are 
selectivity discarded from the solid sorbent. Conversely, the analytes of interest 
are desorbed by an eluting solution. The eluent resulting from desorption of the 
analytes is then concentrated by evaporation. The SPE technique, unlike LLE, can 
be utilised both offline or fully automated online. It consumes less organic solvent 
and incorporates a clean-up step. However, it has a number of limitations, 
including the fact that it is a multi-step technique, it is time-consuming and the 
volume of the sample must be large to meet the limit of detection [208]. 
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Table 2-4: Selected procedures applied to SC using LLE techniques 
Name of SC Drugs Matrix Sample 
preparation 
methods 
Detection Validation parameters Instrumentation  Ref. 
Mephedrone, MDMA, 3-FMC, MDPV and some other compounds Urine LLE EI, full 
scan 
LOD GC−MS [209, 
210] 
Mephedrone Hair LLE EI, SIM Linearity, accuracy, 
precision, selectivity, 
LOD, LOQ 
GC−MS [211] 
Mephedrone, methedrone Blood LLE, TFA EI Linearity, accuracy, 
precision 
GC−MS [143] 
MDPV Urine LLE, HFBA EI, SIM Linearity, accuracy, 
precision, LOQ, LOD 
GC−MS [212] 
Cathinone, methcathinone, ethcathinone, mephedrone, 
flephedrone, methylone, methedrone, butylone, cathine, 
norephedrine, ephedrine, pseudoephedrine, methylephedrine, 
methylpseudoephedrine and mephedrone. 
Blood LLE ESI, SRM Linearity, accuracy, 
precision, selectivity, 
recovery, LOD, LOQ, 
stability, matrix effect 
LC-MS-MS- 
QQQ 
[213] 
Mephedrone Hair LLE ESI, MRM Linearity, accuracy, 
precision, selectivity, 
LOD, LOQ 
LC-MS-MS- 
QQQ 
[214] 
Mephedrone and methedrone Hair LLE ESI, MRM Linearity, accuracy, 
precision 
LC-MS-MS- 
QQQ 
[143] 
Methcathinone and mephedrone Blood 
and 
serum 
LLE ESI, MRM Linearity, accuracy, 
precision, selectivity, 
recovery, LOQ, LOD 
HPLC-DAD [215] 
11 cathinone derivatives Equine 
plasma 
LLE ESI, MRM Linearity, accuracy, 
precision, recovery, LOD, 
LOQ, selectivity 
LC-MS-MS [206] 
25 designer cathinones Blood LLE ESI, MRM Linearity, accuracy, 
precision, LOD, LOQ 
LC-MS-MS [207] 
Abbreviations: MDMA (methylenedioxy-methamphetamine), TFA (trifluoroacetic anhydride), HFBA (heptafluorobutyric anhydride), 3-FMC (3-fluoromethcathinone), MDPV ((methylenedioxy-pyrovalerone), 
LLE (liquid-liquid extraction), EI (electron ionisation), SIM (selected ion monitoring), ESI (electrospray ionisation), SRM (selected reaction monitoring), MRM (multiple reaction monitoring), LOD (limit of 
detection), LOQ (limit of quantification), GC-MS (gas chromatography–mass spectrometry), LC-MS-MS-QQQ (liquid chromatography-mass spectrometry-triple quadrupoles),   HPLC-DAD (high performance 
liquid chromatography-diode array detection).                
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The SPE technique is the method most used for the extraction of compounds in 
simple or complex matrices. It provides the desired recovery using clean products, 
without harming the instruments. There are innumerable articles published using 
the technique on biological samples. Reviews of SPE in biological samples and 
trace elements were completed by Ibrahim et al. [216] and Buszewski et al. [217]. 
Modern trends in solid-phase extraction (review) were recently published to 
explore its application to new sorbent media [218]. A review on its application to 
imprinted polymers and the binding assay was discussed by Caro et al. [219]. There 
are five devices for SPE, based on applications in food, environment, forensic 
toxicology and biomedical samples: multi-well plates, cartridges, pipette tips, 
disks and sorbent mixed with sample [218].  
Multi-well SPE plates have been extensively illustrated for clinical applications 
[220] by monitoring several types of xenobiotics [221]. It can be used for the 
extraction of drugs in human urine and plasma. The main advantage of the multi-
well device is its ability to deal with large samples (96, 384 or 1536 wells in one 
plate [220, 222]) in a short period of time with less labour and less elution solvents 
[218].  A 96-well plate was used to analyse cis-3-(4-((4-chlorophenyl) sulfonyl)-4-
(2,5difluorophenyl) cyclohexyl) propanoic acid in a plasma sample using HPLC-MS-
MS with a recovery between 82 and 89% [223]. A 384 well plate device was used 
for the extraction of methotrexate and 7-hydroxymethotrexate in urine and 
plasma using liquid chromatography-mass spectrometry (LC-MS)-MS. The results 
showed a high recovery of >95% [224]. Both examples above used the octadecyl 
modified silica extraction material. Another device for the extraction of various 
drugs in matrices is the cartridge SPE. It was used for the extraction of 
glyphosate, glufosinate and bialaphos in serum and urine using UPLC–MS-MS and 
provided a recovery between 63 and 74% using zirconia-coated silica as the 
material of extraction [225]. An additional study used the cartridge device for the 
extraction of the theophylline drug in serum using HPLC-UV. The recovery was 
between 79 and 84% using molecularly imprinted polymers as the material of 
extraction [226].  
SPE pipette tip has recently become a desirable technique because it can provide, 
to some degree, the requirement for green analytical methods. It is a 
miniaturisation device used for the extraction of substances in biological samples. 
Pipette tip SPE successfully extracted methamphetamine and amphetamine in 
Chapter 2-31 
human whole blood, in conjunction with GC−MS. It showed excellent linearity, and 
the LOD for both drugs was 0.2 ng mL-1. Relative standard deviation (RSD) and bias 
were both less than 14% for all drugs tested [227]. The technique was also used 
for the determination of mequitazine in human plasma by GC−MS. The results 
showed that the device monotip C18 tips bonded with monolithic silica gel was 
robust for the analysis of the medical drug with an LOD equal to 0.06 ng mL-1 and 
90% recovery [228]. 
The disk SPE efficiently extracted amphetamine, methamphetamine, MDA and 
MDMA from urine using gas chromatography-mass spectrometry (GC−MS). The 
recoveries were between 70 and 105% with LOD less than 4 ng mL-1 for all drugs 
tested [229]. It was also used for the extraction drugs of abuse in urine for 
screening purposes in a toxicology laboratory. The RSD was less than 5%, and the 
recovery  was 75–100% for all drugs tested [230]. The application of SPE sorbent 
mixed with the sample was reviewed by Augusto et al. [231]. The evaluation of 
three different SPE, hydrophilic balance, mixed-mode and molecularly imprinted 
polymer sorbents was undertaken for the extraction of five amphetamines using 
LC-MS-MS by Iria González et al. [232]. Molecularly imprinted polymer sorbent was 
the preferred choice, as it provided clean extracts with great precision and 
accuracy and less matrix effects.  
SPE and cathinones, Castro et al. [233] developed an SPE and LC-MS-MS procedure 
for the determination of eight cathinones in oral fluid. The extraction device used 
was the Strata X cartridges. 0.5 mL of oral fluid and 2 mL of borate buffer pH 9 
were added. The target analytes were eluted using dichloromethane. 0.1% (v/v) 
HCl was added before the contents were evaporated using nitrogen and then 
reconstituted by adding 0.1% (v/v) formic acid. The samples were then introduced 
into the LC-MS-MS system.  
Mayer et al. [234] developed a selective and rapid HPLC–diode array detection 
method for the confirmation of mephedrone, flephedrone and 4-MEC in human 
urine. Samples were prepared by SPE using as internal standard procaine 
hydrochloride. The specimens were eluted twice using 400 µL of 0.5 M ammonia–
acetonitrile. The recovery of SPE was between 71 and 82%, while LOD and LLOQ 
were 40 and 100 ng mL-1 respectively. Other papers on the subject of SC detection 
using SPE techniques are summarised in Table 2-5.  
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Table 2-5: Selected toxicological applications applied to synthetic cathinones using SPE  
Name of Drugs Matrix Sample Preparation Detection Validation parameters Instrumentation 
Name 
Reference 
Methedrone, methylone, 
mephedrone, MDPV, 
fluoromethcathinone  
Oral fluid SPE MRM Selectivity, LOD, LOQ, precision, accuracy, 
recovery 
LC-MS-MS [233] 
Mephedrone, 4-MEC and 
flephedrone 
Urine SPE Diode array 
detection 
Stability, recovery, matrix effect, linearity, 
accuracy, precision, LOD, LOQ 
HPLC–DAD [234] 
MDPV, MPHP, PPP, MPPP, MOPPP, 
MDPPP, MPBP, α-PVP 
Urine EHCC, SPE, TMS EI and full 
scan 
LOD GC−MS [127, 235] 
Methylone and its metabolites Rat and 
human 
plasma 
Protein precipitation 
and SPE 
MRM Precision, stability, accuracy, LOQ, LOD, 
ion suppression  
LC-TMS [236] 
Some cathinones and more than 150 
drugs of abuse and poisonous 
compounds 
Human whole 
blood 
Online-SPE Full scan-ESI Screening methods, LOD, recovery LC-TOF-MS [237] 
32 cathinone derivatives Serum Supelco Visiprep-DL 
Disposable Liner SPE 
MRM LOD, LOQ, precision, accuracy LC-QQQ-MS-MS [238] 
28 synthetic cathinones Urine Solid phase cation 
exchange extraction 
(SOLA SCX) 
EI Stability, recovery, matrix effect, linearity, 
accuracy, precision, LOQ, LOD 
LC-HRMS [129] 
MDPV, Mephedrone, BZP and TFMPP 
 
Whole blood, 
serum, urine 
CSDAU206 Clean 
Screen SPE 
ESI Stability, LOQ, LOD LC-TMS [239] 
30 synthetic cathinones Urine Solid phase cation 
exchange extraction 
(SOLA SCX) 
ESI Stability, matrix effect, linearity, accuracy, 
precision, LOD, LOQ, ionization 
suppression/enhancement 
LC–HRMS [240] 
10 synthetic cathinones Oral fluid SPE ESI-MRM  Accuracy, precision, linearity, selectivity, 
matrix effect, recovery 
UHPLC –MS-MS [241] 
Methcathinone, mephedrone and 4-
MEC 
Autopsy, 
blood 
SPE with 0.1 M 
carbonate buffer (pH 
9.3) 
ESI Matrix effect, LOD, LOQ, precision, accuracy LC-MS-MS [130] 
Abbreviations: MDPV (methylenedioxy-pyrovalerone), 4-MEC (4-methylethcathinone), MPHP (4-methyl-α-pyrrolidinohexiophenon), PPP (α‐pyrrolidinophenone), MPPP (methyl‐α‐pyrrolidinopropiophenone), MOPPP (methoxy‐α‐
pyrrolidinopropiophenone), MDPPP (methylenedioxy‐α‐pyrrolidinopropiophenone), MPBP (methyl‐α‐pyrrolidinobutyrophenone), α-PVP (α-Pyrrolidinopentiophenone), BZP (benzylpiperazine), TFMPP 
(trifluoromethylphenylpiperazine), SPE (solid-phase extraction), EHCC (extrahepatic cholangiocarcinoma), TMS (trimethylsilyl), EI (electron ionisation), ESI (electrospray ionisation), MRM (multiple reaction monitoring), LOD 
(limit of detection), LOQ (limit of quantification), GC-MS (gas chromatography–mass spectrometry), LC-MS-MS (liquid chromatography-mass spectrometry), HPLC-DAD (high performance liquid chromatography-diode array 
detection), LC TMS (liquid chromatography-tandem-mass spectrometry), LC–HRMS (liquid chromatography–high resolution mass spectrometry).  
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2.4.3 Other exhaustive techniques applied to SC 
There are many other exhaustive extraction techniques that have been applied 
for SC, including matrix solid-phase dispersion (MSPD), protein precipitation, 
dilute-and-shoot technique, microwave assisted extraction (MAE), ultrasonic 
assisted extraction (UAE), the toxic lab system, perchloric acid, enzymatic 
hydrolysis, methanol, enzymatic digestion and the ultra-filtration technique. 
Matrix solid-phase dispersion technique was developed for the extraction of 
cathine, psychoactive phenylpropylamino alkaloids, norephedrine and cathinone 
from khat by HPLC with diode array detection [242]. Protein precipitation was 
used for the extraction of mephedrone from post-mortem samples by GC–MS and 
HPLC [141]. Other papers using this method applied to SC are summarised in Table 
2-6. Dilute-and-shoot (DS) or direct injection method has been successfully 
applied for the detection several components in toxicology samples using LC-MS 
(DS-LC-MS-MS). The applications of DS applied to analytical toxicology matrices 
were reviewed by Deventer et al. [243]. This method has several disadvantages, 
including yielding bad responses and detection with high noise in the background, 
it harms the injector port and column in GC. However, it is easy and rapid for 
screening and reduces the effect of the matrix [243, 244]. Papers published using 
this method applied to SC are summarised in Table 2-6.  
Microwave-assisted extraction (MAE) and ultrasonic assisted extraction (UAE) are 
the techniques used for the extraction the target analytes by heating the solvents 
in contact with a matrix by emitting microwave energy in order to partition the 
target analytes from the matrix into the solvent [245]. The applications of MAE 
and UAE for the identification of drugs of abuse were published by [244, 246] and 
[247] specifically for cathininones, see Table 2-6. Toxi-lab system (or thin-layer 
chromatography) is a device for the extraction of toxicological drugs for screening 
only. The evaluation and performance of this technique were evaluated by [248]. 
The papers that used this technique for the analysis of illegal drugs were reported 
by [249, 250]. The-toxi lab was used to evaluate the effects of pesticide on khat 
leaves using GC−MS [251]. It was also similarly applied to methcathinone [167].  
Perchloric acid can be used in deproteinisation to remove any protein remaining 
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in the sample (whole blood or body fluids). It additionally enables any small 
molecules in the target analytes to be stabilised. The deproteinisation procedure 
was used for the quantification of SC in oral fluid [252] and in other matrices [76, 
253, 254]. This method was thought to improve the recoveries of SC [76]. Acidic 
or enzymatic hydrolysis with ethylation or acetylation were performed coupled 
with SPE extraction and GC−MS in biological samples for the extraction of SC [255, 
256]. The evaluation of methanol as an extraction solvent for SC was demonstrated 
by [206, 257]. 
Enzymatic digestion was employed in human hair samples by placing the hair in a 
glass tube containing enzyme proteinase K and Cleland's reagent for the digestion 
of hair samples. The extraction was carried out using LLE, and full validation was 
successfully achieved for the detection of mephedrone with two metabolites: 4-
methylephedrine and 4-methylnorephedrine, using LC-MS-MS [214].  
Ultra-filtration technique (UF) was developed [213] for the detection of more than 
10 cathinones by LC–ESI-MS-MS in a whole blood sample. Methanol was added to 
the blood sample for extraction, and the supernatant was then ultra-filtrated by 
UF filter cup. Before centrifugation, 10 µL of formic acid was added and diluted 
twice by distilled water. There was no significant loss of SC after the filtration 
was applied (the drugs were stable even though the filtration procedure was 
employed) [258].  
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Table 2-6: Selected applications that were applied to SC using protein precipitation, dilution techniques and ultrasonic-assisted extraction 
Name of Drugs Matrix Sample Preparation Detection Validation parameters Instrumentation  Ref. 
Mephedrone Autopsy 
samples 
Protein 
precipitation 
Diode array Not mention HPLC–UV and GC–MS [141] 
BZP, TFMPP, MeOPP, MDBP, 4-MTA, 
mephedrone, MDMA, 3-FMC, 3-BMC, MDPV 
Urine Protein 
precipitation 
HR-ESI-MS LOD LC–HR-MS [210] 
Mephedrone, methylone, butylone, 
methedrone, BZP, TFMPP and MDPV 
Urine Dilution  ESI, SRM Rapid screening, LOD, 
LOQ, recovery, 
precision, matrix 
effect, linearity, 
accuracy 
LC-MS-MS  
QQQ 
[259] 
Screening of synthetic cathinones and some 
other related NPS 
Urine Dilution Reversed-
phase method 
Linearity, LOD, LOQ, 
matrix effect 
LC-MS-MS [260] 
Butylone, ethylone, ethcathinone, 
mephedrone, methylone, MDPV, methedrone, 
cathinone and some other related NPS 
Pills and 
powders  
Ultrasonic-assisted 
extraction with 3 
mL of acetone 
ESI Not mention LC-QTOF-MS [247] 
Cathinone, methcathinone, ethcathinone, 
amfepramone, mephedrone, flephedrone, 
methedrone, methylone, butylone, cathine, 
norephedrine, ephedrine, pseudoephedrine, 
methylephedrine and methylpseudoephedrine 
Whole 
blood 
Protein 
precipitation, 
addition of 
methanol and 
ultrafiltration 
method 
SRM Recovery, LOD, LOQ, 
stability 
LC–ESI-MS-MS [213] 
Abbreviations: BZP (benzylpiperazine), TFMPP (3-trifluoromethylphenylpiperazine), MeOPP (para-methoxyphenylpiperazine), MDBP (methylenedioxybenzylpiperazine), 4-MTA (4-methylthioamphetamine), 3-
FMC (3-fluoromethcathinone), 3-BMC (4-bromomethcathinone), HR-ESI-MS (high resolution- electrospray ionisation), SRM (selected reaction monitoring). 
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2.4.4 Other exhaustive sample preparation applied to forensic 
toxicology matrices. 
Other exhaustive extraction methods applied for the detection of substances in 
forensic toxicology matrices are supercritical fluid extraction (SFE), supercritical 
fluid chromatography (SFC), pressurised-liquid extraction (PLE), accelerated 
solvent extraction (ASE), solid-supported liquid-liquid extraction (SLLE), solid 
phase dynamic extraction (SPDE) and soxhlet extraction.  
The general applications of supercritical fluid extraction (SFE) coupled with 
chromatographic analysis in the forensic field were published by [261, 262], and 
specifically for drugs of abuse by [263]. SFE is a safe and rapid method but it is 
expensive. It yields better precision compared to conventional techniques [264]. 
SFE and pressurised-liquid extraction (PLE) were applied for the extraction of 
amphetamines by [265-267]. PLE achieved a short extraction time with minimum 
solvent. The extraction products using the filtration technique were high 
compared with SFE and microwave-assisted extraction (MAE). Solid-supported 
liquid-liquid extraction (SLLE) was used for the extraction of benzodiazepines in 
[260, 268]. The application of solid-phase dynamic extraction (SPDE) to drugs of 
abuse was published in [246, 260, 269]. Accelerated solvent extraction (ASE) was 
applied to extract cocaine and benzoylecgonine [270]. Soxhlet extraction 
apparatus were generally used for herbal, soil and solid samples. It was used for 
the extraction of herbal drugs of abuse by Meyer [271], and it was used for the 
extraction of khat by Glick and Kuehne [272]. The automated soxhlet extraction 
system was applied for extraction from hair specimens for the detection of 20 NPS 
coupled with HPLC–ESI-MS-MS, as well as benzodiazepines and metabolites in [273, 
274].  
More than 40 therapeutic drugs were extracted using dispersive solid-phase 
extraction (DSPE) and GC-ion trap MS in whole blood and plasma. The DSPE was 
developed and validated for eight drugs. Acetonitrile, magnesium sulfate and 
sodium chloride were initially added to blood, and the contents were mixed, 
shaken and centrifuged for separation. The organic layer was then cleaned from 
the residual of water by D-SPE using bulk sorbents with magnesium sulfate. The 
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method in this article used the QuEChERS approach, which was developed for the 
determination of pesticides in food. The D-SPE coupled with the PSA sorbent 
obtained more acceptable results than aminopropyl and styrene-divinylbenzene 
sorbent. The recovery was more than 80% and RSD was 10% for most drugs tested. 
LOD was less than 20 ng mL-1 [275]. 
Six fluoroquinolones in serum specimens were extracted using a molecular 
imprinting matrix dispersion technique combined with a chromatographic 
separation instrument. The method was developed using the sorbent and ethylene 
glycol dimethacrylate as a crosslinker for the elimination of interferences in the 
serum. The recovery was above 70% for all compounds tested with an RSD of 6.6% 
[276]. The molecularly imprinted matrix of dispersant sorbent was also developed 
for the extraction of fluoroquinolones collected from swine tissues and chicken 
eggs. The molecular imprinting matrix sorbent material was compared with other 
sorbents, such as Florisil, C18, silica and sand. The recovery was greater when the 
molecular imprinting matrix sorbent was used and no interferences were observed 
[277].  
2.5 General review of microextraction techniques 
Microextraction is a common approach of non-exhaustive extraction technique 
that employs small quantity of sorbent or liquid in the extraction phase for the 
extraction of the analytes from the matrix. Sample preparation using non-
exhaustive extraction techniques has been used to decrease the volume size of 
the solvents, chemicals and samples while ensuring that the sampling is introduced 
conveniently with minimum time and cost. Additionally, this technique can be 
operated in automated system coupled with hyphenated chromatographic 
spectrometry instruments [278]. Many review papers have been published focus 
on microextraction techniques. See Table 2-7 for the papers published in the last 
decade.  
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Table 2-7: Review papers have been published on microextraction techniques within (2007-2018).   
Title Year Ref. 
Review: automation of solvent microextraction techniques  2007 [279] 
Review: automated, on-line membrane extraction 2007 [280] 
Application of solid-phase microextraction in analytical toxicology 2007 [281] 
Sorbent and liquid-phase microextraction techniques with gas chromatographic analysis: a review 2008 [282] 
A review of current trends and advances in modern bio-analytical methods: Chromatography and 
sample preparation 
2009 [283] 
Review of solvent microextraction techniques- general methods 2010 [284] 
Liquid-phase microextraction approaches combined with atomic detection: A critical review 2010 [285] 
Review of environmental fate and toxicities of ionic liquids 2010 [286] 
Recent developments and applications of microextraction techniques in drug analysis 2010 [287] 
Solid-phase microextraction in bioanalysis: New devices and directions 2010 [288] 
Protocol for solid-phase microextraction method development 2010 [289] 
Recent developments in matrix solid-phase dispersion extraction 2010 [290] 
Recent developments in solid-phase microextraction 2010 [291] 
Recent advances in applications of single-drop microextraction: a review 2011 [292] 
Liquid-phase and dispersive liquid–liquid microextraction techniques with derivatization: recent 
applications in bioanalysis 
2011 [293] 
Dispersive liquid-liquid microextraction 2011 [294] 
Recent advances in SPME techniques in biomedical analysis 2011 [295] 
Review: comprehensive sampling and sample preparation for biological and medical applications 2012 [296] 
Review: recent advances in coupling single-drop and dispersive liquid–liquid microextraction  2012 [297] 
Single-drop microextraction as a powerful pretreatment tool for capillary electrophoresis: a review 2012 [298] 
Trends in liquid-phase microextraction, and its application to environmental and biological samples 2012 [299] 
Solid-Phase Microextraction in Perspective 2012 [300] 
Single-drop microextraction for bioanalysis: present and future 2013 [301] 
Review: automation of solvent microextraction techniques 2013 [302] 
Advances in solvent-microextraction techniques: a review 2013 [303] 
Perspective: Hollow fibre liquid-phase microextraction – principles, performance, applicability, and 
future directions 
2013 [304] 
Recent developments and future trends in solid phase microextraction techniques towards green 
analytical chemistry 
2013 [305] 
Review of liquid-phase microextraction techniques based on ionic liquids  2014 [306] 
Review of ionic liquid-based microextraction techniques for trace-element analysis 2014 [307] 
Review: recent developments of liquid-phase microextraction techniques  2014 [308] 
Review of derivatisation approaches using solvent microextraction techniques 2014 [309] 
Applications of liquid-phase microextraction techniques in natural product analysis: a review 2014 [310] 
Application of solid-phase extraction for trace elements in environmental and biological samples: a 
review 
2014 [216] 
Review of solvent microextraction techniques theory and practice text 2015 [311] 
Sample preparation with solid phase microextraction and exhaustive extraction approaches: 
Comparison for challenging cases 
2015 [312] 
Application of molecularly-imprinted polymers in solid-phase microextraction techniques 2015 [313] 
Recent Developments and Applications of Solid Phase Microextraction (SPME) in Food and 
Environmental Analysis—A review 
2015 [314] 
New developments in microextraction techniques in bioanalysis. a review 2016 [315] 
Modern trends in solid-phase extraction: new sorbent media 2016 [280] 
Strengths and weaknesses of in-tube solid-phase microextraction: A scoping review 2016 [316] 
A review on procedures for the preparation of coatings for solid phase microextraction 2016 [317] 
Review of microextraction techniques for forensic drug analysis in saliva 2017 [318] 
Liquid-phase microextraction of biomarkers: a review on current methods 2017 [319] 
Ten years of dispersive liquid–liquid microextraction and derived techniques 2017 [320] 
Microextraction and its application to forensic toxicology analysis 2017 [321] 
Review of geometries and coating materials in solid phase microextraction: Opportunities, limitations, 
and future perspectives 
2017 [322] 
Advances in Solid Phase Microextraction and Perspective on Future Directions 2018 [323] 
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2.5.1 Liquid-phase microextraction (LPME) 
Liquid-phase microextraction (LPME) was industrialised in 1989 to minimise the 
volume of organic solvent and matrix to the microlitre scale [324] and to reduce 
the disadvantages of LLE [287, 325]. LLE is time and solvent consuming, forms 
emulsions and no automation can be achieved. The exposure to large amounts of 
toxic solvents can cause the following; increased waste, decreased safety, more 
negative impacts on health and the environment. For solving or reducing the above  
effects, liquid microextraction (miniaturisation) methods have been introduced 
[325, 326]. Liquid-microextraction or liquid-phase microextraction techniques 
(LPME) can be classified [327] as follows (Figure 2-6):  
 
Figure 2-6: The classification of liquid-microextraction techniques 
2.5.1.1 Single-drop microextraction technique (SDME) 
In SDME, a single drop of the organic solvent (sized 1-10 µL) is placed on the tip of 
a syringe and then introduced in the matrix for extraction. The syringe withdraws 
the extraction contents to directly inject into the instrument for analysis. The 
hand-operated system, formation of air bubbles and losing the single drop of 
solvent from the needle have kept this technique from being widely used in 
Liquid 
microextraction 
techniques 
Solvent-liquid 
microextraction 
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microextraction-two 
phase 
- Directly suspended drop [212]
- Direct immersion [213]
- Continuous flow [214]
- Drop-to-drop [215]
Single-drop 
microextraction-three 
phase 
- Simultaneous solvent microextraction with 
back-extraction [216]
- Head space [217]
- Liquid liquid lquid microextraction [173]
Dispersive liquid liquid microextraction [188, 218-220]
Solvent bar microextraction [349]
Membrane 
assisted 
microextraction 
Film membrane
or 
Tube membrane
- Membrane bag [221]
- Hollow fiber [222]
Steady state 
exhaustive 
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- Flat sheet membrane [223] 
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laboratories [325].  SDME is used for the extraction of the analyte through either 
two (organic solvent and donor phases) or three phases (here, the back extraction 
in the acceptor phase is included). SDME use a non-exhaustive technique for 
extraction. SDME use as either a static approach (direct immersion) or a dynamic 
approach (headspace). After the extraction processes, the micro drop of acceptor 
phase (extraction phase) is suspended by the syringe, and then analysed using 
quantitative instrumentation methods such as GC−MS or HPLC [284, 324, 325]. 
Although SDME is simple, cheap, rapid and in micro-scale, the method is not 
suitable for the complex matrices, unionised substances and any substance not 
sensitive to pH [284, 324, 325]. 
There was no extensive study in the literature that showed the strength of the 
method for the analysis. For example, no study was published when used for 
quantification purposes in forensic toxicology samples. Most applications of the 
method were covered with water, oil, wine and juice samples. The reasons for the 
limitations in using the method on complex matrices resulted from: instability of 
solvent, drop dislodgment, the formation of air bubbles, extra care required 
during extraction, the filtration necessary and the time required for stirring. These 
factors showed that the negative impacts outweighed the positive for its 
suitability to be used in a routine procedure [311, 325, 326]. 
2.5.1.2 Single-drop-liquid-liquid-liquid microextraction (SD-LLLME)  
LLLME was designed for ionisable substances that must have three phases: sample, 
organic and acceptor. The three-phase LLLME has two modules. The first module 
occurs in the organic phase that can be placed as a single drop onto a top of the 
sample phase to form a solvent membrane or into a porous hollow fibre 
membrane. The second module occurs in the acceptor phase, and it can either be 
placed into the hollow fibre membrane via microsyringe, or it can be withdrawn 
from the single drop after it is formed into the solvent membrane [187]. The main 
drawback of three-phase SDME is that the target analytes are extracted twice in 
the procedure (the first one in the organic phase, and the second in the acceptor 
phase) and as a result, the extraction efficiency can be low. However, this may 
not always be the case; for example, the efficiency factor (EF) increased from 500 
to 730 when the three phases microextraction system in SD-LLLME was used for 
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weakly basic compounds (amphetamine and methamphetamine) in urine samples 
combined with HPLC–UV detection [187]. The urine sample in the donor phase is 
adjusted to a strong basic state using NaOH for ionisation and protonation of the 
basic amines. The single drop of solvent was then transferred into the sample 
solution using stirring assistance and a hot plate to complete and promote the 
extraction. The basic amines were protonated in the back-extraction phase (acidic 
acceptor phase) and yielded charged species that had a weak affinity for the 
organic solvent phase. The total products in this procedure produced a high EF 
because the volume ratio of analytes in the donor and acidic acceptor phases were 
large [284, 328]. Another study was performed using three-phase SD-LLLME with a 
CE instrument in human urine for chiral analysis of amphetamines. The weakly 
basic amine drugs were treated by adding NaOH in the donor phase. A single drop 
of the acidic acceptor phase was covered by an octanol layer to separate the 
different pH donor and acceptor phases. These processes were used to 
concentrate the basic analytes into the acceptor phase drop. The (+)-(18-crown-
6)-tetracarboxylic acid was selected for the separation of enantiomers amines, 
and the result was an EF increasing 1000-fold with a 0.5 ng mL-1 LOD for 
amphetamine [196].  
2.5.1.3 Headspace-single-drop-liquid-liquid microextraction (HS-SDLLM) 
HS-SDLLM or headspace in a single-drop microextraction technique (HS-SDME) 
technique is similar to headspace solid-phase microextraction (HS-SPME) but the 
fibre in SPME is replaced with a single micro-organic solvent drop. This provides a 
significant advantage for this method. After the optimisation of the method, it 
can be automated with an autosampler system like SPME [196]. In addition, the 
headspace mode in SDME is used as an alternative to DI-SDME because the solvent 
in DI-SDME may dislodge from the tip of the syringe during the direct immersion. 
HS-SDME was developed for the extraction of analytes in biological samples to 
avoid contamination. The method was developed for the extraction of acetone, 
hexanal, heptanal, anisaldehyde isomers, amitriptyline, nortriptyline, isomers of 
12 non-hydrolysed amino acids, short-chain fatty acids and the lung cancer 
biomarkers in urine and blood plasma using GC–MS [329-334].  
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2.5.1.4 Drop-to-drop technique 
Drop-to-drop technique is one form of SDME technique exclusively used for the 
analysis of limited volume matrices; for instance, if the volume of the urine sample 
is in microscale. Less than 30 µL of blood, serum and urine were successfully 
extracted using this method, providing excellent LOD. 30 µL of patient plasma was 
used for the extraction of β-blocker drugs by adding 5% NaCl (pH 11) (w/v) and 
drop to drop of toluene (1.8 µL) on the tip of a 10 µL syringe. The acceptor phase 
was suspended and deposited into another vial for analysis of β-blocker using 
matrix-assisted laser desorption/ionisation MS (MALDI-MS). The extraction 
efficiency of the method was low compared to traditional exhaustive methods, 
such as SPE technique, because the recoveries after using the technique were ten-
fold less than the unextracted recoveries in similar matrices and drugs [335]. The 
extraction of nicotinic acid in urine specimens used a similar technique, procedure 
and instrument [336]. The conclusion illustrated the expediency and purification 
of the method for extraction from microlitre volumes of known drugs in complex 
matrices [311].  
2.5.1.5 Directly suspended drop 
The directly suspended drop with melting liquid technique was developed for the 
extraction of chlorpyrifos (the pesticide chlorpyrifos is very potent and causes 
neurotoxicity) and its metabolites in urine samples [337]. Due to the popularity of 
using the pesticide, the study provided an efficient, simple, sensitive and cheap 
technique for medical laboratories to examine this pesticide. 5 mL of urine was 
filtered and mixed with 10 µL of 2-dodecanol at 800 rpm and 70°C for 40 minutes. 
The vial was then placed in a freezer until the drop became solid (10 minutes was 
sufficient). The solid drop (acceptor phase) was transferred and centrifuged for 
melting and separation purposes using a conical vial (the conical vial was used for 
the separation of the acceptor phase from the remaining water content). The 7 
µL of extracted content (bottom layer) was taken and analysed by GC−MS.  
2.5.1.6 Continuous flow droplets 
Continuous flow droplets was a low-cost technique developed by integrating the 
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microfluidic device with the waveguide mid-IR optical detector for the extraction 
of cocaine from human saliva specimens [338]. The flow droplets of 
perchloroethylene and saliva were continuously passed through the waveguide 
channels of the microfluidic extractor method for cocaine analysis. The flow rate 
of droplets was 5 and 20 µL min-1 for perchloroethylene and saliva, respectively. 
The validity of the method was not apparent as the cocaine was only tested when 
it was spiked in saliva in high concentrations (500 µg mL-1).  
2.5.1.7 Dispersive liquid-liquid microextraction (DLLME) 
DLLME was used to avoid the above-mentioned drawbacks specifically when 
solvent microextraction methods are applied in complex matrices. DLLME was 
invented by Assadi et al. in 2006 [339]. It is cheap, fast and delivers high extraction 
efficiency with great recovery. However, the technique is difficult to install and 
automate [303, 340, 341]. The mixture of the extraction and solvent contents is 
quickly injected by high turbulence to form small droplets. As a result, a cloudy 
extracting system is formed when the surface area increases. After centrifugation, 
the solvent appears in the bottom of the tube for collection. For instance, DLLME 
followed by HPLC-UV detection were used for the extraction and examination of 
cannabidiol, Δ9-tetrahydrocannabinol and cannabinol in urine specimens. The 
method was effectively applied for the analysis of three male positive urine 
samples, and it offered great recoveries [342]. A similar extraction method 
combined with the solidification of a floating organic drop was applied for the 
detection of amphetamine and methamphetamine in human urine using HPLC-UV 
[343].  
2.5.1.8 Solvent-bar microextraction (SBME) 
SBME is demonstrated in Figure 2-7. Most papers show similar experimental design 
for the development of solvent-bar extraction procedures in biological matrices. 
The main differences between studies were in the experimental processing design 
or the type of solvent used (differences in pH, extraction time, stirring rate, ionic 
strength, the temperature in the extraction step and matrix volume). These 
parameters played a significant role in increasing the extraction efficiency, and 
the selectivity and sensitivity of the method. These parameters are not only used 
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for SBME, but are also fundamental for developing sample preparation methods, 
especially for non-exhaustive techniques, such as LPME and SPME.  
SBME was optimised for the determination of tramadol in plasma and urine using 
GC−MS. The experimental parameters optimised were: extraction time, solvent 
type, pH, the volume of contents, ionic strength and stirring rate. They were 
optimised using a box–Behnken and a plackett–Burman system. The hollow-fibre 
membrane (1.5 cm segments) was cleaned and one end in the membrane was 
sealed. 4 µL of n-nonanol solvent was suspended in the microsyringe. The needle 
was inserted into the hollow fibre through the open hole to introduce the organic 
solvent for 20 seconds, and then the end was sealed. Next, the solvent bar (SB) 
was immersed in the matrix (12 mL) for extraction. The SB was the removed from 
the fibre and withdrawn into a microsyringe for analysis. LOD was 0.02 μg mL-1, 
and the RSD was 4.5%. The data was reported using plackett–Burman screening 
design, ANOVA and Pareto charts. The pH, stirring rate and extraction time were 
the most significant parameters that increased the extraction efficiency of a 
target analyte. No significant effect on the extraction efficiency was observed 
when the ionic strength and temperature of the extraction step were modified 
[344].  
 
Figure 2-7: The experimental design of SBME 
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2.5.1.9 Hollow-fibre membrane liquid-phase microextraction (HF-LPME) 
HF-LPME is derived from membrane assisted-microextraction techniques for the 
extraction of target analytes in different matrices. Some of the disadvantages of 
solvent microextraction techniques were avoided using hollow fibre LPME (HF-
LPME). It was invented by Pedersen et al. in 1999, is convenient and cheap, and 
prevents organic solvents from being lost [345]. The method has two models: the 
hollow fibre film membrane and the hollow fibre in tube membrane [310, 346]. It 
was reviewed in terms of its application in [287, 299, 345, 347]. The extraction 
efficiency, recovery, extraction speed, enrichment factor, application and 
selectivity of HF-LPME coupled with the instruments of capillary electrophoresis, 
capillary gas chromatography, HPLC were reviewed by Rasmussen and Pedersen, 
where it was found that the HF-LPME can provide an excellent clean technique 
with high extraction efficiency for pre-concentration target analytes [348].  
Most articles on the HF-LPME method used urine and plasma matrices. There were 
few studies showing HF-LPME in whole blood. Polypropylene (PP) fibre was the 
most commonly used fibre, followed by polyvinylidene fluoride (PVDF) and 
polyethersulfone fibres, respectively. Cocaine and its metabolites in urine were 
extracted using the two fibres, and the PP fibre provided more reproducible 
results than the PVDF fibre [349]. Another study showed irreversible results, due 
to the specification of the fibres used [350]. Using HF-LPME in complex matrices 
required hard work in development to obtain the desired results. For example, 
the extraction of ATS and barbiturates in hair and liver samples used three-phase 
HF-LPME in [327, 351].  
2.5.1.10 Electro membrane extraction (EME) 
EME is also another form of LPME. It is a recent technique that has been used in 
the electrical field. It initially appeared in 2006. The review and development of 
this technique were discussed in [352-354]. According to Huang et al. [354] there 
are more than 100 papers published on EME. 
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2.5.2 The applications of LPME used for the extraction of SC 
LPME was reviewed in terms of its application in [287, 299, 347]. The detection of 
cathinone and five other drugs of abuse was investigated by Jamt et al. [355]. The 
study used electro membrane extraction and LPME methods by UPLC-MS-MS with 
MRM in forensic blood samples. The samples were collected from three forensic 
autopsy cases and authors used a supported-liquid membrane containing 1-ethyl-
2-nitrobenzene. The supported-liquid membrane provided an effective barrier by 
segregating the macromolecules and acidic substance in the sample. When the 
electric field was applied, only the cationic compounds were efficiently removed 
across the membrane. The procedure produced clean extracts using LC-MS for 
detection. When 15 V was applied across the SLM with an extraction time of 5 
minutes, 10-30% of recovery was achieved. The results obtained were in 
conformance with the results of the analysis conducted using conventional sample 
preparation methods, such as LLE. The LOD was between 40 and 2610 pg mL-1, and 
the linearity was between 10 and 250 ng mL-1. 
2.5.3 Solid-phase microextraction (SPME) 
SPME was used for the first time in 1989 by Pawliszyn and colleagues. It was used 
to reduce the amount of solvents and samples on the microlitre scale when 
analysing water pollutants [356]. The method is used as a sample preparation 
method for known and unknown drugs in matrices for screening and confirmation 
determinations. SPME is easy to employ, allowed for rapid screening and minimum 
contact with the toxic solvents. It can be both manual and automated, is sensitive, 
efficient and reduce the time required for the extraction and its cost [287]. It is 
highly efficient for screening purposes due to its speed and ease of use. The 
problems of sample loss, contamination and dilution are avoided using this 
technique. The main functional differences between SPE and SPME are that SPE 
relies on exhaustive extraction technique whereas SPME relies on the equilibrium 
reaction between the analytes and the stationary phase [357]. There are two 
modes commonly performed: Headspace (HS-SPME) and Direct Immersion (DI-
SPME). HS-SPME is appropriate for the analysis of highly volatile compounds, 
simple and complex liquid matrices. DI-SPME is suitable to compounds with high 
polarity, low-to-medium volatility compounds, gas or simple liquid matrices, and 
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it can be immersed in any liquid sample [287, 356-358]. SPME is classified into two 
main categories [295, 359, 360]; see the Figure 2-8.  
 
Figure 2-8: The classification of SPME 
2.5.3.1 The SPME fibre 
The SPME fibre has been successfully employed for the extraction of forensic 
toxicology samples. It is a basic syringe device consisting of three main 
components: micro-tubing for holding the fibre, the needle and the septum.  
The history, fundamentals and development of SPME fibre were stated in three 
books by Pawliszyn et al. [202, 361] and Moldoveanu et al. [362].  Fibre coatings 
can be applied using fused silica with an appropriate stationary phase coupled 
with a device, such as polydimythyl silocoxane (PDMS), carboxen (CAR) /PDMS, 
PDMS/ divinylbenzene (DVB), polyacrylate (PA), carbowax (CW), CW/ templated 
resin (TPR), immunoaffinity fibre, alkyl-diol-silica (ADS) fibre, sol-gel fibre, 
molecularly imprinted polymer (MIP)-coated fibre, silica particle coated fibre and 
multi-carbon-tape fibre (thickness between 7–100 μm) [288, 295, 359]. The 
optimisation of the method and selecting the right coating are crucial. Fibre 
•SPME fiber
•Stir bar sportive extraction (SBSE)
•Thin film microextraction (TFME)
Sample stir microextraction
•In-tube SPME
•Coated capillary
•Sorbent packed capillary
•Fiber packed capillary
•In-needle SPME 
•Solid phase dynamic extraction
•Microextraction in a packed syringe
•Fiber packed needle microextraction 
•In-tip SPME
•Sorbent packed tip
•Fiber packed tip
Sample flow microextraction
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selection is based on the physical and chemical properties of the coating and 
analytes, including volatility, polarity, the thickness of fibre [202, 288]. The key 
drawbacks are that the fibre gets broken-up easily and it is expensive. Fused silica 
fibre is used in both SPE and SPME techniques. The fibre in SPME is enclosed in a 
stainless-steel casing in order to avert mechanical damage when the septum is 
being pierced.  
In HS-SPME, the SPME needle penetrates the septum cap, causing the SPME fibre 
to be exposed to the space above the sample. The sample vial is sealed, agitated 
and incubated to increase the movement of analytes in the space above the matrix 
until dynamic equilibrium is achieved. This process leads to the absorption of the 
gaseous analytes onto the fibre phase. Once optimum conditions are applied, and 
equilibrium reaction is reached, the fibre containing the absorbed analytes is 
withdrawn enclosed in its shielded steel casing. The needle can then be removed 
from the sample vial and enters the GC injection port for desorption of the 
analyte. The analytes are then released thermally from the fibre in the injector 
port and remain concentrated on the top of the GC column.  
Direct Immersion (DI) SPME is similar to HS-SPME but differs in the way the fibre 
is exposed. In DI SPME, the SPME fibre is immersed in the liquid sample matrix 
[202, 363-365]. There are a number of factors influencing the sensitivity and 
efficiency of SPME, and a number of operational parameters must be developed 
in order to maximise affinity between the coating fibre and the analyte. These 
parameters include the type and thickness of the coating fibre, pH, ionic strength, 
agitation of sample, salts, temperature, extraction and desorption time and 
speed. It is essential that these parameters are optimised to attain the required 
LODs and recoveries for the detection of the target analytes [202].  
2.5.3.2 Stir-bar sorption extraction (SBSE) 
SBSE is a form of SPME. The method was reviewed in [282, 305, 366-373]. The most 
significant indicator showing that SBSE has advantages over other sorbent 
microextraction methods is the sheer volume of papers published, with over 1000 
scientific papers published in the last decade alone. Hundreds of papers were 
published on the advantages and applications. Good examples of SBSE-PDMS 
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applications are the analysis of target substances in the areas of forensics, 
pharmaceuticals, food, natural products and biomedicine. The complex matrices 
can strongly affect the efficiency of SBSE, which could yield low recovery and 
increases interferences. Therefore, the optimisation of the method is crucial, and 
validation should be performed to confirm the target analyte behaviour and to 
avoid any possibility of interference. In some cases, the standard addition can be 
added to compensate the matrix effect. SBSE-PDMS was found to be a remarkable 
sorption-bar microextraction for polar solutes, volatile to semi-volatile, non-polar 
and medium polar compounds in different matrices. The direct immersion SBSE 
linked with the in-situ derivatisation was applied for the detection of forensic 
toxicology and biomedical samples [374].  
SBSE was developed for the extraction of steroid sex hormones from the urine of 
pregnant women using HPLC- diode array detection [375]. The novelty of the work 
was the use of the polymethacrylic acid stearyl ester-ethylene dimethacrylate as 
the sorbent in SBSE. The development parameters were performed before 
validation. The LOD and LLOQ were (0.062–0.38) and (0.20–1.20) ng mL-1, 
respectively. This new technique can efficiently extract polar analytes in the 
monolithic material copolymerization of methacrylic acid stearyl ester in SBSE 
with a solvent of a porogen mixed with 1-propanol and 1,4-butanediol, with 
methanol used for desorption.  
The extraction of dimethyl trisulfide (used to treat cyanide poisoning) using SBSE-
PDMS and GC−MS in rabbit whole blood was fully validated with an LOD of 0.06 μM, 
RSD of 10% and bias of 15% [376]. Another similar technique was used for direct 
immersion fabric phase sorptive media coated and sol-gel poly (ethylene glycol) 
(sol-gel PEG) for the extraction of benzodiazepines in human serum using HPLC-
diode array detection. The recovery was 27% for bromazepam, 63% for lorazepam, 
42% for diazepam and 39% for alprazolam [377]. Five fluoroquinolones were 
extracted by graphene oxide-polyethyleneglycol SBSE and sol-gel techniques using 
an HPLC-fluorescence detector in chicken muscle and liver. This method achieved 
great results for polar and less polar substances [378]. SBSE was used for the 
extraction of three β2-agonist residues in pork [379],  the analysis of 
pharmaceutical drugs and metabolites in urine [380], pulmonary tuberculosis 
drugs [381] testosterone and epitestosterone in human urine samples [382], and 
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glyoxal and methylglyoxal in-situ derivatisation [383].  
The SBSE-PDMS coupled with HPLC-FLD (fluorescence detection) was developed 
for the determination of serotonin reuptake inhibitors (fluoxetine, citalopram and 
venlafaxine–norfluoxetine, desmethyl, didesmethylcitalopram, o-
desmethylvenlafaxine and some active metabolites) in plasma and brain tissue 
(male and animals) [384]. Matrices were mixed in 1 mL of borate buffer (pH = 11, 
0.1 M). The contents were put in 4 mL vial with a stir bar (1100 rpm for 30 minutes 
at 75°C). The stir bar was removed before the desorption stage, then cleaned with 
distilled water and tissue. The method was optimised as follows: 300 μL of 
acetonitrile were used in 15 minutes of desorption. 300 g L−1 NaCl was the ionic 
strength and extraction time was 30 minutes. The method showed excellent 
sensitivity and selectivity over three matrices. Caffeine and its metabolites were 
extracted using the alkyl-diol-silica coating and restricted access material in SBSE 
of rat plasma using HPLC-UV. The procedure used immobilisation material coating 
and was complicated by many steps over a long period of time; hence, the 
extraction efficiency showed that the method could be repeated 50 times with 
minimum loss of the target analytes. LOD was 25 ng mL-1 [385].  
2.5.3.3 Thin-film microextraction (TFME) 
The theory and applications of TFME were reviewed in [386]. TFME was introduced 
to increase the thickness of the stationary phase and the coated material. 
According to the theory, the sensitivity of the technique enhances when the area 
(thickness of the coated device) and the volume of the sample are large. 
Increasing the thickness of the device coating extended the reaction and 
equilibrium time. This cannot be achieved using the SPME fibre techniques, due 
to the small space (diameter) of the SPME needle [387]. 
2.5.3.4 In-tube SPME 
In-tube SPME was reviewed regarding its development and application by Kataoka 
and Hiroyuki [388]. It was used online for organic compounds in liquid samples 
that were typically connected with the autosampler of HPLC or LC-MS. The 
extraction and concentration of the sample was monitored through the stationary 
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phase of the capillary column using an exposed tubular fused-silica by repetitively 
drawing and ejecting the sample matrix. It is a cheap, automatable, solvent-free 
and fast technique applied to medicine, forensic, food and environment matrices. 
2.5.3.5 In-tip SPME 
SPME tip or SPME pipette tip was used for the first time in 2011 for drug analysis 
by Xie et al. [389, 390]. It was developed and validated with derivatisation for the 
examination of vitamin D3 using HPLC–MS-MS methods in human serum. The tips 
were coupled with the handling automation system and delivered a new sample 
preparation method for routine drug analysis. The fibre in tips can be coated in 
fibres that were usually applied in traditional SPME fibre, such as PDMS. The 
disposable tips were used for eliminating the carryover effect and precondition 
steps that are normally seen in the traditional SPME fibre technique. The 
technique provided accuracy and precision with a simple, convenient, fast and 
high throughput method.  
2.5.3.6 General application of SPME  
The application of SPME has been reviewed in biological samples and forensic 
toxicology fields in several papers [281, 295, 317, 359, 391-393]. The recent 
development of microextraction techniques and application in drug analysis has 
been reviewed in [295, 359, 391-393].  
In general, SPME has been widely used as the extraction method in various 
matrices without issue, except for its application in whole blood. Whole blood 
contains large macromolecules, metabolites, parent products, proteins, platelets, 
phospholipids and cellular components. These components co-elute and interfere 
with known or unknown drugs, producing matrix effects. In forensic cases, the 
preferred post-mortem specimens sample is whole blood collected from the 
femoral veins as the sample remains unchanged for long periods after death [394]. 
There are limited studies that show the proper coating available to isolate the 
target analytes in whole blood. Hence, the use of polyacrylonitrile coating fibre 
in direct immersion with the C18 phase for the analysis of benzodiazepines in 
whole blood has been tested using liquid chromatography-tandem mass 
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spectrometry [395].  
Recently, in 2018, SPME was used in the transmission mode device made from 
polyether ether ketone mesh for the determination of drugs of abuse in urine and 
oral fluid via direct analysis in real time tandem mass spectrometry. The method 
could be used in workplace or roadside for rapid screening [396]. A new method 
of unknown organic iodine was developed in microvolume using in-tube SPME and 
nanospray high-resolution mass spectrometry (HR-MS). The new scheme was a 
combination of in-tube and nanospray HR-MS, and was confirmed using iodine in 
urine. The unknown compound C12H23O11I was identified in human milk, and the 
method also can be used for the detection of unknown compounds by interpreting 
fragmentation ions [397].  
2.5.4 The applications of SPME on the extraction of SC 
The selected application of SPME for the extraction of SC is illustrated in Table 
2-8 and for whole blood [140, 143, 207, 213, 215, 237, 239, 355, 398-402], plasma 
[206, 236, 403], serum [140, 215, 238], hair [143, 211, 214, 404-408], oral fluid 
[241, 252]  and urine [108, 122, 140, 210, 409-416]. Various instruments were used 
for the detection of SC, in GC−MS or GC−MS-MS [108, 122, 143, 146, 404, 416-419], 
LC-MS or LC MSMS [122, 125, 143, 206, 214, 233, 403, 415, 420, 421], nuclear 
magnetic resonance (NMR) [44, 45, 419, 422], HPLC [423] and Fourier transform 
infrared spectroscopy (FTIR) [422].   
LaPointe et al. [413] examined three cathinones and three of metabolites in urine 
using direct analysis in real time mass spectrometry (DART-MS). The work was 
performed for the development and validation of SPME as a rapid screening 
method with no internal standards added as well as no corrections, extraction, 
derivatisation and sample preparation used. The fibres of SPME were developed, 
coated with 200 µm of C18, 200 µm of PDMS/DVB and a strong cation exchange 
resin. PDMS/DVB provided higher peak area responses for the metabolites of 
cathinones than C18 and vice versa for cathinones. The downside of this study was 
that the validation of the method was not performed. 
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Saito et al. [398] evaluated four types of fibres to analyse whole blood in a fatal 
poisoning case for the detection of α-PVP, MDPV and PV using GC−MS. The favoured 
extraction fibre was 65 µm PDMS/DVB; the fibres were used under similar criteria 
and conditions. The development parameters were evaluated based on pH, 
temperature and the extraction time. Method validation was performed, LOD and 
LOQ were (0.5 -1) and (1-10) ng mL-1, respectively, and precision and bias were 
9.5 and 9.8%, respectively. The recovery was 5%. Although the quantification 
method was achieved, no other identical samples were tested to ensure similar 
results were obtained.  
2.5.5 Other microextraction techniques 
Ultrasound-assisted emulsification microextraction is a sensitive, selective, 
effective and reliable method [424]. It was applied to pesticide, pollution and 
water samples [425]. Carbamazepine and amphetamines were detected using GC-
FID in biological samples [244, 426]. Micro pulverised extraction technique was 
used for the detection drugs of abuse in hair or nails in [427-429]. However, there 
was no paper on the detection of SC by applying the above two methods. 
2.5.6 Conclusion 
In this chapter, SC and ATS are discussed in terms of their history, prevalence, 
chemical structures, metabolites, pharmacology, toxicology, administration, fatal 
cases and legal status. The chapter also involves review for the most preparation 
methods used in forensic toxicology laboratories. The review includes more than 
46 techniques, most of them are related to the one from the following: solid-phase 
extraction, liquid-liquid extraction and microextraction techniques such as solid-
phase microextraction and liquid-phase microextraction. General applications, 
advantages, and disadvantages of each were briefly discussed with linking in 
somewhat their uses in forensic toxicology. Sample preparation methods applied 
to SC are also reviewed and discussed. In the next chapters, some of these are 
developed and applied to the selected substances.    
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Table 2-8: SPME applied to SC 
Name of Drugs Matrix Type of coating Extraction 
mode 
Instrument 
name 
Ref. 
3,4-dimethylmethcathinone (3,4-DMMC), 3,4-DMMC metabolites, 
4-EMC, β-hydroxy metabolite of pentedrone, 2-
methylmethcathinone, mephedrone metabolite (β-hydroxy) 
Urine C18, PDMS/DVB and a 
strong cation 
exchange resin 
Automated sit between the 
DART source and the mass 
spectrometer inlet 
DART-MS [413] 
Butylone, diethylpropion, flephedrone, mephedrone, 
methedrone, MDPV, methylone, and naphyrone 
Oral fluid PDMS/PA HS-SPME and DI-SPME GC−MS [430] 
MDPV and α-PVP  Blood PDMS/DVB HS-SPME GC−MS [398] 
Some synthetic cathinones and some other NPS for screening   Hair Not mention Not mention LC- TMS [408] 
4-FMC, α-PVP, MDPV and 11 NPS Liquids, 
powders and 
herbs 
PDMS DH-HS-SPME GC−MS [431] 
Abbreviations: MDPV (methylenedioxypyrovalerone), α-PVP (α-pyrrolidinopentiophenone), PDMS/DVB (polydimethylsiloxane/divinylbenzene), PA (polyacrylate), DART-MS (direct analysis in real time mass 
spectrometry), HS-SPME (head space-solid phase microextraction), DI-SPME (direct immersion-solid phase microextraction)
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3. Investigation of derivatisation agents for determination 
of synthetic cathinones using gas chromatography–
mass spectrometry 
3.1 Introduction 
Immunoassay methods traditionally used for screening purposes in forensic 
toxicology specimens have not proven effective for the detection of SC 
compounds. ATS or SC immunoassays such as Randox DOA−V assay or 
(methcathinone/mephedrone) kit [432, 433] often do not detect a wide range of 
ATS or SC, due to how fast design drug stimulants with variety of chemical 
structures that appears in the recreational illegal market. Some SC produce false- 
negatives, false-positives or even cross reactivity in immunoassays with high 
variability between manufacturer kits [433-435];  for example, de Castro et al. 
stated that SC have obtained cross reactivity with ATS compounds, such as 
amphetamine and MDMA [233]. A variety of structural SC substances presents the 
need for chromatographic mass spectrometry, not only for screening but also for 
confirmation determination. 
The GC−MS is desirable because no cutoffs have been mandated by the government 
for screening and confirmation of SC in all matrices, and due to the popularity of 
GC−MS in forensic toxicology, it was used in this study. 
3.1.1 Gas chromatography – mass spectrometry (GC−MS)  
Chromatography was invented by Mikhail Tsvet in 1905 during research on 
chromatographic adsorption analysis. Martin and Synge suggested the use of 
partition chromatography between gas and liquid in 1941. The first GC detector, 
capillary column and mass spectrometry were invented by James and Martin, 
M.J.E. Golay and Gohlke et. al in 1952, 1957 and 1959, respectively [436-440].  
The general principle of GC is very simple: a volatilised substance is injected into 
the injector port for transforming the phase from liquid to gas by increasing the 
temperature. The volatile compound travels from the injector port into the 
column carried by a mobile phase (carrier gas). The column contains a stationary 
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phase (silica particles- these are not analysed) that interacts with the analytes 
during mobilisation. The different analytes reach the detector at different times 
based on the physical and chemical properties of those phases and analytes. These 
compounds all detected as peaks in the chromatogram.  
The fragmentation of analytes occurs in a mass detector after the ionisation of 
molecules by one of the following methods: electron ionisation (EI), chemical 
ionisation, electrospray ionisation, fast−atom bombardment, 
atmospheric−pressure chemical ionisation or matrix−assisted laser desorption 
ionisation [441, 442]. The technique most often used in forensic toxicology 
laboratories is EI, and accordingly, it was used in this project. In EI, the analyte 
passes through the interface line into the ionisation chamber, where a stream of 
high energy electrons from a heated filament in the ion source (typically 70 eV) 
bombards the molecules of the analyte. The molecules are then positively charged 
and lose an electron (see Equation 3−1). In the repeller, lenses are focused on 
the positively charged molecules before the mass detector. Finally, an analysis is 
conducted by the mass detector and associated software [442, 443].  
𝑀 + 𝑒− → 𝑀+ + 2𝑒−  
Equation 3−1: The EI of a molecular ion (parent ion) [443] 
Each volatile and non−polar compounds can be detected by GC−MS without the 
need for derivatisation, whereas detection of polar compounds can be improved 
using the derivatisation agents. The interpretation of fragmentation ions of a 
compound is crucial in forensic laboratories. Scan mode can be used to produce a 
total ion chromatogram, which is mostly used for the detection of unknow 
compounds or to study interferences. Alternatively, selective ion monitoring (SIM) 
mode can be used in routine work for the detection of target analytes. 
Interpretation of fragmentation patterns of known or unknown compounds 
depends upon the scope of the analysis; for example, the study of fragmentation 
patterns of unknown compounds should match a library (such as National Institute 
of Standards (NIST)) and should present sufficient knowledge of the mass 
spectrum.  
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3.1.2 Derivatisation reagent, SC and GC−MS analysis 
The derivatisation reagent is a compound that is used to chemically amend an 
analyte to yield a new substance which is suitable for GC−MS analysis. GC methods 
are designed for the detection of volatile and compounds with low-to-medium 
polarity compounds, and derivatisation reagents may be used to improve the 
volatility and decrease the polarity of the mixtures. Derivatisation for the analysis 
of xenobiotics and drugs of abuse in matrices using GC have been comprehensively 
discussed and reviewed [444-447]. 
In forensic toxicology, the most derivatised functional classes of molecules are 
hydroxyl−groups, aminoalkenes and carboxylic acids. In general, alkylation, 
acylation and silylation reactions are the most commonly used techniques in 
GC−MS, but the reagent techniques most widely used in forensic toxicology are 
acylation and silylation. The acylation reaction is dominant and effective for ATS 
and SC, using acetic acid anhydrides, acid halides or fluorinated anhydrides such 
as PFPA, TFA and HFBA. Active hydrogen presents in cathinones (−NH), is 
submitted to the acylation reaction where the cathinones are converted into 
amides. Hence, tertiary amines lack the active hydrogen necessary to complete 
the reaction because of the presentation of the benzene ring instead of a hydrogen 
substance [448]. The reactions included in this study are summarised in Figure 
3-1.  
The GC−MS analysis of SC mostly involves the usage of derivatising agents to 
improve suitability (by modifying the chemical structure of the SC), efficiency (by 
improving the peak resolution and reducing interference or co−elution) and 
detectability (by increasing the sensitivity and producing multi fragmentation 
patterns or more mass ions in the detector) [449]. To choose suitable 
derivatisation reagents for GC−MS analysis, the following criteria should be 
considered as guidelines [449]:  
a) More than 95% of complete derivatives should be produced by reagent. 
b) The new derivative products that result from the reaction should not rearrange 
or alter the structure of the compound during formation of the derivative. 
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c) The sample should not be lost during the reaction. 
d) The derivative compounds should not interact with the column in GC. 
e) The derivatives should be stable over time.    
                                       
 
 
Figure 3-1: Acylation of primary, secondary and tertiary SC using PFPA (1), TFAA (2), PA (3), 
CLF2AA (4), AA (5), HFBA (6); the active H is illustrated in red. 
Acylation was preferred for this work because it is a common technique applied 
to SC and GC−MS, as Table 3-1 shows, documenting the up-to-date published GC–
MS analysis methods and derivatisation reagents applied to cathinones. These 
reagents were extensively used to enhance the sensitivity and specificity of the 
electron capture detector (ECD), provide more fragmentation ions in the mass 
spectrum by altering the original compounds, improve the resolution of the 
chromatogram and reduce the artifact peaks by dropping the polarity of analytes. 
Acylation reagents are similarly beneficial for thermolabile drugs when the analyte 
of interest has inadequate detection ions, which commonly occurs to various SC. 
However, the use of extra reagent may damage the column or cause detector 
contamination. The acylation reagents pentafluoropropionic anhydride (PFPA), 
trifluoroacetic anhydride (TFA), chlorodifluoroacetic anhydride (CLF2AA), 
heptafluorobutyric anhydride (HFBA), acetic anhydride (AA) and propionic 
anhydride (PA) were selected for this evaluation study. See Figure 3-2 for the 
chemical structures of the reagents. This is the first study that includes CLF2AA 
derivative for the detection of SC. It is also the first evaluation study that presents 
the fragmentation patterns of the selected cathinones using the CLF2AA reagent.   
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Table 3-1: The recent published techniques including the analysis of derivative cathinones 
using GC–MS 
SC  Derivatisation  Year Ref.  
Three methcathinones PFPA and HFBA  2006 [48] 
MBDB, Methylone and methcath PFPA 2007 [404] 
Butylone and ethylone  TFAA  2009 [125] 
Mephedrone  PFPA  2010 [146] 
Methedrone  TFAA  2010 [143] 
Mephedrone  BSTFA  2011 [141] 
Methylone  HFBA  2012 [450] 
GHB and Mephedrone PFPA 2012 [451] 
3−bromomethcathinone and 3−FMC Acetic anhydride–pyridine mixture  2012 [210] 
DMMC  TFAA  2013 [452] 
Ethylone PFPA 2014 [453] 
4−MEC Acetic anhydride–pyridine mixture 2015 [454] 
Mephedrone MSTFA  2017 [455] 
26 stimulants drugs Hexyl chloroformate 2018 [456] 
 
PFPA 
 
TFA 
 
CLF2AA 
 
HFBA 
 
AA 
 
PA 
 
Figure 3-2: Chemical structure of selected derivatisation reagents 
3.1.3 Problems and aims  
The GC−MS conditions were optimised until excellent responses and separations 
were achieved in the chromatogram. During the development work, however, it 
was noted that MDPV−PFPA (tertiary amine) had one mass spectra fragment with 
a base peak of m/z 126, while the remaining ions were relatively small (less than 
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5%). Cathinones are widely known for having poor detection characteristics 
(sensitivity) with little fragmentation of mass spectra (selectivity), meaning that 
there are very few qualifier ions. Some SC have positional isomers, such as 
butylone and ethylone that have identical fragmentation patterns with only minor 
differences in spectra intensity. MDPV and pyrovalerone are not derivatised, 
therefore the SC are reliant on a limited number of mass spectra ions. Internal 
standards (ISD) of cathinones overlap with high abundance ions of cathinones, such 
as mephedrone and mephedrone-d3. Thermal degradation of SC in the injector 
port is another concern when the temperature is very high. 
From the viewpoint of the above problems, an investigation should be undertaken 
to avoid the legal implications of false interpretation, particularly in the screening 
tests for SC. The sensitivity and selectivity could be improved by adding 
derivatisation techniques and acidified methanol. The derivatisation agents are 
required to produce more fragmentation patterns and increase the resolution of 
peaks. After an extensive literature review, there was a distinct lack of 
publications on this significant issue. Therefore, the detailed aims of the project 
are as follows: 
1. Comparison of six derivatising agents: trifluoroacetic anhydride (TFA), acetic 
anhydride (AA), chlorodifluoroacetic anhydride (CLF2AA), heptafluorobutyric 
anhydride (HFBA), pentafluoropropionic anhydride (PFPA) and propionic 
anhydride (PA) for the determination of nine SC in GC−MS: mephedrone, 
flephedrone, pentedrone, methylone, ethylone, methedrone, MDPV, butylone 
and pyrovalerone. This is after optimisation of the conditions and investigate 
the thermal lability of SC in the injector port, the assessment of which included:  
• Reaction time and temperatures during the incubation and evaporation stages. 
• The maximum values of peak areas. 
• Quality of fragmentation patterns in each reagent. 
• The fragmentation patterns in terms of relative intensity ions. 
• Interference study. 
• Number of fragmentation ions in each cathinone derivative. 
• Quality of the reagents, using recovery, linearity, LOD, accuracy and precision 
applied to SC. 
•  Complete three−way ANOVA for data treatment analysis [457].  
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• Study underivatised tertiary amines of cathinones, such as MDPV and 
pyrovalerone.   
•  Study ISD vs derivatisation agents using best−fit regression approach. 
2. Study the effects of adding acidified methanol on the sensitivity of the method.   
3. Study the recovery of two extraction methods: SPE and LLE. 
4. Determination of five cathinones (mephedrone, flephedrone, methylone, 
methedrone, butylone) in whole blood, SPE−PFPA.  
The GC−MS method was optimised to provide the best separation, selectivity and 
sensitivity in the chromatogram and detector. The SC for this project were 
selected as those being frequently abused in the UK [458]. Additionally, 
compounds from each class of SC (secondary and tertiary amines) were included 
to cover a wide range of cathinones. All compounds stated above are previously 
illustrated in Table 2-2. 
3.2 Materials and methods 
3.2.1 Materials 
3.2.1.1 Chemicals and reagents 
Nine SC reference standards at 1 mg mL−1  (butylone, ethylone, flephedrone, 
MDPV, mephedrone, methedrone, methylone, pentedrone and pyrovalerone), five 
internal standards (ISD) at 100 µg mL−1 (butylone−d3, mephedrone−d3, ethylone−d5, 
methylone−d3 and MDPV−d8) as their hydrochloride salts and seven derivatisation 
reagents (propionic anhydride  (PA) ≥ 99%, chloro di−fluoro acetic anhydride 
(CLF2AA) ≥ 98%, pentafluoro−propionic anhydride (PFPA) ≥ 99%, 
heptafluoro−butyric anhydride (HFBA) ≥ 99%, trifluoro−acetic anhydride (TFA) ≥ 
99%, acetic anhydride (AA) ≥ 99% and butyric anhydride (BA) ≥ 98%) were 
purchased from Sigma−Aldrich, Gillingham, UK.  
Ethyl acetate (EtOAc), sodium phosphate dibasic, sodium phosphate monobasic, 
sodium chloride (NaCl), sodium dihydrogen orthophosphate monohydrate 
(NaH2PO4), disodium hydrogen orthophosphate anhydrous (Na2HPO4), methanol 
(MeOH), isopropanol (IPA), dichloromethane (DCM), ammonium hydroxide 
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(NH4OH), hydrochloric acid (HCl) and acetic acid were supplied by VWR 
International, East Grinstead, UK. Human whole blood was obtained from the 
Scottish National Blood Transfusion Service collected at Gartnaval Hospital, 
Glasgow. Sodium phosphate and phosphate buffer were purchased from Fisher 
Scientific, Loughborough, UK. Solid-phase extraction (SPE) 200 mg cartridges (part 
number ZSDAU20) were supplied by Chromatography Direct, Runcorn, UK. The 
deionised water was produced by ultrapure water purification (Water 
deionizer−Merck Direct QR 3UV).  
3.2.1.2 General laboratory equipment  
 Table 3-2: General laboratory equipment used in the thesis 
Equipment  Specification  
Balance  
Sartorius TE 64-0CE  
Mettler Toledo XPE105 Deltarange 
Vortex mixer  
VWR Analog Vortex Mixer  
Fisher Scientific Topmix FB15024 
Centrifuge  
VWR Microstar 17  
Sigma 4-16 
Nitrogen evaporator  
Thermo Scientific Reacti-Therm III #TS18826 
Evaporation Unit  
Ultrasonic bath  
Grant XUBA3  
Grant XUB5 
pH meter  
pH Electrode SJ223 662-1395 + Hanna 
Instrument pH210 Microprocessor  
Microbiological safety cabinet  MSC12 BS5726-Jouan Part 1-1992  
Thermometer  Fisher Scientific Traceable Calibration  
 
3.2.1.3 Saline solution  
The solution was prepared by dissolving 9.5 g of NaCl in 500 mL of deionised water 
(d.H2O) (w/v). The contents were then transferred to a 1 litre volumetric flask 
and made up to the mark using d. H2O.  
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3.2.1.4 Blank blood preparation 
Blank human whole blood was prepared by adding 500 mL of packed red blood cell 
to a volumetric cylinder with a 1% saline solution defrosted in a ratio of 1:1 (v/v). 
The blood saline solution was then mixed carefully, transferred to a glass bottle, 
and stored in the refrigerator at 4°C until use. 
3.2.1.5 Preparation of phosphate buffer (pH 6)  
Phosphate buffer at 0.1 M at a pH of six was prepared by dissolving 1.7 g of 
Na2HPO4 and 12.14 g of NaH2PO4 in 800 mL of d.H2O in a beaker. The contents 
were then transferred to a 1 L volumetric flask and d.H2O was added to the mark. 
The volumetric flask was then inverted several times to mix the contents. The pH 
was adjusted to six using 0.1 M dibasic sodium phosphate to increase the pH or 0.1 
M monobasic sodium phosphate to decrease the pH. The solution was then stored 
at 4°C for use within three months. 
3.2.1.6 Preparation of 0.1 M acetic acid 
5.75 mL of glacial acetic acid (99.6% acetic acid; stock solution is 17.4 M) was 
transferred into 800 mL of water in a volumetric flask in a fume hood. This was 
gently mixed and then topped up to 1 L mark with d.H2O. The solution was then 
kept at room temperature (RT) to be used within six months. 
3.2.1.7 Preparation of DCM: IPA: NH4OH (78:20:2) (v/v/v) 
2 mL of 28% NH4OH solution was transferred to 20 mL of IPA in a 100 mL volumetric 
flask and then mixed. DCM was then added up to the 100 mL mark and mixed 
again. This solution was freshly prepared each day and then kept at RT until use. 
The preparation was carried out in a fume hood. 
3.2.1.8 Preparation of derivatised SC  
Acylation reagents are difficult to prepare, because interferences may occur 
during the reactions between the reagents and other products. Unreacted 
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reagents must be removed before GC analysis. Acylation derivatives are odorous, 
sensitive, hazardous and moist [448], therefore solvents were introduced to the 
mixture to reduce negative impacts.  
The preparation of PFPA and EtOAc (2: 1), TFA and EtOAc (2: 1, v/v), CLF2AA and 
EtOAc (2: 1, v/v), HFBA and EtOAc (3: 2, v/v), AA and EtOAc (3: 2, v/v), PA and 
pyridine (2: 1, v/v) and BA and pyridine (2: 1, v/v) was carried out in a fume hood. 
4 mL of PFPA, TFA and CLF2AA with 2 mL of EtOAc were aliquoted to 7 mL glass 
tubes for each derivative. 3 mL of HFBA and AA were separately transferred to 7 
mL glass tubes and mixed with 2 mL of EtOAc for each agent. 4 mL of PA and BA 
were added to 7 mL glass tubes and mixed with 2 mL of pyridine in each reagent. 
All tubes were then capped and mixed for a few seconds. These reagents were 
again prepared by the same procedure after consumed. 
3.2.1.9 Preparation of acidified methanol (1:9) (v/v)  
1 mL of concentrated HCl was mixed with 9 mL of MeOH in a 10 mL volumetric 
flask and then transferred to an amber glass bottle. The solution was stored at RT 
until use. 
3.2.1.10 Preparation of stock standards 
Stock standard solutions were prepared for each substance individually, by 
dilution of butylone, ethylone, flephedrone, MDPV, mephedrone, methedrone, 
methylone, pentedrone and pyrovalerone to achieve a concentration of 100 μg 
mL−1. These were prepared by transferring 1 mL of each reference substance (1 
mg mL−1) into a 10 mL volumetric flask using MeOH to fill the flask up the mark 
(1:10, v/v dilution). The flasks for each drug were then shaken several times 
before each stock solution was transferred to single amber glass bottles and stored 
at −20°C. 
3.2.1.11 Preparation of standard solutions  
An individual solution for each drug was prepared to achieve concentration of 10 
μg mL−1 in methanol. These were prepared by adding 1 mL from each stock solution 
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(butylone, ethylone, flephedrone, MDPV, mephedrone, methedrone, methylone, 
pentedrone and pyrovalerone) at a concentration of 100 μg mL−1 to a 10 mL 
volumetric flask, the volume was made up to the mark.  
3.2.1.12 Preparation of working solution (mixture)  
Comparison of derivatisation study  
Preparation of the mixture working solution was made by adding 1 mL from each 
stock standard (100 µg mL−1) to a 10 mL flask of MeOH in order to achieve 10 μg 
mL−1. The mixture of nine drugs (butylone, ethylone, flephedrone, MDPV, 
mephedrone, methedrone, methylone, pentedrone and pyrovalerone) was 
transferred to an amber glass bottle and stored at −20°C until use. This working 
solution was used for the comparison study of derivatisation. A mixture of five SC 
(methylone, mephedrone, flephedrone, methedrone and butylone) was also 
prepared and used for the determination of whole blood samples.  
For determination of five SC in whole blood sample study  
Working Solution One was prepared by diluting stock solutions (100 µg mL−1) at a 
1:10 ratio in methanol for preparation of five SC (mixture) at 10 µg mL−1 
(methylone, mephedrone, flephedrone, methedrone and butylone). Working 
Solution Two (1 µg mL−1) of the five mixture drugs was prepared by diluting 
Working Solution One (10 µg mL−1) by a ratio of 1:10 (v/v) in methanol.  
3.2.1.13  Preparation of mixture working solution for ISD 
A mixture of butylone−d3, mephedrone−d3, ethylone−d5, methylone−d3 and 
MDPV−d8 was produced by transferring 1 mL of each drug (100 µg mL−1) to a 50 mL 
flask of MeOH in order to reach 2 μg mL−1. The mixture of ISD was transferred to 
an amber glass bottle and stored at −20°C until use. Similarly, a mixture of two 
ISD (mephedrone−d3 and methylone−d3) was prepared for the determination of the 
selected drugs in whole blood.  
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3.2.2 Methods 
3.2.2.1 Optimisation study of six derivatisation reagents  
The general procedure was as follows:  
SC were derivatised using the following procedure. 50 μL of nine SC (mixture of 
10 μg mL−1 from working solution stated in section 3.2.1.12) and 50 μL of five ISD 
(mixture of 2 μg mL−1 from working solution stated in section 3.2.1.13) were 
added to a 7 mL vial. The sample was evaporated under a stream of nitrogen at 
RT. The sample was then placed under the fume hood for the preparation of the 
derivatisation reagents. One reagent was added to each sample (glass tube), which 
consisted of 50 μL of PFPA and EtOAc (2:1, v/v); 50 μL of TFA and EtOAc (2:1, 
v/v), 50 µL of CLF2AA and EtOAc (2:1, v/v), 65 μL of HFBA and EtOAc (3:2, v/v), 
50 μL of AA and EtOAc (3:2, v/v) or 50 μL of PA and pyridine (2:1, v/v). Each 
sample was covered and mixed rapidly for 5−15 seconds and then incubated for 
various durations (5−10−15−20−25−30−35 or 40 minutes) and temperatures (RT, 
40°C, 55°C or 70°C). The samples were evaporated again at different temperatures 
(RT, 40°C or 50°C) under a stream of nitrogen using a hot block. 50 μL of EtOAc 
was then added for reconstitution of the sample. The content of the EtOAc was 
transferred to a GC vial for GC−MS analysis. The syringe of GC was rinsed in EtOAc 
three times before the analysis. 1 µL of each sample was injected at 225°C and 
GC−MS was run under the conditions outlined in section 3.2.2.12. 
In detail:  
Triplicate samples were prepared and repeated eight times on eight different days 
at final concentrations of 0.50 μg mL−1 for the mixture of SC and 0.10 μg mL−1 for 
the mixture of ISD. A total of 72 derivatised tubes included 18 tubes in each 
specific time at 10, 20, 30, and 40 minutes at RT on day one, 40°C on day two, 
55°C on day three and 70°C on day four. There were 72 tubes in each day = 3 
(triplicate) × 6 (derivatisation reagents) × 4 (times) × 1 (temperature). 
The samples were then set similarly to previous days but the times were modified 
to 5, 15, 25 and 35 minutes, carried out from day five until day eight. The samples 
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were then transferred for evaporation under nitrogen gas at RT for all reagents on 
days one through four. On days five through eight PFPA, TFA and HFBA were placed 
at RT, AA and CLF2AA were set to 40°C and PA was set at 50°C.  
On day nine, the 72 tubes included 18 tubes for each temperature under a stream 
of nitrogen examined using turboVap® for solvent evaporation in the following 
procedure. Triplicated specimens were set at 50°C under the hot block, and the 
incubation was 20 minutes at RT, 40, 55 and 70°C. 72 tubes = 3 (triplicate) × 6 
(derivatisation reagents) × 4 (temperatures) × 1 (time).  
An additional method was carried out on day ten to observe the effect of pyridine 
as a solvent when mixed with BA and PA using the following technique. 200 μL of 
the SC mixture (10 μg mL−1) was added to all tubes and then the samples were left 
at RT for evaporation. The triplicates of 18 samples of BA and PA were capped and 
mixed for 15 seconds and then incubated at 90°C for 30 minutes. The samples were 
kept for evaporation again at RT, 40 and 50°C. 18 tubes = 3 (triplicate) × 2 
(derivatisation reagents) × 3 (temperatures) × 1 (time).  
54 tubes were set similarly to the above on a separate day for the assessment of 
temperature on the reaction, considering RT, 55°C and 70°C in 30 minutes (18 
samples for each temperature). Both evaporation steps were completed at RT. 54 
tubes = 3 (triplicate samples) × 6 (derivatisation reagents) × 3 (temperatures). 
This procedure was to confirm if the obtained results on one day are within an 
acceptable error range of the previous results using similar parameters. Figure 
3-3 shows an example of data analysis and Figure 3-4 illustrates an example of 
derivatisation laboratory work.   
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Figure 3-3: An example of data treatment analysis in excel sheet on day one using three samples applied to nine SC in PFPA 
The incubation time and temperature were 10 min at RT, hot block for the evaporation was set at RT. *Q. value is the relative ion intensities % (Q. value 
interprets how the quantification ions in ratio % related to the qualification ions). **The concentrations above were calculated using ChemStation software 
data analysis (the true value was 500 ng mL−1). The mean, median, standard deviation (SD) and RSD above are related to the responses of triplicate samples 
for each drug. The mean of concentration, SD, RSD and accuracy are related to the concentration results (ng mL-1). All the 720 samples including 6480 tests 
were calculated in similar way. 
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Figure 3-4: Diagram of the laboratory work from day one to day eight at varied temperatures 
and times 
3.2.2.2 Optimised procedure 
The final method is illustrated in Table 3-3. This procedure was determined after 
the optimisation of incubation times and temperatures, as well as the 
temperatures of hot block for the derivative of SC. The excel sheet produced 
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contained 6480 tests: (9 days × 72 samples × 9 drugs) + (1 day × 54 samples × 9 
drugs) + (1 day × 18 samples × 9 drugs). The concentration, average, median, SD, 
RSD and error of accuracy (± %) of each triplicate sample were calculated (see the 
Equation 3−4 for the RSD calculation and Equation 3−5 for the accuracy 
calculation). The average of the highest responses in each target mass ion for each 
derivative and compound was used for conclusion the optimised method.  
The optimum procedure was subsequently applied to study the validation 
parameters, including precision, accuracy, linearity and recovery. Additionally, 
this procedure was applied to the samples used for the determination of the five 
PFPA SC in whole blood and urine.  
Table 3-3:  The optimised procedure of derivative cathinones 
Derivatisation 
reagents 
Incubation time Temperature of 
incubation 
Temperature of hot 
block 
PFPA and TFA 20 min RT−PFPA and 40°C− 
TFA 
RT 
CLF2AA and HFBA 25 min for CLF2AA and 20 
min for HFBA   
55°C 40°C 
AA and PA 25 min 70°C 50°C 
3.2.2.3 Linearity study  
Linearity study for comparison of derivatisation reagents:  
Triplicate unextracted samples were prepared at seven concentrations (2, 1, 0.75, 
0.50, 0.25, 0.10, and 0.05 μg mL−1) and then spiked with the mixture of nine SC. 
These concentration points are commonly used in forensic toxicology laboratories 
for the detection of ATS substances. The work was accomplished in two days; the 
first day was for PFPA, TFA and CLF2AA and the second day was for HFBA, AA and 
PA derivatives. 63 samples were analysed per day. (7 (concentration points) × 3 
(triplicate) × 3 (derivatisation agents) per day).     
Linearity study for determination of 5 SC in whole blood sample:  
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Duplicated samples were prepared and repeated at nine concentration points (5, 
2, 1, 0.500, 0.250, 0.100, 0.050, 0.025, 0.010 μg mL−1). This procedure was 
performed for the extraction of SC (flephedrone, mephedrone, methedrone, 
methylone and butylone) using SPE and whole blood, and it was also repeated for 
the examination of unextracted samples. The purpose of plotting unextracted and 
extracted SPE calibration curves is to study the recovery over these points. The 
calibration points were prepared for derivatisation and determination of whole 
blood studies as illustrated in Table 3-4 and Table 3-5 , respectively.  
 
Table 3-4: The volume of nine SC solutions added of unextracted samples for the linearity 
study of derivatisation 
Conc. of calibration 
points (μg mL−1)  
Mixture of nine SC at (10 μg mL−1), 
the volume added (μL)  
Mixture of nine SC at (1 μg 
mL−1), the volume added (μL)  
2 200 − 
1 100 − 
0.750 75 − 
0.500 50 − 
0.250 − 250 
0.100 − 100 
0.050 − 50 
Table 3-5: The volume of five SC solutions spiked to 1 mL of whole blood for the linearity 
study 
Conc. of calibration 
points (μg mL−1)  
Mixture of five SC at 10 μg 
mL−1, volume added (μL) 
Mixture of five SC at 1 μg 
mL−1, volume added (μL) 
Final 
volume 
(μL) 
5 500 − 1000 
2 200 − 1000 
1 100 − 1000 
0.5 − 500 1000 
0.25 − 250 1000 
0.1 − 100 1000 
0.05 − 50 1000 
0.025 − 25 1000 
0.010 − 10 1000 
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Calculation methods:  
Each linearity point was calculated using the peak area ratio of the analyte and 
its ISD, as follows in Equation 3−2. 
Equation 3−2: Peak area ratio of target analyte  
= 𝑨𝒏𝒂𝒍𝒚𝒕𝒆 𝒑𝒆𝒂𝒌 𝒂𝒓𝒆𝒂 (𝒕𝒂𝒓𝒈𝒆𝒕 𝒊𝒐𝒏 𝒓𝒆𝒔𝒑𝒐𝒏𝒔𝒆) ÷  𝑰𝑺𝑫 𝒑𝒆𝒂𝒌 𝒂𝒓𝒆𝒂 (𝒕𝒂𝒓𝒈𝒆𝒕 𝒊𝒐𝒏 𝒓𝒆𝒔𝒑𝒐𝒏𝒔𝒆) 
The calibration curve was generated by plotting the area against the 
concentration. The equation of linearity and the correlation of coefficient (R2) 
were determined.  
The ISD applied for each analyte are demonstrated in Table 3-6 for the comparison 
study and Figure 3-5 for the whole blood determination study.  
 
 
Figure 3-5: SC substance with its ISD used to calculate the peak area ratios for whole blood 
determination study 
Mephedrone-d3
• Mephedrone
• Flephedrone
• Methedrone 
Methylone-d3
• Methylone
• Butylone
Table 3-6: SC substance with its ISD used for comparison study of derivatisation reagents. 
SC/Derv. PFPA  TFA  CLF2AA  HFBA  AA  PA  
Flephedrone  Mephedrone-d3 Mephedrone-d3 Methylone-d3 Mephedrone-d3 Mephedrone-d3 Mephedrone-d3 
Mephedrone  Mephedrone-d3 Mephedrone-d3 Methylone-d3 Mephedrone-d3 Mephedrone-d3 Mephedrone-d3 
Pentedrone  Mephedrone-d3 Mephedrone-d3 Methylone-d3 Mephedronevd3 Mephedrone-d3 Mephedrone-d3 
Methedrone  Mephedrone-d3 Mephedrone-d3 Methylone-d3 Mephedrone-d3 Mephedrone-d3 Mephedrone-d3 
Methylone  Methylone-d3 Methylone-d3 Methylone-d3 Methylone-d3 Methylone-d3 Methylone-d3 
Butylone  Butylone-d3 Butylone-d3 Butylone-d3 Butylone-d3 Butylone-d3 Methylone-d3 
Ethylone  Ethylone-d5 Ethylone-d5 Ethylone-d5 Butylone-d3 Butylone-d3 Methylone-d3 
Pyrovalerone  MDPV-d8 MDPV-d8 Butylone-d3 Butylone-d3 MDPV-d8 MDPV-d8 
MDPV  MDPV-d8 MDPV-d8 Butylone-d3 Butylone-d3 MDPV-d8 MDPV-d8 
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3.2.2.4 Limit of detection (LOD) 
The limit of detection (LOD) was measured by determining the lowest 
concentration at which the compound could be detected. At least three ions were 
considered for the assessment of each substance’s LOD in each reagent (see Table 
3-9 for the ions used). The signal−to−noise (S/N) ratio must be greater than three 
to be considered above the LOD. This was achieved using the Agilent 
instrumentation software (ChemStation software version 6.5 data analysis). The 
calculation of S/N ratio is illustrated in Equation 3−3.  
Equation 3−3: Signal−to−noise S/N ratio 
= 
𝑻𝒉𝒆 𝒉𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒎𝒂𝒔𝒔 𝒇𝒓𝒂𝒈𝒎𝒆𝒏𝒕 𝒊𝒐𝒏 𝒊𝒏 𝒕𝒉𝒆 𝒂𝒏𝒂𝒍𝒚𝒕𝒆
𝑻𝒉𝒆 𝒏𝒐𝒊𝒔𝒆 𝒊𝒏 𝒕𝒉𝒆 𝒃𝒂𝒔𝒆𝒍𝒊𝒏𝒆 𝒐𝒇 𝒃𝒂𝒄𝒌𝒈𝒓𝒐𝒖𝒏𝒅
 
Seven concentrations (250, 100, 50, 25, 10, 5, 1 ng mL−1) of nine cathinones were 
spiked in derivative methanolic samples and repeated three times using SIM mode. 
The preparation of above concentrations was completed in a similar practice to 
that mentioned in section 3.2.1.12. The S/N ratio in the whole blood sample was 
determined at a concertation of 10 ng mL−1 only for the assessment of LOD for 5 
SC.  
3.2.2.5 Relative standard deviation and accuracy for the evaluation of 
derivatisation agents 
The RSD (%) values at concentrations of 0.5 μg mL−1 for SC and 0.1 μg mL−1 for ISD 
were calculated based on the optimal procedure (see section 3.2.2.2) of each 
derivative and drug using Equation 3−4, and the accuracy (bias) values were 
calculated from Equation 3−5. 
Equation 3−4: Relative standard deviation (RSD) 
= ((𝑻𝒉𝒆 𝒂𝒗𝒆𝒓𝒂𝒈𝒆 𝒐𝒇 𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅 𝒅𝒆𝒗𝒊𝒂𝒕𝒊𝒐𝒏 (𝑺𝑫)) ÷ (𝑻𝒉𝒆 𝒂𝒗𝒆𝒓𝒂𝒈𝒆 𝒐𝒇 𝒕𝒂𝒓𝒈𝒆𝒕 𝒂𝒏𝒂𝒍𝒚𝒕𝒆𝒔 𝒓𝒂𝒕𝒊𝒐)) ×
𝟏𝟎𝟎 
Equation 3−5: The accuracy (bias) calculation  
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=  ((𝑻𝒉𝒆 𝒂𝒗𝒆𝒓𝒂𝒈𝒆 𝒄𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 – 𝑻𝒓𝒖𝒆 𝒗𝒂𝒍𝒖𝒆𝒔 (𝟎. 𝟓
𝝁𝒈
𝒎𝑳
))
÷  (𝑻𝒓𝒖𝒆 𝒗𝒂𝒍𝒖𝒆𝒔 (𝟎. 𝟓
𝝁𝒈
𝒎𝑳
))) × 𝟏𝟎𝟎 
The final calculation results used the above equations for the final determination 
of RSD and bias results in each derivative and drug. The SDs and the means above 
were calculated in accordance with triplicate samples obtained from the 
optimised method only.  
3.2.2.6 Recovery study for the examination of derivatisation reagents in 
whole blood 
1 mL of whole blood and 300 µL of the mixture of nine SC at a concentration of 3 
µg mL−1 were added into a culture tube and vortexed with 1 mL of 0.10 M 
phosphate buffer (pH=6). All culture tubes were then vortexed for few seconds 
and centrifuged at a speed of 3000 rpm for 10 minutes. The SPE column was 
conditioned by adding 3 mL of MeOH and deionized water, respectively followed 
by 1 mL of 0.10 M phosphate buffer at pH6 to clean the DAU cartridges and 
eliminate undesirable materials (DAU cartridges are UCT’s main cartridge type 
(copolymeric bonded phase, reverse C8, and benzenesulfonic acid ion exchange 
phases) for forensic analysis and are the most commonly encountered in 
publication applicable to acid, basic and neutral drugs). The whole blood 
specimens were added and permitted to distribute and pass across the columns 
completely. 3 mL of d.H2O and 1 mL of 100 mM acetic acid, followed by 3 mL 
MeOH were added for washing, and the contents were then dried under a full 
vacuum for five minutes. The specimens were eluted using 3 mL of DCM: IPA: 
NH4OH (78:20:2). The samples were then put under a gentle stream of nitrogen 
for evaporation at RT to dry. The extraction contents were derivatised using the 
technique mentioned in the section 3.2.2.2 (optimisation procedure). The 
triplicate samples for each reagent were extracted without ISD present. The 100 
µL mixture of five ISD (10 µg mL−1) was added prior to the evaporation stage.  
On the same day, the triplicate of unextracted samples of nine SC were added 
into 7 mL glass tubes at 3 µg mL−1 with 100 µL of the five ISD mixture (10 µg mL−1). 
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15 samples of the above were extracted (3 × 5 reagents: PFPA, TFA, CLF2AA, HFBA 
and AA) and the three samples of unextracted tubes were evaporated at same 
time. The calculation of recovery % for each compound was used Equation 3−6: 
Equation 3−6: Recovery (%) 
= ((𝑷𝒆𝒂𝒌 𝒂𝒓𝒆𝒂 𝒓𝒂𝒕𝒊𝒐 𝒐𝒇 𝒆𝒙𝒕𝒓𝒂𝒄𝒕𝒆𝒅 𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅𝒔) ÷
 (𝑷𝒆𝒂𝒌 𝒂𝒓𝒆𝒂 𝒓𝒂𝒕𝒊𝒐 𝒐𝒇 𝒖𝒏𝒆𝒙𝒕𝒓𝒂𝒄𝒕𝒆𝒅 𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅𝒔)) × 𝟏𝟎𝟎 
3.2.2.7 Internal standards (ISD) evaluation   
The procedure for ISD evaluation was accomplished on the day of linearity study 
by adding 50 µL of the mixture ISD drugs at 2 µg mL-1 (see section 3.2.2.3 for the 
procedure used). This was carried out by applying each ISD a lone in each drug 
using ChemStation Software Version 6.5 and the conclusion results based on the 
regression square (R2).   
3.2.2.8 Carryover 
Carryover was assessed by injecting triplicates of blank blood with the mixture of 
nine SC at a concentration 10 µg mL−1. 100 µL of 100 µg mL−1 was added to three 
culture tubes of whole blood, and the method was then conducted using SPE 
followed by PFPA derivative procedures.    
3.2.2.9 Acidified methanol study  
Duplicate blank blood samples with the mixture of selected drugs were extracted 
using the SPE procedure at concentrations of 2000, 1000, 500 and 100 ng mL−1 
using two ISD (mephedrone-d3 and methylone-d3 at 100 ng mL−1). 20 µL of acidified 
MeOH (concentrated HCL: MeOH (9:1) (v/v)) was then added before evaporation. 
The PFPA derivative was added (50 µL and kept 20 min at RT), followed by 
evaporation (at RT using nitrogen gas) and reconstitution (by ethyl acetate). The 
above procedure was repeated with no acidified menthol.  
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3.2.2.10 Evaluation of two extraction methods (SPE and LLE)  
The aim of the study is to determine which extraction method performs a better 
recovery before proceeding with the long−term stability validation study; thus, 
two extraction methods were selected for evaluation: SPE and LLE. These 
techniques effectively remove interferences and contaminants from the 
specimens, while providing excellent recovery. The recovery calculation methods 
used for the assessment are already illustrated in Equation 3−6.  
For long−term stability, a urine sample was selected, and applied as a matrix for 
evaluation. For that, blank urine samples were collected on the day of the 
laboratory experiment. Triplicate 1 mL urine samples for each method (SPE and 
LLE) with triplicate unextracted samples were analysed at a concentration of 1 µg 
mL−1. The SPE procedure used was similar to that outlined in section 3.2.2.6. 
For LLE, a 1 mL urine specimen was mixed with 100 µL mixture of 6 SC at 10 µg 
mL−1 in a conical glass tube (the final concentration= 1 µg mL-1). 0.1 mL of 25% 
NaOH (w/v) and 2 mL of DCM were added to the tube, which was then capped and 
vortexed for 1 minute. The specimen was thereafter centrifuged at 2500 rpm for 
10 minutes. The bottom layer was carefully transferred into a round−bottom glass 
tube, avoiding gel particles and taking extra care to remove aqueous droplets. 25 
µL of acidified methanol (methanol + concentrated HCl, 9:1 v/v) was added to   all 
nine tubes (SPE, LLE and unextracted tubes). This was followed by 50 µL of ISD 
(mephedrone-d3 at 10 µg mL−1). The samples were left for evaporation at RT under 
a gentle stream of nitrogen until completely dry. The procedure was then 
completed as demonstrated in section 3.2.2.2 using PFPA for derivatisation. 
3.2.2.11 Thermal degradation of SC method  
This was completed by injecting 50 μL of nine SC (mixture of 10 μg mL−1). The 
samples were used for optimisation the GC-MS methods (oven temperature and 
injector port).  
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3.2.2.12  The optimum condition methods in GC−MS 
GC−MS was operated using a 7890A GC/5975C MSD (triple−axis detector), coupled 
with a split/splitless inlet and a DB−5MS (5% phenyl/95% methylpolysiloxane; 30 m 
× 0.25 mm × 0.25 µm film thickness) separation fused−silica capillary column (All 
Agilent Technologies, Waldbronn, Germany). Helium with a purity of 99.99% was 
used as the carrier gas at 1.0 mL min-1. Splitless injection at 225°C was employed. 
The MS transfer line temperature remained at 250°C. The MS functioned in 
electron impact ionisation mode (70 eV). The ion source continued at 200°C. MS 
data acquisition began after seven minutes and was set to selected ion monitoring 
(SIM) mode and scan mode (based on scope). The column temperature was started 
at 70°C and was then raised 10°C per minute until 280°C with a final hold time of 
23 minutes. The mass spectrometer was run in full scan mode (50 – 450 m/z) to 
study the ion fragmentations and peak interferences. Selected ion monitoring 
(SIM) mode was obtained to study the validation parameters. All data collection 
and processing was conducted on the GC/MSD ChemStation Software Version 6.5. 
See Table 3-7 summarising the GC−MS parameters. 
3.3 Results and discussion  
3.3.1 Study of the fragmentation patterns and interferences with relative 
ion intensities  
GC−MS was primarily conditioned for the separation of nine derivative cathinones 
until adequate responses and separations were achieved in the chromatogram and 
Table 3-7: Summary of GC−MS parameters  
Injector port mode Splitless 
Temp. at injector port  225°C 
Column type DB−5 capillary column (30 m x 0.25 mm I.D., 0.25 µm film thickness) 
Carrier gas Helium 
Flow rate  1 mL min-1 
Initial temperature  70°C 
Ramp 1  10°C per min to finish at 280°C 
Run time  23 min 
Transfer line temp. 250°C  
Solvent delay  7 min 
Ionization voltage  70 eV  
Mass-to-ion-ratio 
range  
50–450 m/z  
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mass with excellent peak shapes. Many GC−MS programs were used in combination 
with changes to the oven temperature in scan mode from 50 to 450 amu; an 
example of the optimisation work is summarised in Table 3-8. The SIM mode was 
then selected after determination of the mixture drugs (see Table 3-9 for the 
selection ions).  
All derivatives drugs (9 (cathinones) × 6 (reagents) = 54 derivatives = 54 tubes) 
were run separately to determine of the fragmentation patterns, mass spectra and 
retention time (tR) using nine SC standards. This was completed by adding 50 μL 
of each stock standard (100 μg mL-1) into a small vial. The content was then 
evaporated using nitrogen at RT, following the procedure mentioned in sections 
3.2.1.8 and 3.2.2.1 for each reagent. 
The fragmentation patterns with relative ion intensities for the SC derivatives are 
shown in Table 3-9. The abundance responses of quantification ions appear in 
bold, as achieved from the optimum conditions stated in section 3.2.2.2. These 
ion patterns were determined for the calculation of validation parameter 
assessments in the following sections.  
Nine derivative SC were tested to evaluate ion fragmentation; see Figure 3-6 for 
the fragmentation and Table 3-10 for the evaluation. The fragmentation patterns 
were investigated for each substance in each reagent. The overall points were 
used for the final evaluation of the fragmentation patterns. The best reagent in 
each factor was given one point (rank 1) and the second−best reagent was given 
two points (rank 2), etc.; meaning, the lower number of points, the better the 
reagents. The factors included for the evaluation were number of ions, number of 
unique ions and the total relative ion fragmentation percentage. These factors 
were estimated for each reagent in each individual compound. From Table 3-11, 
the best reagent for the evaluation of fragmentation patterns was AA (8 points) 
followed by CLF2AA (9 points), PFPA and PA (10 points), TFA (12 points) and then 
HFBA (16 points). 
The interference study is shown in Figure 3-7, where the elution of all peaks was 
showed a different tR in chromatogram, which were well separated from one 
another. Co−elution of peaks was not observed for any substances or reagents, 
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except in two situations where the ethylone could not be separated efficiently 
from butylone using AA and PA reagents. In spite of this, ethylone has a unique 
ion at m/z 178 for both AA and PA, permitting the substances to be discriminated 
from one another. Ethylone and butylone are very similar in terms of M.W, 
structure and isomers. The differentiation of fragmentation pattern and chemical 
structure for butylone and ethylone in GC−EI−MS is discussed in more detail in [2, 
459].  
Table 3-8: An example of GC−MS conditions used for the optimisation of SC 
Conditions Method number Final 
1 2 3 4 5 6 
Initial oven temp. (°C) 100 60 80 75 70 65 70 
Ramp 1 (min/temp. (°C))  10/280 10/260 8/300 11/240 11/220 13/280 10/280 
Ramp 2 (min/temp. (˚C))   − − − 10/280 10/280 − − 
Run time (min) 18 20 27.5 19 20 16.5 23 
The injector− temp. (°C) 250 250 250 225 225 250 225 
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Table 3-9: Fragment ions with relative ion intensities in SIM mode 
(quantification ions in bold were used in the calculation of peak area ratios, the remaining ions were used for qualification ions (confirmation ions), underlined ions are the unique ions, the ions 
between the brackets are the target ion of internal standards, the base ions that have 100% were used to calculate the highest peak areas, the italic is the molecular ions.  
Target 
Compounds 
PFPA TFA CLF2AA HFBA AA PA 
(tR)  m/z          Relative ion 
intensity (%) 
(tR)  m/z          Relative ion 
intensity (%) 
(tR)   m/z          Relative ion 
intensity (%) 
(tR)  m/z          Relative ion 
intensity (%) 
(tR)  m/z          Relative ion 
intensity (%) 
(tR)  m/z          Relative ion intensity (%) 
Flephedrone 10.22 204 100 10.26 154 100 12.40 170 100 10.63 254 100 12.87 58 100 13.61 58 100 
123 54 123 74 123 51 123 42 100 67 114 63 
160 32 110 29 95 29 210 27 95 23 95 24 
95 26 95 28 75 11 95 17 123 19 75 12 
Mephedrone 11.81 119 100 11.93 119 100 14.00 119 100 12.16 119 100 14.58 58 100 15.25 58 100 
204 
(207) 
29 
- 
91 
154 
25 
21 
170 
91 
32 
26 
254 
(257) 
36 
- 
100 
(103) 
83 
- 
114 
(61) 
70 
- 
91.1 24  (157) - 65 11 91 23 91 23 91 23 
160 17 65 2 - - 210 14 119 21 233 3 
Pentedrone 12.02 232 100 12.17 182 100 14.20 198 100 12.36 282 100 14.73 86 100 15.34 86 100 
190 66 140 68 156 46 240 58 128 61 142 48 
105 41 105 55 105 37 103 30 77 17 77 13 
77 27 77 31 77 29 79 16 105 10 105 11 
Methedrone 13.60 135 100 13.77 135 100 15.74 135 100 13.89 135 100 16.34 58 100 16.93 58 100 
204 12 77.1 10 170 10 254 13 100 77 114 66 
77 11 91 8 77 10 210 7 135 34 135 28 
160 8 154 8 - - 169 7 235 6 77 18 
Methylone 14.61 149 100 14.77 149 100 16.72 149 100 14.89 149 100 17.29 58 100 17.85 58 100 
204 
(207) 
19 
- 
154 
(157) 
14 
- 
170 
121 
20 
12 
254 
(257) 
22 
- 
100 
(61) 
65 
- 
114 
(117) 
57 
- 
160 13 121 13 319 6 121 11 149 24 149 21 
353 6 303 6 - - 210 11 249 22 263 9 
Butylone 15.15 149 100 15.37 149 100 17.25 149 100 15.41 149 100 17.80 72 100 18.34 72 100 
218 
(221) 
27 168 
(171) 
19 184 
(187) 
27 268 
(271) 
31 114 
(75) 
55 128 
- 
48 
- 
367 10 121 12 121 12 210 10 149 14 149 16 
160 6 317 6 333 6 417 5 236 8 277 3 
Ethylone 15.30 149 100 15.55 149 100 17.42 149 100 15.51 149 100 17.87 72 100 18.38 72 100 
218 
(223) 
37 
- 
168 
(173) 
28 
- 
184 
(338) 
37 
- 
268 
417 
40 
3 
114 
- 
60 
- 
128 
- 
48 
- 
190 18 140 13 333 12 - - 149 14 149 16 
121 12 121 12 156 10 -  - 178 7 178 2 
Pyrovalerone 15.68 126 100 15.68 126 100 15.68 126 100 15.68 126 100 15.68 126 100 15.68 126 100 
149 9 91 7 127 6 127 9 91 7 91 5 
MDPV 18.23 126 
(134) 
100 
- 
18.23 126 
(134) 
100 
- 
18.23 126 
(134) 
100 
- 
18.23 126 
(134) 
100 
- 
18.23 126 
(134) 
100 
- 
18.23 126 
(134) 
100 
- 
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Figure 3-6: Ion fragmentation pattern for each reagent applied to selected SC. Lower than 10% relative fragmentation ions were removed. The 
fragmentation patterns were using the determined optimum method.
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Table 3-10: Evaluation of fragmentation patterns 
Reagent & drug 
names 
Flephedrone Mephedrone Pentedrone Methedrone Methylone Butylone Ethylone Pyrovalerone MDPV Total The 
reagent 
rank  
Overall 
points 
PFPA No. of ions 4 4 5 3 3 6 4 1 1 31 1 10 
No. of unique ions    2 1 1 1 0 0 1 0 0 6 6 
Total relative ion 
fragmentations % 
211 170 234 131 138 143 167 122 113 1428 3 
TFA No. of ions 5 3 6 2 3 3 4 1 1 28 3 12 
No. of unique ions          3 1 1 1 0 0 1 0 0 7 5 
Total relative ion 
fragmentations % 
230 147 254 126 132 137 153 120 117 1416 4 
ClF2AA No. of ions 4 4 5 3 4 3 4 1 1 29 2 9 
No. of unique ions          3 1 3 1 1 1 1 0 0 11 2 
Total relative ion 
fragmentations % 
191 169 212 127 138 144 159 114 115 1369 5 
HFBA No. of ions 4 4 4 2 4 3 2 1 1 25 6 16 
No. of unique ions          2 1 4 2 1 0 0 0 0 10 4 
Total relative ion 
fragmentations % 
186 173 204 128 144 146 107 121 116 1325 6 
PA No. of ions 4 3 4 4 4 3 3 1 1 27 5 10 
No. of unique ions          2 1 3 1 1 1 1 0 0 10 4 
Total relative ion 
fragmentations % 
210 227 188 216 211 177 181 113 111 1632 1 
AA No. of ions 4 4 4 3 4 3 3 1 1 27 5 8 
No. of unique ions          2 1 4 2 1 1 1 0 0 12 1 
 
Total relative ion 
fragmentations % 
199 196 172 212 186 168 166 110 109 1518 2 
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Figure 3-7: Chromatograms for six acetylation derivatives of SC at a concentration of 0.50 µg 
mL−1 
1-Flephedrone 
2-Mephedrone + ISD 
Mephedrone d3 
3-Pentedrone 
4-Methedrone 
5-Methylone + ISD 
Methylone d3 
6-Butylone + ISD 
Butylone d3 
7-Ethylone + ISD 
Ethylone d5 
8-Pyrovalerone 
9-MDPV 
PFPA 1-Flephedrone 
2-Mephedrone + ISD 
Mephedrone d3 
3-Pentedrone 
4-Methedrone 
5-Methylone + ISD 
Methylone d3 
6-Butylone + ISD Butylone 
d3 
7-Ethylone + ISD Ethylone 
d5 
8-Pyrovalerone 
9-MDPV 
TFA 
1 
 
1 
2 
 
2 
 
3 
 
3 
 
4 
 
4 
 
5 
 
5 
 
6 
 
6 
 
7 
 
7 
 
8 
 9 
 
9 
 
CLF2AA 1-Flephedrone 
2-Mephedrone + ISD Mephedrone d3 
3-Pentedrone 
4-Pyrovalerone 
5-Methedrone 
6-Methylone + ISD Methylone d3 
7-Butylone + ISD Butylone d3 
8-Ethylone + ISD Ethylone d5 
9-MDPV 
1 
2 
 
3 
 
4 
 
5 
 
6 
 
7
 
 
8 
 
9 
 
8 
 
HFBA 
1-Flephedrone 
2-Mephedrone + ISD Mephedrone d3 
3-Pentedrone 
4-Pyrovalerone 
5-Methedrone 
6-Methylone + ISD Methylone d3 
7-Butylone + ISD Butylone d3 
8-Ethylone + ISD Ethylone d5 
9-MDPV 
AA PA 
1-Flephedrone 
2-Mephedrone + ISD 
Mephedrone d3 
3-Pentedrone 
4-Pyrovalerone 
5-Methedrone 
6-Methylone + ISD 
Methylone d3 
7-MDPV 
8-Butylone + ISD Butylone 
d3 
9-Ethylone + ISD Ethylone 
d5 
 
5 
2 
3 
4 
1 
 1 
2 
1 
4 
3 
1 
6 
7 
8 
9 1 
2 
3 
4 
5 
6 
7 
8 
9 
6 
7 
8 
9 
Chapter 3—84 
 
3.3.2 Thermal degradation of SC 
The decomposition of cathinones in the injector port of GC has been documented 
since 1994 by injecting methcathinone [167, 460]. The degradation product was 
caused by two missing hydrogen atoms, resulting a 2 Da lower mass than the base 
peak in mass spectra. Kerrigan et al. discussed this issue in terms of the effect of 
temperature in injector port when underivative cathinones were involved. It was 
concluded that the lower the temperature in the injector port the more thermally 
stable the SC compounds [459]. However, reducing the temperature of the 
injector port may result in an incomplete reaction [444] and a decrease in the 
volatilisation of analytes [461]. In this project, during the GC method 
optimisation, the temperature of the injector port was successfully reduced from 
250°C to 225°C to prevent the decomposition of SC. Temperatures any lower (for 
example 200°C or 185°C) produced lower peak area responses. Therefore, 225°C 
was used as the optimum temperature in the injector port.  
3.3.3 The optimum temperature and time reaction  
The optimum procedure for each derivative cathinone is shown in Table 3-11. The 
following points were noted: 
• All samples applied to SC−PA must follow the optimised procedure; specifically 
the temperature of hot block in the evaporating stage at 50°C. The GC−MS always 
provided poor responses or the lowest peak area values when the samples were 
set at RT in the hot block with the RSD and accuracy typically above 20% error.  
• The samples under all derivative reagents occasionally provided bad responses 
or even above 20% errors, based on accuracy and/or precision calculations.  
• The optimised procedures stated in Table 3-11 were selected because their 
results provided better responses, accuracy and precision for most derivative 
drugs tested. It was also selected due to the ANOVA study discuss in the following 
section.  
• Ethylone−AA in most samples provided poor peak area response, though the RSD 
and accuracy were valid in some samples (under 20% error), this is because the 
ISD was used in the calculation; see Figure 3-8.  
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• MDPV and pyrovalerone were frequently underivatised under all reagents and 
conditions. 
• In general, according to the maximum peak area responses, the derivative 
cathinones regularly achieved good responses for a reaction of 20−25 minutes at 
70°C for AA and PA; see Figure 3-9 for the results. While cathinones in AA and PA 
usually performed well at 70°C, both obtained poor responses at RT during the 
incubation stage. The effect of temperature on the reagents of CLF2AA/HFBA and 
TFA/PFPA are shown in Figure 3-10 and Figure 3-11, respectively. 
• Cathinones need high temperature for the completion of the reaction. For most 
experimental cases, the higher the temperature, the quicker reaction with the 
better the responses. This may be due to the chemical and physical properties. 
The boiling point (BP) and molecular weight (M.W) of each reagent and drug are 
examples that have effects on the reaction. PA, AA, HFBA, CLF2AA, TFA and PFPA 
have the following BPs: 167, 140, 120, 97, 72 and 69°C, respectively. When the 
boiling points of these reagents are high, the temperature in the hot block should 
also be high for the completion of the reaction, and high peak area values to be 
observed. The M.W in each SC also has certain effects; mephedrone and 
flephedrone, for example, are more volatile than other drugs due to a smaller 
M.W. Therefore, the smaller the M.W, the less temperature required; see Table 
3-12 for the overall explanation.  
• The time required for the completion of the reaction was under 15−25 minutes 
for all reagents and drugs. See Figure 3-12 for the example results of the PFPA 
agent. 
• Butylone, ethylone, MDPV and pyrovalerone presented better responses and 
greater peak area values when the samples were left at 50°C in nitrogen gas hot 
block (after derivatisation) using all reagents.   
• Butyric anhydride is the one reagent that was also involved in the evaluation. 
Unfortunately, despite attempting to increase the temperature during reaction 
and evaporation, very poor peaks and responses were observed for all nine SC. 
This might be related to the BP of the reagent, which is high (198°C) and prevents 
the excess reagent from evaporating even when the hot block temperature was 
set to 90°C for 20 minutes. As a consequence, this reagent was not involved in the 
comparison study.  
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Table 3-11: Optimisation of temperature and incubation time 
This is according to the average of the highest peak areas at concentration of 0.50 µg mL−1. The temperature that is presented between brackets is the 
optimised temperature in the evaporation stage (when the samples were left in hot block after derivatisation).  
Drug Name/ derivative PFPA (RT) TFA (RT) CLF2AA (40
°C) HFBA (40°C) AA (50°C) PA (50°C) 
FLEPHEDRONE  20 min RT 20 min 40°C 20 min 40°C 20 min 40°C 25 min 55°C 25 min 70°C 
MEPHEDRONE 10 min RT 20 min 40°C 25 min 70°C 25 min 55°C 20 min 40°C 25 min 70°C 
PENTEDRONE 20 min RT 20 min 40°C 25 min 55°C 20 min 40°C 25 min 55°C 25 min 55°C 
METHEDRONE 20 min 40°C 20 min 40°C 25 min 55°C 25 min 70°C 25 min 55°C 25 min 70°C 
METHYLONE 35 min 70°C 20 min 40°C 25 min 55°C 20 min 40°C 25 min 55°C 25 min 70°C 
BUTYLONE 20 min 40°C 20 min 40°C 25 min 55°C 20 min 40°C 25 min 70°C 25 min 70°C 
ETHYLONE 20 min 40°C 20 min 40°C 25 min 55°C 20 min 40°C 15 min 70°C 25 min 70°C 
PYROVALERONE 35 min 70°C 25 min 70°C 25 min 70°C 25 min 55°C 25 min 70°C 25 min 70°C 
MDPV 35 min 70°C 25 min 70°C 25 min 70°C 25 min 55°C 15 min 70°C 25 min 70°C 
Optimisation 20 min RT 20 min 40°C 25 min 55°C 20 min 55°C 25 min 70°C 25 min 70°C 
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55°C 
 
Table 3-12: The correlation between the required temperature, volatility, M.W and BP for 
the completion of the reaction during the incubation stage.  
Drug name Molar mass g moL-1 Temperature Volatility bp. 
MDPV 275    
PYROVALERONE 245    
ETHYLONE 221    
BUTYLONE 221    
METHYLONE 207    
METHEDRONE 193    
PENTEDRONE 191    
FLEPHEDRONE  181    
MEPHEDRONE 177    
Abbreviation: bp. (boiling point), M.W (molecular weight) 
 
Figure 3-8: Poor response of ethylone derivative by AA at 55°C in hot block for the 
completion of the reaction and 50°C during the evaporation stage, n= 3. 
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Figure 3-9: The effect of temperature during the reaction of six derivative cathinones using 
AA and PA reagents after 25 min, where the temperature in the evaporation stage was 50°C, 
n= 3. 
 
Figure 3-10: The temperature effect on six SC using CLF2AA and HFBA reagents, the time for 
the reaction was 20 min and the temperature of hot block during the evaporation stage was 
40°C, n= 3. 
0.E+00
5.E+05
1.E+06
2.E+06
2.E+06
3.E+06
3.E+06
AA at RT AA 40°C AA 55°C AA 70°C PA at RT PA at 40°C PA at 55°C PA 70°C
Th
e
 a
ve
ra
ge
 r
e
sp
o
n
se
 o
f 
ta
rg
e
t 
io
n
Flephedrone Mephedrone Pentedrone Methedrone Methylone Butylone
0.E+00
1.E+06
2.E+06
3.E+06
4.E+06
5.E+06
6.E+06
7.E+06
8.E+06
9.E+06
1.E+07
CLF2AA at
RT
CLF2AA 40°CCLF2AA 55°C CLF2AA70°C HFBA at RT HFBA at
40°C
HFBA at
55°C
HFBA 70°C
Th
e
 a
ve
ra
ge
 r
e
sp
o
n
se
 o
f 
ta
rg
e
t 
io
n
Flephedrone Mephedrone Pentedrone Methedrone Methylone Butylone
Chapter 3—89 
 
 
Figure 3-11: The temperature effect on six SC using TFA and PFPA reagents, the time was 25 
min and the temperature of hot block during the evaporation stage was RT, n= 3. 
 
Figure 3-12: Time required for the completion of the reaction applied to five SC in PFPA 
incubated and evaporated at RT, n= 3. 
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3.3.4 Three-way ANOVA  
The purpose of using three−way ANOVA was to confirm whether the responses 
were significantly different or not when the procedure of derivative SC was 
modified over different incubation times and temperatures, as well as hot block 
temperatures. The R programming language was applied to study a three−way 
ANOVA by analysing three factors (time and temperature during incubation, and 
temperature during the evaporation stage) as independent variables. The 
dependent variables (54 derivative SC = 9 SC × 6 derivatisation reagents) were the 
average target ion responses for a specific time, temperature, substance and 
reagent.  
The ANOVA was produced from 5184 tests (5184 tests = eight different days × 72 
samples per day × nine SC). The tests consisted of the response values of target 
ions that were obtained from the procedure mentioned in section 3.2.2.1. 
One of three independent variables must have statistically significant with at least 
5% confidence level in order to conclude that there was variance in the result. 
Once the average response values of SC target ions were higher than 5% (using the 
F factor), the responses within the variables for each derivative drug showed no 
statistically significant difference. The obtained results in Table 3-13 show that 
the derivative sample should be set using a specific time and temperature during 
the incubation and evaporation periods if there is significant difference. This 
means the procedure for each reagent should be strictly followed, and if not the 
response would be variable then resulting in errors or uncertainties. For instance, 
the optimised procedure should be followed for all samples that were derivatised 
using PA to provide high responses, and if not the responses values will be beyond 
the 95% confidence limit and may provide poor responses, accuracy and precision.  
The optimum conditions were determined based on the information in Table 3-11 
and Table 3-13. For instance, the optimum condition for derivative samples using 
PFPA was at RT for 20 minutes with RT for the evaporation. The question is, why 
were these temperatures and times selected as the optimum conditions? The 
answer, as the ANOVA study states, is that there is no significant difference in the 
results when the procedure was altered for all derivative drugs in PFPA, with 
exception of mephedrone and flephedrone.  
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Table 3-13: Three-way ANOVA for incubation time and temperatures as well as evaporation temperature in hot block.  
(Significant difference = probability (<F) is always less than 5%), (No significant difference = probability (>F) is always higher than 5%), samples above 20% error 
in RSD were excluded.  
Drug Name/ derivative. PFPA 
 
TFA  
 
CLF2AA  
 
HFBA  
 
AA  
 
PA 
 
FLEPHEDRONE  SIG. DIFF.   NO SIG. DIFF.   NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. 
MEPHEDRONE SIG. DIFF. NO SIG. DIFF. SIG. DIFF. NO SIG. DIFF. SIG. DIFF. SIG. DIFF. 
PENTEDRONE NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. 
METHEDRONE NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. SIG. DIFF. SIG. DIFF. 
METHYLONE NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. SIG. DIFF. NO SIG. DIFF. SIG. DIFF. 
BUTYLONE NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. SIG. DIFF. NO SIG. DIFF. SIG. DIFF. 
ETHYLONE NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. NO SIG. DIFF. SIG. DIFF. 
PYROVALERONE NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. 
MDPV NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. NO SIG. DIFF. SIG. DIFF. 
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3.3.5 Study of maximum peak area values 
In this study, the greatest base peak values that provide 100% of the relative ion 
intensities in the background of the mass spectrum ions were used for the 
assessment of derivatisation reagents. Each reagent in each drug has different 
fragmentation patterns, therefore base ions were selected instead of target ions 
for more accurate comparison results. See Figure 3-13 for the results, where all 
derivatised drugs have adequate peak areas, excluding AA for ethylone and 
methedrone as well as CLF2AA for pentedrone. This is all after using the 
optimisation procedure conditions. The best reagents were PFPA followed by TFA, 
HFBA, PA, CLF2AA and AA, respectively.  
3.3.6 Internal standards (ISD) 
The reason behind studying ISD was to investigate the application of ISD to 
cathinones and to answer the following questions:  
• Are one or two ISD sufficient to provide the required quantification method when 
applied to nine derivative cathinones?  
• Do the ISD provide the fit−regression with valid linearity results? Are there 
variances between the results? 
Due to the expensive list of available ISD, only five were evaluated. If one or two 
were successful in providing the fit−regression, then there is no reason to use 
more, which will reduce costs. Each ISD was investigated alone as it applied to 
nine derivative SC using the linearity study.  
All ISD applied to PFPA and TFA SC worked well and results of R2 value were greater 
than 0.990. The ISD that obtained poor regression were avoided in further studies 
in the next sections and chapters. The ISD results are demonstrated in Table 3-14. 
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Figure 3-13: The average of the greatest responses of relative ion intensities for base peak area values in nine SC and reagents at a concertation of 
0.5 µg mL−1, n= 3.
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Table 3-14: Examination of the quality (R2) of the target ion of selected internal standards 
for each drug. All drugs listed according to elution in chromatogram (tR).  
*ISD in bold were used to study validation parameters. B.R is bad response =<0.900.  
Compound with ISD/derivative PFPA (R2) TFA (R2) CLF2AA (R2) HFBA (R2) AA (R2) PA (R2) 
FLEPHEDRONE − MEPHEDRONE-d3 0.998 0.999 B.R 0.998 0.997 0.999 
FLEPHEDRONE − METHYLONE-d3 0.996 0.999 0.999 B.R 0.990 0.991 
FLEPHEDRONE − BUTYLONE-d3 0.997 1.000 0.999 0.995 0.995 B.R 
FLEPHEDRONE − ETHYLONE-d5 0.995 0.990 0.995 B.R B.R B.R 
FLEPHEDRONE – MDPV-d8 0.994 0.998 B.R 0.996 0.991 0.999 
MEPHEDRONE − MEPHEDRONE-d3 0.999 0.999 B.R 0.999 0.997 1.000 
MEPHEDRONE − METHYLONE-d3 0.997 0.997 0.997 B.R 0.942 0.995 
MEPHEDRONE − BUTYLONE-d3 0.997 0.996 1.000 0.994 0.959 B.R 
MEPHEDRONE − ETHYLONE-d5 0.995 0.996 0.998 B.R B.R B.R 
MEPHEDRONE – MDPV-d8 0.994 0.989 B.R 0.994 0.941 0.988 
PENTEDRONE − MEPHEDRONE-d3 0.998 0.998 B.R 0.998 0.997 0.997 
PENTEDRONE − METHYLONE-d3 0.995 0.995 0.997 B.R 0.955 0.978 
PENTEDRONE − BUTYLONE-d3 0.995 0.995 0.997 0.997 0.967 B.R 
PENTEDRONE − ETHYLONE-d5 0.994 0.995 0.994 B.R B.R B.R 
PENTEDRONE – MDPV-d8 0.994 0.988 B.R 0.998 0.954 0.986 
METHEDRONE− MEPHEDRONE-d3 1.000 0.999 B.R 1.000 0.999 0.996 
METHEDRONE − METHYLONE-d3 0.996 1.000 0.999 0.999 0.999 0.999 
METHEDRONE − BUTYLONE-d3 0.994 0.999 1.000 0.996 0.999 B.R 
METHEDRONE − ETHYLONE-d5 0.998 0.999 0.998 B.R B.R B.R 
METHEDRONE – MDPV-d8 0.996 0.996 B.R B.R 0.999 0.997 
METHYLONE − MEPHEDRONE-d3 0.998 0.999 B.R 0.998 0.999 0.995 
METHYLONE − METHYLONE-d3 0.999 0.999 0.998 0.999 0.998 1.000 
METHYLONE − BUTYLONE-d3 0.999 0.999 1.000 0.998 0.999 B.R 
METHYLONE − ETHYLONE-d5 0.999 0.998 0.999 B.R B.R B.R 
METHYLONE – MDPV-d8 0.993 0.998 B.R B.R 0.997 0.997 
BUTYLONE − MEPHEDRONE-d3 0.997 0.999 B.R 0.996 0.999 0.996 
BUTYLONE − METHYLONE-d3 0.999 1.000 0.995 0.999 0.997 1.000 
BUTYLONE − BUTYLONE-d3 0.999 1.000 0.999 1.000 1.000 B.R 
BUTYLONE − ETHYLONE-d5 0.999 0.999 0.997 B.R B.R B.R 
BUTYLONE – MDPV-d8 0.995 0.997 B.R B.R 0.996 0.996 
ETHYLONE − MEPHEDRONE-d3 0.994 0.999 B.R B.R 0.995 0.996 
ETHYLONE − METHYLONE-d3 0.998 1.000 0.996 0.942 0.998 1.000 
ETHYLONE − BUTYLONE-d3 0.999 1.000 0.999 0.978 0.994 B.R 
ETHYLONE −ETHYLONE-d5 0.999 0.999 0.999 B.R B.R B.R 
ETHYLONE – MDPV-d8 0.998 0.997 B.R B.R 0.997 0.996 
PYROVALERONE − MEPHEDRONE-
d3 
0.992 0.994 B.R 0.998 0.995 0.986 
PYROVALERONE − METHYLONE-d3 0.996 0.995 0.997 0.997 0.998 0.998 
PYROVALERONE − BUTYLONE-d3 0.997 0.995 0.996 0.996 0.994 B.R 
PYROVALERONE − ETHYLONE-d5 0.997 0.994 0.992 B.R B.R B.R 
PYROVALERONE − MDPV d8 0.997 0.999 B.R B.R 0.998 0.994 
MDPV − MEPHEDRONE-d3 0.990 0.992 B.R 0.998 0.995 0.982 
MDPV − METHYLONE-d3 0.996 0.993 B.R 0.993 0.995 0.996 
MDPV − BUTYLONE-d3 0.997 0.993 0.909 0.994 0.988 B.R 
MDPV − ETHYLONE-d5 0.997 0.992 B.R B.R B.R B.R 
MDPV – MDPV-d8 0.999 0.999 B.R B.R 0.995 1.000 
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3.3.7 RSD and accuracy studies  
The RSD and accuracy were obtained for the evaluation of the nine SC within six 
reagents at concentration of 0.50 µg mL-1. The results in Table 3-15 were 
calculated based on the optimised procedure only (see section 3.2.2.2).  
For both RSD and bias, optimised results were less than 20% for all drugs and 
reagents. The favoured reagent was determined according to the concentration 
errors (0.50 µg mL-1) of RSD and accuracy obtained. Hence, the RSD was from 
lowest to highest was: TFA (2.71%), AA (4.34%), PFPA (4.73%), CLF2AA (6.0%), HFBA 
(7.0%) and PA (7.4%).  
The bias results from lowest to highest were obtained for TFA (0.68%), PA 
(−0.71%), PFPA (0.73%), HFBA (1.97%), AA (−2.32%) and CLF2AA (−13%).  
3.3.8 Linearity and limit of detection (LOD) studies  
For the linearity study, the regression of correlation coefficients (R2) was 
constructed for each reagent and drug using the ChemStation software, based on 
triplicate samples at seven concentrations (2, 1, 0.75, 0.5, 0.25, 0.1 and 0.05 μg 
mL−1). All average values of R2 for all reagents and drugs were above 0.900; see 
Table 3-16 for the results.  
The best fit regression was greater than or equal to 0.992. The best results (R2) 
were PFPA (0.999), HFBA (0.999), TFA (0.998), PA (0.996), CLF2AA (0.996) and AA 
(0.996). These were determined based on the average of (R2) for all derivative 
drugs, with the exception of ethylone, pyrovalerone and MDPV. 
For the LOD study, the SIM mode was calculated using the method from section 
3.2.2.4. The method was applied in triplicate samples for all anhydrides and SC 
at seven concentrations from 1 to 250 ng mL−1. The best LOD results were attained 
using PFPA (2.33 ng mL−1), HFBA (3.83 ng mL−1), TFA (5.0 ng mL−1), PA (7.5 ng 
mL−1), CLF2AA (16 ng mL−1) and AA (66 ng mL−1). The conclusions were obtained 
from the average of the lowest LOD for all substances, excluding ethylone, MDPV 
and pyrovalerone.  
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Table 3-15: RSD and accuracy (bias) 
The average is the average of the highest peak area value of the base peak ion response at 
concentration of 0.50 µg mL-1 (n=3).  
Drug name & reagent PFPA TFA CLF2AA HFBA AA PA 
Flephedrone Mean 2283223 1178147 1881598 3563229 2407035 1263952 
RSD  4.07% 3.41% 10% 14% 1.13% 5.5% 
Bias 1.81% −9.8% −19% −4.83% 3.67% 1.81% 
Mephedrone Mean 4467040 3657740 3698786 3702338 1086728 2523269 
RSD  1.96% 0.99% 6.4% 2.02% 2.71% 11% 
Bias 4.79% 3.47% −12% −0.36% −9.0% −12% 
Pentedrone Mean 2714988 1860552 368017 2582720 2145452 3099143 
RSD  1.51% 2.37% 2.20% 4.33% 2.59% 12% 
Bias 10% 4.09% −9.3% 11% −9.3% 10% 
Methedrone Mean 7144720 6822530 6657846 6353019 574827 2489097 
RSD  4.49% 2.89% 4.43% 7.7% 2.59% 0.18% 
Bias 5.62% 12% −7.1% 13% 5.2% −12% 
Methylone Mean 6296421 9973042 5487420 3591150 2099231 1157643 
RSD  1.46% 1.76% 0.45% 0.98% 1.76% 0.06% 
Bias −11% −1.11% −12% −2.55% −6.8% 1.42% 
Butylone Mean 5835783 5881945 5132108 4476375 2139855 5185680 
RSD  1.96% 7.6% 8.2% 9.7% 2.43% 5.6% 
Bias −3.28% −13% −16% −7.5% 8.5% −3.28% 
Ethylone Mean 4630147 4161097 4026282 1914781 63541.29 5185680 
RSD  1.14% 1.81% 7.9% 6.8% 3.82% 5.6% 
Bias 2.09% −12% −9.0% 14% −17% 0.44% 
Pyrovalerone Mean 5801857 2929385 5626518 7895943 6658780 4976504 
RSD 12% 1.01% 4.74% 6.8% 10% 12% 
Bias −13% 15% −19% 14% 3.43% 13% 
MDPV Mean 4735925 3709708 4519016 6421153 4600039 5523840 
RSD  14% 2.54% 10% 11% 12% 15% 
Bias 9.5% 7.5% −16% −19% 0.39% −5.8% 
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 Table 3-16: Linearity (R2) and LOD (ng mL-1). 
Reagent & drug name  PFPA  TFA CLF2AA HFBA AA PA 
Flephedrone LOD  1 5 10 1 50 10 
(R2) 0.998 0.995 0.992 0.998 0.996 0.997 
Mephedrone LOD 1 5 5 1 25 10 
(R2) 0.999 0.999 0.995 0.999 0.99 0.981 
Pentedrone LOD 1 5 5 1 1 5 
(R2) 0.997 0.998 0.997 0.998 0.996 0.997 
Methedrone LOD 1 5 5 5 50 10 
(R2) 0.999 0.999 0.994 0.999 0.999 1 
Methylone LOD 5 5 25 10 25 5 
(R2) 0.999 0.999 0.998 1 0.998 0.999 
Butylone LOD 5 5 50 5 250 5 
(R2) 0.999 0.997 0.998 0.999 0.998 0.999 
Ethylone LOD 5 10 25 100 100 5 
(R2) 0.998 0.999 0.996 0.935 0.996 0.998 
Pyrovalerone LOD 50 50 50 100 25 5 
(R2) 0.956 0.912 0.955 0.912 0.998 0.996 
MDPV LOD 50 50 50 100 25 5 
(R2) 0.944 0.985 0.978 0.905 0.995 0.994 
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3.3.9 Recovery studies 
The evaluation of recovery was investigated to check that the nine substances 
could be derivatised after extraction from whole blood. A concentration of 3 μg 
mL−1 was extracted from whole blood using the SPE technique. The procedure and 
calculation method was demonstrated in section 3.2.2.6. The results of recovery 
and RSD are illustrated in Table 3-17. The best reagents for the recovery study 
were AA, TFA, CLF2AA, PFPA and HFBA.  
Table 3-17: The evaluation of recovery in whole blood samples at 3 μg mL−1 (n = 3)  
Figures between brackets are the rank of the reagent, the best reagent has one point, the 
second reagent has two points, etc. 
Drug names vs. reagents PFPA TFA CLF2AA HFBA AA 
Flephedrone Recovery 69% 69% 100% 59% 81% 
RSD  7.4% 12% 17% 6.2% 2.14% 
Mephedrone Recovery 107% 104% 94% 64% 121% 
RSD 7.1% 1.43% 9.7% 20% 7.6% 
Pentedrone Recovery 70% 112% 92% 43% 68% 
RSD 2.63% 3.48% 17% 20% 5.2% 
Methedrone Recovery 107% 129% 100% 110% 94% 
RSD 9.6% 7.9% 7.5% 19% 10% 
Methylone Recovery 101% 98% 98% 126% 82% 
RSD 0.75% 2.37% 3.59% 16% 2.35% 
Butylone Recovery 145% 51% 37% 53% 75% 
RSD 5.3% 0.84% 56% 1.80% 18% 
Ethylone Recovery 229% 117% 97% 14% 119% 
RSD 32% 1.27% 5.4% 7.3% 15% 
Pyrovalerone Recovery 77% 19% 64% 52% 187% 
RSD  1.90% 11% 23% 15% 15% 
MDPV Recovery 58% 122% 63% 134% 106% 
RSD  1.13% 2.86% 20% 3.76% 3.24% 
The average recovery and 
RSD (%) for all drugs in 
each reagent (excluding 
ethylone, MDPV and 
pyrovalerone) 
Recovery 120% (5) 113% (4)  104% (2)  91% (3) 104% (1)  
RSD  6.56% (2)  5.6% (1)  22% (5) 17% (4) 9.1% (3) 
Number of drugs between (80−120% 
recovery) for each reagent 
3 (4) 4 (3) 6 (2)  1 (5) 5 (1)  
Number of drugs between (0−20% RSD) 
for each reagent 
8 (3) 9 (1) 6 (5) 7 (4) 9 (1)  
Overall points for each reagent (the less 
points, the better the reagent) 
14 (3) 9 (2) 14 (3) 16 (5) 6 (1) 
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3.3.10 Overview for the evaluation of derivatisation reagents 
All points from the above sections were collected in order to decide the favoured 
reagents. This was based on nine parameters, demonstrated in Table 3-18. The 
overall best reagent for the selected SC was PFPA, followed by TFA, AA, CLF2AA, 
HFBA and PA. Therefore, PFPA was selected for the following steps of the studies.  
The assessment of the reagents above is important for application to forensic 
sample examination. Each drug has a different fragmentation and response to each 
reagent, and this study can help decide which drug and reagent provide the results 
with the best fragmentation patterns. For instance, the best reagent for the 
detection and quantification of mephedrone is PFPA because:  
• It has variety of fragmentation ions.  
• It shows the greatest peak area values. 
• It is within acceptable error, using the accuracy and precision parameters. 
• The sensitivity of the instrument is high, as it offers the lowest LOD compared 
to other reagents.   
• It presents excellent regression under the linearity study.  
• It has a unique ion.  
• It has more total ions than other reagents. 
• The relative ion ratio percentage is high, associated to the base peak of the 
mass spectra (119 m/z); see Figure 3-14.  
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Table 3-18: The best reagents for selected cathinones and parameters 
The best reagent has one point, the second has two, etc. 
Parameters & reagents PFPA TFA CLF2AA HFBA PA AA 
No. of ions 1 3 2 6 4 4 
No. of unique ions 6 5 2 4 4 1 
Total relative ion fragmentation % 3 4 5 6 1 2 
The maximum peak area  1 2 5 3 6 4 
RSD  3 1 4 5 6 2 
Accuracy  3 1 6 4 2 5 
Linearity R2 1 3 5 2 4 6 
LOD 1 3 5 2 4 6 
Recovery  4 2 3 5 6 1 
Total points (the rank) 23 (1) 24 (2) 37 (4) 37 (4) 37 (4) 31 (3) 
 
Figure 3-14: Consistent fragmentation with high relative ion intensities using PFPA 
3.3.11 Acidified methanol study  
The results of the duplicate blank blood samples spiked with the selected SC 
showed that adding the acidified methanol before evaporation was crucial in order 
to increase the sensitivity of the instrument. See Figure 3-15 for the comparison 
results. This is because the cathinones are basic drugs, where adding the acid will 
decrease the volatility of the compounds during evaporation under a nitrogen 
stream. 
m/z 
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Figure 3-15: Comparison study when acidified MeOH was added to samples or not. 
No: no acidified MeOH was added. Yes: the acidified MeOH was added. The concentration points are in ng mL−1. BL is whole blood 
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3.3.12 Evaluation of two extraction methods (SPE and LLE)  
This study was carried out to evaluate the recovery results using two sample 
preparation methods: LLE and SPE. Henceforth, the favoured extraction method 
is used in the stability work. Two extraction methods were applied to six SC in 
urine specimens. The results are illustrated in Figure 3-16. These results show 
that both techniques achieved high recovery with no less than 75% in SPE and 76% 
in LLE for all drugs examined. At least four out of six drugs were between 80−120% 
in SPE, but LLE had only three drugs in that range. The average of all drugs tested 
was better in SPE (97%) compared to LLE (105%). Over 100% recoveries were 
observed for some compounds, which may have originated from the evaporation 
step, where drugs of unextracted samples were partially lost. In general, and 
based on the limited repeatability with only triplicate samples, the findings 
indicate that the both techniques are suitable for application to SC using the 
procedures stated in the method and material section.  
Though LLE provided comparable recovery results, SPE was selected for the 
upcoming work. SPE is well known for its ability to obtain cleaner products with 
less interferences in the chromatogram. The advantages and disadvantages of both 
techniques are discussed in chapter two. 
 
Figure 3-16: Recoveries (%), RSD and average of six SC in triplicate urine samples at 1 µg 
mL−1 by SPE and LLE methods (n= 3),  
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Butylone
Mean
Flephedrone Mephedrone Pentedrone Methedrone Methylone Butylone Mean
RSD-LLE 1.90% 2.09% 1.49% 4.31% 12% 3.71% 4.18%
LLE % 96 129 126 96 76 106 105
RSD-SPE 5.4% 9.4% 15% 3.51% 4.16% 7.4% 7.6%
SPE % 75 103 81 102 97 125 97
Comparision of recovery (%) between SPE and LLE
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3.3.13 Linearity, signal−to−noise ratio and carryover examination 
using whole blood, SPE and PFPA  
The method was applied to five SC (flephedrone, mephedrone, methedrone, 
methylone and butylone) using the SPE−PFPA and whole blood. For the linearity 
study, all the results were above 0.991 (R2). Figure 3-17 displays results for 
unextracted and extracted drugs. Signal−to−noise (S/N) ratio was inspected at 10 
ng mL−1, as demonstrated in Table 3-19 for each ion of five SC.  
No carry over interferes were found after injecting triplicates of whole 
blood−blank high concentration 10 µg mL−1 samples.  
 
Figure 3-17: The comparison curves between unextracted and extracted SPE−PFPA in whole 
blood samples for the examination of flephedrone 
Note: Similar findings were observed for the remaining five drugs.  
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Table 3-19: Signal−to−noise (S/N) ratio of five SC at 10 ng mL−1 in whole blood samples 
using SPE−PFPA methods. 
Mephedrone Flephedrone Butylone Methedrone Methylone 
Ion / (S/N) ratio Ion / (S/N) ratio Ion / (S/N) ratio Ion / (S/N) ratio Ion / (S/N) ratio 
119/429 123/16 218/11 135/2252 149/3 
91/146 95/8 149/103 77/4 218/22 
160/34 160/19 160/6 160/87 367/25 
65/294 204/24 367/36 204/32 121/7 
3.4 Conclusion 
Six acylation reagents (PFPA, TFA, CLF2AA, HFBA, AA and PA) were investigated 
for nine SC compounds (butylone, ethylone, flephedrone, MDPV, mephedrone, 
methedrone, methylone, pentedrone and pyrovalerone) using GC−MS. The GC 
conditions were primarily optimised by altering the temperature of the injector 
port to reduce the degradation of SC substances. Additionally, the oven 
temperature was adjusted until the desired separation and detection were 
achieved. The reagents were optimised for incubation period and temperature as 
well as the hot block temperature in the evaporation stage. These conditions were 
briefly discussed using a three-ways ANOVA and peak area values until the 
optimum procedure was determined. Derivative cathinones generally performed 
better under higher temperatures for the reagents that have high M.W and BP, 
though the converse was found for the other cathinones. Five minutes was 
sufficient for the completion of the reaction; however the maximum peak areas 
were improved after 20 minutes.  
After the method was optimised, various parameters were applied for the 
comparison study, such as the relative ion fragmentation intensities, number of 
ions, number of unique ions, the uppermost peak area values, recovery, LOD, 
linearity, RSD, bias and interferences. The final conclusion was that all acylation 
anhydrides were suitable for the detection of SC substances. PFPA agent was 
favoured, based on the criteria and parameters used. PFPA was investigated 
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further in whole blood using linearity, recovery, signal−to−noise ratio and 
carryover parameters.  
In this chapter, one ISD was found to be sufficient to achieve excellent linearity 
in all types of anhydrides and SC. Acidified methanol was examined to increase 
the sensitivity of the GC−MS, and the results showed that adding the acidified 
methanol before drying the samples significantly improved the detection of the 
selected drugs. The extraction methods of LLE and SPE were compared using a 
recovery study. Both techniques had excellent recoveries for most drugs tested, 
and both could be used for the extraction of SC compounds. However, the 
application of SPE was adopted, due to its advantages.  
Butyric anhydride applied to SC was investigated for the first time. No or very poor 
responses were observed in the chromatogram during method development. The 
tertiary amines MDPV and pyrovalerone were mostly not derivatised with the 
reagents assessed.  
Therefore, in the next chapter, the selected PFPA reagent will be fully validated 
using the optimum conditions of SPE−PFPA and GC−MS in urine samples.    
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4. Determination of synthetic cathinones and 
amphetamine−type stimulants in urine using solid-phase 
extraction and gas chromatography–mass spectrometry 
4.1 Introduction 
A urine specimen is one of the most commonly used matrices in forensic toxicology 
laboratories. Collection method of urine specimen is inherently less harmful or at 
risk for contamination, an adequate volume is usually available, and the 
concentration of analytes is generally high compared to other matrices. Positive 
urine samples indicate the presence of the parent drug and/or its metabolites. 
Parent drug/metabolite ratios occasionally estimate when the drug was taken, 
due to processing changes in the metabolism. SC are normally taken in high doses 
and the parent substances can be determined in urine [129, 260, 399, 462].  
SC and ATS were previously detected using screening and confirmation methods in 
urine samples, however published papers that included SC, metabolites and ATS 
in a single method using GC−MS were non−existent. Therefore, a comprehensive 
screening and confirmation technique for the detection and quantification of ATS 
and SC in urine using a single method was demanded. The GC−MS was optimised 
until a specific and sensitive method was developed for the detection of 29 SC and 
ATS, including three SC metabolites. 20 out of 29 drugs were valid for confirmation 
purposes.  
New methods should be capable of differentiating between a variety of substances 
that have similar chemical behaviour, which may be present in the sample. 
Therefore, it is very important to prove the validity of such methods in order to 
ensure that it is robust and reliable for screening and confirmation in forensic 
toxicology. This is significant because the obtained results have substantial 
authority over individuals encountering the criminal justice system. The validation 
work should be completed in agreement with international guidelines and 
recommendations. Even though there are a lot of guidelines available for the 
purpose, the Scientific Working Group for Forensic Toxicology (SWGTOX) guideline 
was selected for the validation work, because it was recently designed for 
validating new methods in forensic toxicology [3].  
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The aims of this chapter are: 
• To optimise the GC−MS for the detection and quantification of 29 frequently 
tested ATS and SC, including three metabolites, as follows: seven ATS 
(amphetamine, methamphetamine, PMA, MDA, MDMA, MDEA, PMMA) and 22 SC 
(cathinone, methcathinone, buphedrine (buphedrone metabolite), flephedrone, 
4−methylephedrine (mephedrone metabolite), 4−methyl−N−ethyl−norephedrine 
(4−MEC metabolite), buphedrone, N−ethylcathinone, mephedrone, pentedrone, 
methedrone, methylone, butylone, ethylone, pyrovalerone, 4−EMC, 4-MEC, 
α−PVP, pentylone, MDPPP, naphyrone and MDPV).  
• To validate the methods using the selected PFPA reagent and SPE (see chapter 
3) for the detection and quantification of the above drugs. The validation 
parameters were RSD, bias, linearity, carryover, selectivity, interferences, limit 
of detection (LOD), lower limit of quantitation (LLOQ), recovery and stability.  
This method was also validated to prove the robustness for studying long−term 
stability of the analytes and the prevalence of the selected ATS and SC in Saudi 
samples discussed in chapter 5 and 7. 
4.2 Materials and methods 
4.2.1 Chemicals and reagents  
All 29 standard drugs, 3 ISD (amphetamine−d11 at 1 mg mL−1, MDA−d5 at 1 mg mL−1 
and butylone−d3 at 100 µg mL−1 with their hydrochloride salts),  derivatising 
reagents, other materials and grade chemicals were obtained from the supplier 
mentioned in section 3.2.1.1. Phosphate buffer and sodium phosphate were 
acquired from Fisher Scientific, Loughborough, UK. Solid-phase extraction (SPE) 
200 mg cartridges (part number ZSDAU20) were purchased from Chromatography 
Direct, Runcorn, UK.  
4.2.2 Drug-free urine (DFU) 
Blank urine samples were collected in the forensic toxicology department from at 
least 10 different healthy volunteers. All collected urine samples were drug-free 
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from the target analyte drugs. The samples were confirmed drug-free (negative) 
from the target analytes by running these samples using the methods and 
procedure outlined in chapter 3 using scan and SIM mode. All urine specimens were 
kept at 4°C in the refrigerator (RF). The drug-free urine samples were collected 
under ethical approval. The protocol was reviewed and approved by the MVLS 
College Ethics Committee, University of Glasgow (200160020), see appendix 1.  
4.2.3 Preparation of drug standard (STD) solutions  
Purchased standards at a concentration of 1 mg mL−1 of all 29 drugs were 
individually prepared in methanol via 1:10 (v/v) dilution to produce final 
concentration solutions of 100 µg mL−1 of each drug. This was obtained by 
transferring the purchased ampule to a 10 mL volumetric flask. The ampule was 
rinsed several times using MeOH to ensure the entire amount was completely 
transferred. MeOH was then transferred to the flask up to the mark, the flask was 
inverted and then mixed with the STD. The contents were labeled using amber 
glass and stored in the freezer (FZ) at −20°C.  
4.2.4 Preparation of ISD  
The purchased ISD of amphetamine−d11 and MDA−d5 at 1 mg mL−1 were diluted to 
100 µg mL−1 using the preparation method described in the section above. The 
mixture of these with butylone−d3 at 100 µg mL−1 were prepared to provide a 
concentration of 10 µg mL−1. This was achieved by transferring the content (1 mL) 
of each to a 10 mL volumetric flask and then completing the preparation method 
outlined above in the section of STD preparation.  
4.2.5 Preparation of working solution for linearity study 
1 mL was taken and transferred from each stock standard solution (100 μg mL−1) 
to a 50 mL volumetric flask via a 1:50 (v/v) dilution in DFU to a concentration of 
2 μg mL−1. This flask was filled up to the mark using DFU. The mixture of the 
working solution was inverted and gently shaken several times before it was 
labeled and kept in the FZ at −20°C in an amber glass bottle. The remaining 
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concentrations (0.05, 0.10, 0.25, 0.50, 0.75 and 1 μg mL−1) were prepared using 
Equation 4−1 to determine the volume of the working solution. 
Equation 4−1:Dilution equation 
(
𝐂𝟏 
𝐕𝟏
) × (
𝐂𝟐 
𝐕𝟐
) 
where V1 = volume of working solution (?), C1 = concentration of working solution 
(2 μg mL−1), V2 = final volume of new point of standard (1 mL) and C2 = final 
concentration of the new point of standard (for example, 1 μg mL−1).  
4.2.6 Linearity method  
The assessment of linearity was carried out using five separate calibration curves 
repeated on five consecutive days using eight calibration points, including DFU 
(50, 100, 250, 500, 750, 1000, 2000 ng mL−1). 1 mL of the mixture drug in urine 
for each calibrator point was added to the culture tube and then the sample 
preparation procedure was executed. The bias of each calibrator point was 
calculated from each calibration curve which should not exceed ±20%. The average 
error for 25 accuracy values in each concentration was obtained in order to 
determine whether the calibrator point was valid or not. Acceptable values should 
be greater than 0.99 in R2 to comply with SWGTOX guidelines. The calculation 
linearity method was previously described in section 3.2.2.3. 
The SIM ion ratios for each drug were monitored throughout the course of the 
validation work to confirm constancy. The monitoring SIM ion ratios assisted in 
interpreting whether a sample was positive or not. The monitoring was carried out 
using the Q value in the ChemoStation software, which should not less than 80%.  
4.2.7 Preparation of working solutions for accuracy and precision study 
Three quality controls (QCs) were prepared at concentrations of 250 (QC1), 750 
(QC2) and 1500 (QC3) ng mL−1. For that, 125, 375 and 750 µL of each stock standard 
solution (100 μg mL−1) were added to 50 mL volumetric flasks (1:50 v/v) dilution 
in DFU for QC1, QC2 and QC3 respectively. The flasks were filled using DFU to the 
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mark. The mixture in the three flasks were inverted several times and transferred 
to amber glass bottles stored in the FZ at −20°C.  
4.2.8 Accuracy and precision method 
Accuracy (bias) of the method was determined using the grand average of the 
results of each quantity detailed in chapter 3; see section 3.2.2.5. The purpose 
of accuracy determination is to study how close the concentration results are to 
the expected true concentration of the QCs. 
Precision (RSD) should be calculated throughout within runs (intra−day) and 
between runs (inter−day) to evaluate the validity of the method. Intra−day and 
inter−day precision were analysed using three quality controls at concentrations 
of 250 (low−QC1), 750 (medium−QC2) and 1500 (high−QC3) ng mL−1. Urine samples 
were prepared together on the same days as the linearity study, and were 
replicated five times each day on five consecutive days (n= 25). Acceptable range 
criteria for each measurement was ±≤20%. The calculation method for precision 
was expressed in chapter 3; see section 3.2.2.5.  
To study precision, intra−day (the largest calculated intra−day precision (%) for 
each concentration was used to measure intra−day precision acceptability) and 
inter−day RSD were calculated using the following equations:  
Equation 4−2: Intra−day precision calculation (RSD) 
𝑹𝑺𝑫 (%) = (
𝑺𝑫 𝒐𝒇 𝒂 𝒔𝒊𝒏𝒈𝒍𝒆 𝒓𝒖𝒏 𝒐𝒇 𝒔𝒂𝒎𝒑𝒍𝒆𝒔
𝑴𝒆𝒂𝒏 𝒄𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 𝒗𝒂𝒍𝒖𝒆 𝒐𝒇 𝒂 𝒔𝒊𝒏𝒈𝒍𝒆 𝒓𝒖𝒏 𝒐𝒇 𝒔𝒂𝒎𝒑𝒍𝒆𝒔
) × 𝟏𝟎𝟎 
 
Equation 4−3: Inter−day precision calculation (RSD) 
𝑹𝑺𝑫 (%) = (
𝑺𝑫 𝒐𝒇 𝑮𝒓𝒂𝒏𝒅 𝒎𝒆𝒂𝒏 𝒇𝒐𝒓 𝒆𝒂𝒄𝒉 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒂𝒕𝒊𝒐𝒏
𝑮𝒓𝒂𝒏𝒅 𝒎𝒆𝒂𝒏 𝒇𝒐𝒓 𝒆𝒂𝒄𝒉 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏
) × 𝟏𝟎𝟎 
Chapter 4—111 
 
4.2.9 Preparation of working solutions for LOD and LOQ studies 
1 mL was taken and transferred from the working solution (2 μg mL−1) to a 10 mL 
volumetric flask (1:10, v/v) dilution in DFU to prepare a concentration of 200 ng 
mL−1. This flask was make using at least three different sources of DFU. The 
concentration points (50, 25, 10, 5, 1, 0.5 ng mL−1) were prepared using the 
dilution equation described above. 
4.2.10 LOD and LLOQ method 
See section 3.2.2.4 in chapter 3 for LOD and LLOQ method. At least three 
different sources of DFU specimens were prepared in three replicates for three 
separate runs spiked at concentrations of 50, 25, 10, 5, 1 and 0.5 ng mL−1. Each 
replicate was independently evaluated. The LOD approach was designed for the 
lowest concentration of analyte when the target ion peaks exceed three times the 
background noise with at least two qualifier ions present at the tR. The LLOQ was 
measured based on the lowest concentration that provides a repeatable GC−MS 
response with an acceptable accuracy (±<20%) and an S/N ≥ 10. The accuracy 
results of the LLOQ were obtained from the linearity study (n= 25 in each 
calibrator point).   
4.2.11 Sample preparation using the SPE−PFPA (procedure)  
The mixture of ISD (50 μL of 10 µg mL−1) and 3 mL of 0.1 M phosphate buffer (pH6) 
were added to all calibrators, QCs and samples (for the sample results see chapter 
7) before being mixed for a few seconds and centrifuged for 10 minutes at 3000 
rpm. 2 mL of MeOH, d.H2O and 0.1 M phosphate buffer were individually added to 
condition the SPE cartridge. Next, samples were added to the SPE cartridge, 
followed by 3 mL of d.H2O, 1 mL of 1M acetic acid and 3 mL of MeOH for washing 
and extraction, after which the cartridges were dried under full vacuum for a 
minute. The cartridges were eluted using 2.5 mL of DCM: IPA: NH4OH (78:20:2) (v/ 
v/v) before 10 μL of acidified MeOH (1:9) (v/v) were added to each tube. The 
specimens were evaporated at 33°C under a stream of nitrogen until fully dry. The 
selected PFPA (see chapter 3) was applied as a reagent to derivatise the specimens 
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by adding 50 μL of PFPA and EtOAc (2:1) (v/v) to all tubes. The tubes were then 
capped and incubated for 15−20 minutes at 60°C before being evaporated once 
again under a gentle stream of nitrogen at RT. Finally, the samples were 
reconstituted using 50 μL of EtOAc prior the contents being transferred to GC−MS 
vials for analysis. 
4.2.12 Recovery method 
Four replicate samples of 1 mL DFU, spiked with the 29 mixture drugs were 
analysed in one day using SPE for extracting the samples at concentrations of 1500, 
750 and 250 ng mL−1. The sample preparation procedure using SPE−PFPA 
mentioned was applied. 29 mixture drugs at the three concentrations were added 
to each tube for the unextracted samples. The mixture of ISD were added before 
the evaporation stage for both unextracted and extracted tubes. The calculation 
method was demonstrated in section 3.2.2.6. 
4.2.13 Carryover method 
Carryover was investigated by rerunning the blank urine sample after the 
calibrator point of 2 µg mL−1 that was prepared in linearity study. This was 
completed to estimate any possible carryover. 
4.2.14 Selectivity and interferences method   
Selectivity was evaluated to detect if any other drug can interfere with the target 
analytes and modify the interpretation of the results. Interferences could either 
be produced by exogenous substances, by any other analytes implanted in the 
specimen or by endogenous substances (the matrix itself). The selected 
independent drugs were analysed in groups, instead of all together.  
The method examined the data attained from the 29 SC and ATS substances using 
SIM mode for a mixture of four groups of specimens.  
100 µL of a 10 µg mL−1 working solution of each drug were placed in 1 mL DFU 
samples, and the samples were prepared and completed using the procedure 
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stated above. The analysed drugs were cocaine, 6−MAM, pregabalin and 
tetrahydrocannabinol (THC) for culture tube 1; gabapentin, clozapine, olanzapine, 
midazolam and LSD for culture tube 2; nor- fentanyl, fentanyl, morphine and 
codeine for culture tube 3; paracetamol, caffeine, oxycodone and hydrocodone 
for culture tube 4.  
The DFU that was applied in the linearity, RSD and accuracy studies were 
conducted for the assessment of interferences. The drug−free urine samples were 
collected from at least 10 different donors under the ethical approval stated 
above. The selectivity was evaluated by looking for new peaks and retention time 
that interfere the peaks and retention time of the target analytes using scan and 
SIM modes. 
4.2.15 GC−MS conditions 
The GC−MS methodology described in chapter 3.2.2.12 was utilised with 
the exception that the temperature condition was optimised as follows: the 
temperature programme of the capillary column began at 70°C then 
elevated to 200°C at a rate of 11°C/min and was then held for 4 minutes 
before increasing to 280°C at a rate of 10°C/min and finally held for 1 min 
with a run time 25 min. All data obtained were used the GC−MS ChemStation 
Software Version 6.5. 
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4.3 Results and Discussion 
4.3.1 Retention time (tR) and fragmentation ion ratios  
Figure 4-1 demonstrates the shape, separation and tR of the peaks. Even though 
some peaks had coelution that resulted in bad resolution in chromatogram, the 
peaks have different tR with different target ions and ratios with at least two 
different qualitative ions. This can be simply achieved using an extracted ion 
chromatogram (EIC) or a total ion chromatogram (TIC) method using a mass 
detector rather than a GC; see Table 4-1 for the tR, target and qualification ions. 
These ions were selected for the evaluation of validation parameters and samples 
results. 
Throughout the validation laboratory work, the five compounds of tertiary amines 
were derivatised in small peaks under different tR of underivatised peaks using 
PFPA, as illustrated in Figure 4-1, however the tertiary underivative amines of 
the mass spectra peak for ion 126 for MDPV, PVP, naphyrone and pyrovalerone and 
ion 98 for MDPPP were the target ions selected for calculation parameters. These 
were selected, because the derivative ion amines provided ≤ 0.9 R2 with more 
than 20% RSD for most examined samples.  
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Figure 4-1: SIM chromatogram showing shape, separation and tR of ATS and SC peaks at a concentration of 2 µg mL
−1 in DFU. Each substance from tertiary 
amines had two peaks, the earliest elution was underivatized and the additional peak was the tertiary amine derivative. The sequence number above was based 
on the first peak eluted until the last.
AMPHETAMINE d11: 
1. AMPHETAMINE 
2. METHAMPHETAMINE 
3. CATHINONE 
4. BUPHEDRONE EPHEDRINE   
5. FLEPHEDRONE  
6. METHCATHINONE 
7. MEPHEDRONE METABOLITE 
(4-Methyl-ephedrine) 
8. 4-METHYL-N-ETHYL-
NOREPHEDRINE (4-MEC 
metabolite) 
9. BUPHEDRONE 
10. N-EC 
11. PMA 
12. MEPHEDRONE 
13. PENTEDRONE 
MDA d5: 
14. MDA 
15. 4-MEC 
16. PMMA 
17. 4-EMC (4-
Ethylmethylcathinone) 
18. METHEDRONE 
19. MDMA 
20. MDE 
21. PVP (Underivatised) 
22. METHYLONE 
23. PVP PFPA 
 
BUTYLONE D3: 
24. BUTYLONE 
25. ETHYLONE 
26. PYROVALERONE 
(Underivatised) 
27. PENTYLONE 
28. PYROVALERONE PFPA 
29. MDPPP (Underivatised) 
30. MDPPP PFPA 
31. MDPV (Underivatised) 
32. MDPV PFPA 
33. NAPHYRONE (Underivatised) 
34. NAPHYRONE PFPA 
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Table 4-1: SIM fragmentation patterns (m/z) and relative ion intensities (ratio %) with retention time (tR). Quantification ions in bold. The remaining ions were used 
as qualifier ions with ratios (%). 
Drug name tR m/z Ratio (%) Drug name tR m/z Ratio (%) 
AMPHETAMINE-d11 8.422 194 100 PENTEDRONE 11.668 
 
232 100 
128 72 190 59 
98 33 105 45 
337 3.90 
AMPHETAMINE 8.486 190 100 MDA-d5 12.191 
 
167 100 
118 79 330 62 
91 36 
65 9.2 
METHAMPHETAMINE 9.791 204 100 MDA 12.198 
 
135 100 
160 31 162 47 
118 24 325 15 
91 14 
CATHINONE 9.937 105 100 4−MEC 12.220 119 100 
77 31 218 37 
51 6.9 190 30 
190 6.0 91 17 
FLEPHEDRONE 10.024 204 100 PMMA 12.408 
 
121 100 
123 59 204 159 
95 19 148 102 
160 42 
BUPHEDRINE 10.030 218 100 4−EMC 12.472 133 100 
119 12 204 20 
308 2.6 160 10 
METHCATHINONE 10.316 105 100 METHEDRONE 13.33 
 
135 100 
204 102 77 8.0 
160 36 160 6.1 
77 30 204 9.1 
4−METHYLEPHEDRINE  10.403 204 100 MDMA 13.679 204 100 
119 13 162 73 
160 18 135 43 
308 2.60 339 12 
4−M−N−E−NOREPHEDRINE  10.706 218 100 MDEA 
 
14.215 
 
218 100 
119 20 353 8.5 
190 22 162 57 
322 2.50 135 25 
BUPHEDRONE 10.905 218 100 PVP 14.384 126 100 
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105 51   77 6.1 
77 21 105 3.2 
160 23 
N−EC 
 
11.091 218 100 METHYLONE 
 
14.716 149 100 
105 45 204 19 
190 40 160 11 
77 23 353 4.90 
PMA 
 
11.11 121 100 PVP PFPA 15.066 214 100 
148 42 70 36 
190 5 229 
214 
33 
18 311 7.4 
MEPHEDRONE 
 
11.482 119 100 MDPPP 
underivatised 
 
18.703 
 
98 
149 
100 
10 204 25 
91 20 
160 14 
BUTYLONe-d3 
 
15.627 
 
221 100 MDPPP PFPA 
 
20.026 
 
96 100 
370 20 245 
176 
36 
22 163 144 
  216 43 
BUTYLONE 
 
15.667 
 
218 100 MDPV 
underivatised 
 
20.539 
 
126 100 
149 480   
160 35   
367 20   
ETHYLONE 
 
15.923 
 
190 100 MDPV PFPA 
 
 
21.052 
 
124 
273 
149 
70 
100 
18 
41 
52 
149 655 
218 198 
367 22 
PYROVALERONE 
underivatised 
16.564 
 
126 100 NAPHYRONE 
underivatised 
 
22.667 
 
126 100 
91 4   
  
  
PENTYLONE 16.946 
 
149 100 NAPHYRONE PFPA 
 
23.063 
 
124 
279 
70 
100 
45 
56 
190 22 
232 19 
381 5 
PYROVALERONE PFPA 
 
17.287 124 100     
243 32   
228 15   
159 11   
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4.3.2 Linearity 
All selected analytes were plotted using the simple unweighted linear regression 
model least squares method, excluding PMA which was plotted using the quadratic 
method. This technique produced correlation coefficients R2 > 0.990 for all 
analysed substances, with the exception of 4−methyl−n−ethyl−norephedrine, 
4−MEC, MDPPP and naphyrone; see Table 4-2 for the average results. 
By using the accuracy approach to calculate each calibrator point, all substances 
fitted the constructed calibration curve for all seven concentration points (50 to 
2000 ng mL−1), excluding the following drugs:  
• 4−methylephedrine, PMA, N−EC and PVP of six calibrator points from the 
concentrations of 100 to 2000 ng mL−1. 
• 4−MEC, ethylone, pyrovalerone, MDPPP, MDPV and naphyrone of five calibrator 
points from 250 to 2000 ng mL−1.  
• 4−Methyl−N−ethyl−norephedrine of four calibrator points from 500 to 2000 ng 
mL−1.  
4.3.3 Accuracy and precision  
In Table 4-3, most examined substances were valid and fell within the SWGTOX 
±≤20% criteria for bias and RSD.  
All underivatised tertiary amines (MDPV, PVP, pyrovalerone, MDPPP and 
naphyrone) were above ±20% in accuracy and precision parameters at 250 and 750 
ng mL−1, and only valid at 1500 ng mL−1. Derivatised tertiary amine ions were 
similarly assessed and were out of accepted range at all QCs.  
The two metabolites of mephedrone and 4−MEC were inaccurate (bias ±≥20%) at a 
concentration of 250 ng mL−1. 4−MEC and PMA were also slightly above 20% when 
intra−day precision was measured at 250 ng mL−1. It can be concluded that 21 out 
of 29 compounds were valid at concentrations of 250, 750 and 1500 ng mL−1 and 
successfully passed the SWGTOX recommendation for accuracy and precision 
parameters. The average within-run precision results were 9.5, 9.2 and 5.9%, and 
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the average the between run results were 3.03, 3.64 and 2.66%. The average 
accuracy was 3.06, −0.01 and −0.19% for the low, medium and high QCs, 
respectively in each parameter. The method can be still beneficial for the 
detection of the eight unacceptable mixture substances for screening purposes, 
or even for quantification work at high concentration, such as 1500 ng mL−1.   
Table 4-2: Linearity study 
Compound name  (R2) Compound name  (R2) 
AMPHETAMINE 0.999 PMA  0.993 
METHAMPHETAMINE 0.998 MEPHEDRONE 0.996 
CATHINONE 0.997 PENTEDRONE 0.998 
FLEPHEDRONE 0.998 MDA 0.998 
BUPHEDRINE 0.996 4−MEC 0.989 (Invalid) 
METHCATHINONE 0.998 PMMA 0.997 
4−METHYLEPHEDRINE 0.995 4−EMC 0.999 
4−M−N−E−NOREPHEDRINE 0.988 (Invalid) METHEDRONE 0.999 
BUPHEDRONE 0.998 MDMA 0.999 
N−EC 0.994 MDEA 0.996 
PVP 0.997 PENTYLONE 0.999 
METHYLONE 0.999 MDPPP 0.988 (Invalid) 
BUTYLONE 0.999 MDPV 0.995 
ETHYLONE 0.997 NAPHYRONE 0.988 (Invalid) 
PYROVALERONE 0.996   
b
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Table 4-3: Accuracy and precision results. The concentration unit of QCs in ng mL−1 
Drug name QCs Intra−day 
RSD 
Inter−day 
RSD 
Bias Drug name QCs Intra−day 
RSD 
Inter−day 
RSD 
Bias 
AMPHETAMINE 250 6.5% 1.93% 3.1% PMMA 
 
250 8.9% 3.02% −1.6% 
750 5.1% 2.30% 1.7% 750 11% 1.39% −3.4% 
1500 2.89% 1.26% −0.6% 1500 3.15% 2.84% 1.4% 
METHAMPHETAMINE 250 12% 4.09% −6.1% 4−EMC 
 
250 7.8% 3.64% 0.7% 
750 9.7% 4.71% −2.7% 750 5.3% 2.38% 0.1% 
1500 5.8% 2.28% −0.1% 1500 4.30% 1.58% −2.6% 
CATHINONE 250 10% 2.78% 4.5% METHEDRONE 
 
250 4.76% 1.26% 8.9% 
750 8.9% 3.00% 2.3% 750 4.61% 1.24% 1.0% 
1500 7.3% 4.21% 3.6% 1500 3.44% 0.71% 0.4% 
FLEPHEDRONE 
 
250 6.9% 2.68% 8.9% MDMA 
 
250 9.2% 2.58% 2.7% 
750 8.5% 2.03% 5.3% 750 9.4% 2.17% −2.2% 
1500 1.85% 0.59% −0.2% 1500 4.70% 1.15% 2.5% 
BUPHEDRINE 250 12% 3.56% 4.7% MDEA 
 
250 19% 5.0% −12% 
750 16% 7.1% 1.0% 750 15% 7.9% −9.5% 
1500 6.1% 2.79% 0.8% 1500 16% 5.7% 1.6% 
METHCATHINONE 250 9.4% 2.13% 10% PVP (underivatised) 
 
250 100% 
(Invalid) 
59% 
(Invalid) 
119% 
(Invalid) 
750 14% 7.5% 1.6% 750 81% 
(Invalid) 
62%  
(Invalid) 
35% 
(Invalid) 
1500 4.61% 2.95% −0.9% 1500 2.00% 0.81% 2.9% 
4−METHYLEPHEDRINE 
metabolite 
250 33% 
(Invalid) 
7.1% 23%  
(Invalid) 
METHYLONE 
 
250 6.3% 0.96% 6.5% 
750 13% 6.2% −4.2% 750 5.4% 0.59% 0.5% 
1500 7.5% 2.11% 1.3% 1500 2.98% 0.46% 1.5% 
4−MEC metabolite  250 46% 
(Invalid) 
16% 42% 
(Invalid) 
BUTYLONE 
 
250 3.87% 1.15% 1.0% 
750 17% 7.0% −7.5% 750 3.79% 0.86% −0.8% 
1500 13% 4.90% 0.6% 1500 1.83% 0.62% −1.3% 
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BUPHEDRONE 250 6.9% 2.70% 8.9% ETHYLONE 
 
250 15% 5.4% −10% 
750 10% 6.0% 6.2% 750 13% 6.2% −8.4% 
1500 4.29% 2.96% −2.5% 1500 13% 3.56% −0.2% 
N−EC 
 
250 17% 4.27% 6.5% PYROVALERONE 
(underivatised) 
 
250 85% 
(Invalid) 
31%  
(Invalid) 
143%  
(Invalid) 
750 14% 5.5% 1.2% 750 284% 
(Invalid) 
267%  
(Invalid) 
231%  
(Invalid) 
1500 11% 3.73% −3.3% 1500 5.4% 2.78% 0.8% 
PMA 
 
250 23% 
(Invalid) 
7.3% −3.9% PENTYLONE 250 4.95% 1.74% 2.6% 
750 13% 7.0% −0.4% 750 4.37% 1.11% 1.3% 
1500 3.80% 1.64% 5.6% 1500 3.34% 2.91% −5.2% 
MEPHEDRONE 
 
250 13% 5.9% 9.3% MDPPP 
(underivatised) 
 
250 116% 
(Invalid) 
49% 
 (Invalid) 
1278%  
(Invalid) 
750 12% 4.25% 1.5% 750 352% 
(Invalid) 
351% 
 (Invalid) 
1565%  
(Invalid) 
1500 9.1% 5.8% 1.4% 1500 8.5% 3.54% 1.8% 
PENTEDRONE 250 12% 4.13% 9.5% MDPV 
(underivatised) 
 
250 108% 
(Invalid) 
41%  
(Invalid) 
383%  
(Invalid) 
750 11% 5.5% 2.6% 750 338% 
(Invalid) 
319%  
(Invalid) 
503%  
(Invalid) 
1500 7.7% 4.97% −0.1% 1500 2.41% 0.75% −0.3% 
MDA 
 
250 5.2% 1.62% 3.1% NAPHYRONE 
(underivatised) 
250 121% 
(Invalid) 
48%  
(Invalid) 
568%  
(Invalid) 750 3.49% 0.98% 2.2% 
1500 2.15% 1.85% −0.4% 750 341% 
(Invalid) 
317%  
(Invalid) 
713%  
(Invalid) 4−MEC 
 
250 21% 
(Invalid) 
10% 5.9% 
750 12% 5.5% −3.4% 1500 4.70% 1.33% −2.0% 
1500 10% 2.61% −2.2% 
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4.3.4 LOD and LLOQ 
The S/N ratios of LOD and LLOQ fell between 0.5 and 10 ng mL−1, and 5 and 50 ng 
mL−1, respectively for all examined substances; see Table 4-4. The detection and 
quantification limit results show that the method had sufficient sensitivity for the 
detection and quantification of the analytes in human urine samples within all 
examined concentrations, excluding the compounds discussed in the linearity 
results.  
Table 4-4: S/N ratio for LOD and LLOQ 
*LLOQ (bias) were applied to 25 replicate calibrator points. All data values in ng mL−1 
Compound name LOD LLOQ LLOQ 
(bias)* 
Compound 
name  
LOD 
 
LLOQ 
 
LLOQ 
(bias) 
AMPHETAMINE 0.5 10 50  PMA 1 10 100  
METHAMPHETAMINE 1 10 50  MEPHEDRONE 10 50 50  
CATHINONE 5 25 50  PENTEDRONE 0.5 5 50  
FLEPHEDRONE 0.5 10 50 MDA 5 25 50  
BUPHEDRINE 5 50 100   4−MEC 5 50 250  
METHCATHINONE 0.5 5 50 PMMA 0.5 10 50 
4−METHYLEPHEDRINE 5 50 50  4−EMC 1 10 50 
4−M−N−E−NOREPHEDRINE 5 50 500  METHEDRONE 1 10 50 
BUPHEDRONE 1 10 50  MDMA 5 50 50 
N−EC 1 25 100  MDEA 10 50 50 
PVP 0.5 10 100  PENTYLONE 5 25 50 
METHYLONE 5 50 50 MDPPP 10 50 250  
BUTYLONE 1 10 50 MDPV 5 50 250  
ETHYLONE 5 50 250  NAPHYRONE 5 50 250  
PYROVALERONE 5 50 250      
4.3.5 Recovery (%) 
The evaluation of recoveries was conducted at three QCs within the linear range 
(low-250, medium-750 and high-1500 ng mL−1). All substances had high recovery 
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between 69 and 126%, excluding MDEA (54%). The results for recoveries with RSD 
are presented in Table 4-5. 
Table 4-5: Recovery results (n= 4).  
Drug name Conc. 
(ng mL−1) 
Mean of 
recovery% 
(RSD)  
Drug name Conc. 
(ng mL−1) 
Mean of 
recovery% 
(RSD)  
AMPHETAMINE 250 83 (10) PMMA 
 
250 89 (7.6) 
750 78 (2.24) 750 95 (4.96) 
1500 80 (1.97) 1500 89 (1.81) 
METHAMPHETAMINE 250 90 (17) 4−EMC 
 
250 81 (6.0) 
750 87 (3.67) 750 76 (4.46) 
1500 89 (4.68) 1500 84 (0.32) 
CATHINONE 250 94 (8.8) METHEDRONE 
 
250 93 (8.2) 
750 113 (16) 750 89 (4.83) 
1500 107 (4.62) 1500 91 (2.21) 
FLEPHEDRONE 
 
250 94 (10) MDMA 
 
250 87 (11) 
750 113 (7.3) 750 94 (1.34) 
1500 98 (3.14) 1500 93 (3.37) 
BUPHEDRINE 250 104 (14) MDEA 
 
250 54 (16) 
750 120 (15) 750 112 (6.8) 
1500 109 (2.64) 1500 98 (13) 
METHCATHINONE 250 90 (12) PVP 
(underivatised) 
 
250 101 (5.2) 
750 108 (8.1) 750 93 (2.74) 
1500 94 (3.84) 1500 92 (5.3) 
4−METHYLEPHEDRINE 
metabolite 
250 121 (14) METHYLONE 
 
250 90 (11) 
750 114 (16) 750 90 (3.65) 
1500 111 (4.11) 1500 92 (7.3) 
4−MEC metabolite  250 115 (15) BUTYLONE 
 
250 73 (8.5) 
750 120 (16) 750 71 (1.00) 
1500 126 (7.3) 1500 69 (1.63) 
BUPHEDRONE 250 95 (12) ETHYLONE 
 
250 93 (8.8) 
750 119 (9.3) 750 120 (8.0) 
1500 96 (4.99) 1500 94 (16) 
N−EC 
 
250 87 (16) PYROVALERONE 
(underivatised) 
 
250 120 (6.9) 
750 103 (14) 750 123 (2.12) 
1500 99 (14) 1500 117 (3.19) 
PMA 
 
250 81 (17) PENTYLONE 250 104 (7.8) 
750 118 (13) 750 101 (4.47) 
1500 120 (4.90) 1500 99 (1.34) 
MEPHEDRONE 
 
250 107 (7.1) MDPPP 
(underivatised) 
 
250 122 (4.01) 
750 111 (14) 750 120 (5.4) 
1500 111 (2.84) 1500 115 (7.4) 
PENTEDRONE 250 114 (12) MDPV 
(underivatised) 
 
250 100 (7.5) 
750 103 (15) 750 130 (3.61) 
1500 111 (1.99) 1500 109 (10) 
MDA 
 
250 106 (8.1) NAPHYRONE 
(underivatised) 
250 108 (4.85) 
750 99 (2.10) 750 101 (5.0) 
1500 102 (2.59) 1500 110 (9.0) 
4−MEC 250 72 (6.8)  
750 118 (6.6) 
1500 81 (12) 
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4.3.6 Selectivity and interferences  
No interferences were observed using all four groups of investigated analytes in 
SIM mode. No matrix interferences were observed using DFU; see Figure 4-2.  
4.3.7 Carryover 
No carryover was observed using the method with the urine blank sample.  
 
 
Figure 4-2: a) SIM chromatogram for DFU specimen. b) SIM chromatogram for DFU included 
ISD, amphetamine−d11, MDA−d5 and butylone−d3. 
  
b) Blank urine with three ISDs at 0.5 µg mL-1  a) Drug-free urine sample 
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4.4 Conclusion 
The GC−MS method developed was valid for the simultaneous screening and 
quantification of 20 SC and ATS (amphetamine, methamphetamine, MDA, MDMA, 
MDEA, PMMA, cathinone, methcathinone, buphedrine, flephedrone, buphedrone, 
N−ethylcathinone, mephedrone, pentedrone, methedrone, methylone, butylone, 
ethylone, 4−EMC and pentylone) under SWGTOX guidelines in urine specimens. The 
nine drugs that were invalid were the five tertiarily amines (pyrovalerone, α−PVP, 
MDPPP, naphyrone and MDPV), two metabolites (4−MEC and mephedrone 
metabolites), PMA and 4−MEC. All examined substances were successfully 
extracted using SPE and reached recoveries of greater than or equate to 69%, 
except in the case of MDEA (recovery = 54%). No observation for endogenous or 
exogenous substances interfered with the target analytes. The sensitivity of the 
method was adequate for the detection of the mixtures concerned. The limits of 
quantitation were sufficient to quantify the adequate analytes specimens. 
Selectivity and carryover presented acceptable results. The repeatability and 
reproducibility of the method using accuracy and precision were satisfactory 
passed for the 21 inspected drugs.  
Even though a large number of analytes were mixed in urine, the method achieved 
the acceptance criteria for the 20 drugs under the validation parameters of 
linearity, bias, RSD, recovery, carryover, selectivity, interferences, LOD and 
LLOQ. This technique provided a rigorous method for screening and confirmation 
purposes using GC−MS under a single procedure to examine urine samples for drug 
abuse testing of 20 mixture compounds in forensic toxicology laboratories. The 
technique that has the ability to quantify a large number of analytes in a single 
procedure is very important in order to meet deadlines and reduce consumable 
chemicals and materials.   
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5. Long-term stability of synthetic cathinones and 
amphetamine-type stimulants in urine using gas 
chromatography-mass spectrometry  
5.1 Introduction  
Forensic toxicology samples are exposed to different diverse conditions 
throughout transport, delivery, storage, handling and liquating between the urine 
collection and its analysis, or during the repetition of analysis. These conditions 
are different temperature, humidity, container type and light that may cause the 
concentration of the compounds not to reflect the real concentration. The drug 
stability impacts should be taken into consideration before the forensic 
toxicological samples analysis. The stability of ATS is extensively described in the 
literature, but the SC are not yet well understood. The determination of SC 
stability in biological matrices is needed as a result of expanding SC prevalence 
worldwide (refer to sections 2.2.7 and 2.2.8).  
In chapter 4, methods were developed for the quantification of 29 substances in 
urine using SPE and GC−MS. The analytical methods were scientifically validated 
with SWGTOX (2013) for 20 ATS and SC compounds; the nine remaining drugs were 
also included in the stability study because the method was able to quantify the 
concentrations of 0.5 and 1 µg mL-1. Therefore, the validated approach was used 
to determine the stability of SC and metabolites in human urine under three 
different temperatures: room temperature (RT), refrigerator (RF) and freezer (FZ) 
over 381 days.  
To date, there are a limited number of papers that have investigated SC stability 
in urine. Guidelines (e.g. the Federal Workplace Drug Testing) necessitate that 
forensic toxicology laboratories keep all positive urine specimens for at least one 
year in freezing storage [463]. The long-term stability of SC in urine for up to six 
months have still not been reported. Additionally, SC have only been investigated 
for a small number of components. ATS drugs were studied in order to investigate 
if the SC breakdown products can interfere with the ATS by providing a false 
negative. The urine specimens were intended to be exposed to the ordinary light 
at RT. This was to match real conditions, as the samples may regularly sit on the 
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bench in the laboratory for several hours until examination. The samples may also 
sit during transportation or may be forgotten until a later time in the urine 
collection location or in laboratories. Drugs remain stable in the dark more so than 
in the light. Therefore, when a drug is stable in the light, it will also be stable in 
the dark. Several papers studied SC and ATS at RT in the dark. Hence, this is the 
first work that investigates the light condition of the selected drugs. 
5.1.1 Synthetic cathinones stability   
In Forensic Toxicology, the analysis of the sample in the screening method should 
not only inspect for target analytes but also metabolites. These products may 
appear because of the degradation that can happen in vivo or in vitro. The 
degradation products in vivo arise from enzymes, chemical processes or other 
physiological circumstances, such as oxidation, reduction, hydrolysis and de-
esterification. The environmental conditions (in vitro) also affect the stability of 
substances, including pH, exposure to light, humidity, storage duration, the type 
of matrix, storage conditions, container type, preservatives and temperatures. 
After collection, samples must be stored in the laboratory based on policy. The 
policy typically states the conditions to prevent in vitro degradation of 
compounds, such as storage temperature, pH, type of tubes and preservatives. 
However, degradation may still occur under some cases and circumstances; for 
example, the specimens take several hours until the laboratories are received the 
samples for the analysis, and in that period of time parent or metabolite 
compounds may begin to break down.  
Studies of NPS stability are limited or still under investigation [54, 213, 464]. 
Instabilities that might arise during transferring, storage, handling or analysis must 
be fully understood for the reliable interpretation of forensic toxicology 
investigations. 
The breakdown of some NPS and SC in biological samples were briefly discussed 
by Soh and Elliott [54]. The tertiary amine of SC was more stable than the primary 
and secondary amine groups [459, 464]. Johnson et al. [465] studied the stability 
of four drugs in three matrices on days two, four, seven and 14 in whole blood, 
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plasma and urine for two synthetic cathinones (MDPV and mephedrone) and two 
piperazine-derived designer drugs (1-benzylpiperazine or BZN and 3-
trifluoromethylphenyl or TFMPP). In the study, all drugs were stable in the freezer 
(FZ) at -20°C. Degradation of mephedrone at room temperature (RT) in the dark 
was initiated on day 2 in whole blood and on day 7 in urine and plasma. 
Mephedrone was stable in the refrigerator (RF) at 4°C in urine and plasma samples. 
Mephedrone in whole blood samples was unstable after seven days. MDPV was 
stable under all conditions and matrices over the period of the study. BZP was 
stable in all matrices and under all conditions examined, except the plasma 
sample at RT which lost 96% on day four and was undetected on day 14. TFMPP in 
plasma and whole blood degraded on day 4 and 7, respectively. TFMPP in urine 
samples was stable. See Table 5-1.  
Table 5-1: Stability of selected cathinones 
This table summarises Johnson et al. [465] paper on stability of Mephedrone, MDPV, BZP and TFMPP in urine, 
plasma and whole blood in human samples under three different conditions (–20, 4 and 22°C). 
Name of 
Drug 
On Day 2 On Day 4 On Day 7 On Day 14 
Mephedrone • Stable in urine 
and plasma 
samples under 
three different 
conditions 
• Unstable in 
whole blood at 
RT 
• Whole blood 
sample was 
stable at FZ and 
4C 
• Stable in 
urine under 
three 
different 
conditions 
• Unstable in 
whole blood 
and plasma at 
RT 
• Stable in 
whole blood 
and plasma at 
RF and FZ 
• Unstable at RT 
in three different 
matrices 
• Unstable in 
whole blood at RF 
• Stable in FZ in 
all matrices 
• Stable in urine 
and plasma at RF   
• Unstable at RT in 
three different 
matrices 
• Stable at FZ in 
three different 
matrices 
• Stable in urine in 
RF 
• Unstable in whole 
blood and plasma 
at RF 
MDPV Stable Stable Stable Stable 
BZP Stable Stable except 
in plasma at 
RT 
Stable except in 
plasma at RT 
Stable except in 
plasma at RT 
TFMPP Stable Stable except 
in plasma at 
RT 
Stable except in 
plasma and whole 
blood at RT 
Stable except 
plasma and whole 
blood at RT 
Li et al. [466] studied the stability of eleven synthetic cathinones (mephedrone, 
buphedrone, flephedrone, 3-fluoromethcathinone (3-FMC), 3-
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ethoxymethcathinone, methedrone, methylone, ethylone, butylone, MDPV and 
naphyrone) in equine plasma samples using LC tandem mass and liquid-liquid 
extraction over six months at -70°C, 30 days at -20°C, seven days at 4°C, 24 hours 
at 25°C and after three freeze/thaw cycles. The initial concentrations (day zero) 
were 0.5, 10 and 50 ng mL-1. All drugs mentioned above were stable under all 
conditions, with the exception of flephedrone, 3-fluoromethcathinone and 
methedrone at RT after 24 hours.  
Sorensen [213] examined the stability of many substances (cathinone, 
methcathinone, ethcathinone, amfepramone, mephedrone, flephedrone, 
methedrone, methylone, butylone, cathine, norephedrine, ephedrine, 
pseudoephedrine, methylephedrine and methylpseudoephedrine) in whole blood 
and human liver in post-mortem samples for six days under RT and RF. This work 
was completed with and without preservative samples by using Venosafe tubes 
containing a fluoride-oxalate additive (pH 7.4) and a fluoride-citrate additive (pH 
5.9). It was concluded that cathinone groups were unstable at RT after six days 
without preservatives, but stability improved after the acidification of the matrix. 
Ephedrines were stable under both conditions, because ephedrines have a 
hydroxyl group instead of a ketone group. However, pH played a significant role 
in minimising the degradation, especially when the samples were preserved under 
acidic conditions. The degradation was 30% on day six in cathinone, 
methcathinone, ethcathinone, mephedrone and flephedrone but when the whole 
blood samples were preserved with a fluoride-citrate buffer, the loss was reduced 
to 10%. 
Concheiro et al. [129] studied the stability of 28 SC and metabolites at RT and 4°C 
for 72 hours in urine. The pH was 7.6 and liquid chromatography was coupled to 
high resolution mass spectrometry and solid phase cation exchange extraction 
(SOLA SCX). The study was completed using two concentrations (3 and 300 ng mL-
1). There was no preservative added to the urine. All compounds were stable after 
3 freeze-thaw cycles after 72 hours at 4°C, except benzedrone and naphyrone that 
lost 33.3%. After 24 hours at RT, MDPPP, MDPBP, α-PVP, 4-MPBP and MDPV were 
stable, while the remaining 28 compounds had lost between 20% and 68%. 
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The stability, degradation products and pathways of mephedrone, flephedrone, 3-
FMC , 2-FMC , methedrone, N-e thylcathinone (EtCAT) and N,N-dimethylcathinone 
(DMC) in alkaline solution were studied by Tsujikawa, Mikuma [464] using GC−MS 
in urine and blood samples with pH values of 4,7,10 and 12 at RT. These 
compounds were stable at pH 4 after 12 hours. The degradation increased as the 
pH was increased. The degradation was more than 80% at pH 12 for primary 
methcathinone compounds. Additionally, the pathways, degradation products and 
the effect of antioxidants were reported in this study. Antioxidants were more 
stable than non-antioxidant compounds [467]. 
A similar study was done by Togawa, Ohmori [468] at pH of 5, 7 and 9. Cathinone 
and methcathinone were stable at pH 5 and unstable at pH 7 and pH 9. The 
degradation of cathinone and methcathinone was pH dependent in urine as tested 
in 2001 by Paul and Cole [118]. They were the first to evaluate cathinone and 
methcathinone stability in urine over a three-month period. The compounds were 
stable at FZ temperatures, but stability only lasted 3 days at RF, and 79% was lost 
in 3 months for both samples. The stability of these substances at RT was not 
investigated. The first stability study of cathinone in plasma was done in 1989 by 
Morad [469]. The stability of cathinones in oral fluid samples were carried out in 
[470].  
The stability of MDMA, 3-trifluromethylphenylpiperazine (3-TFMPP) and 
mephedrone were investigated at RT in post-mortem samples (tissue) after adding 
formaldehyde solution (5, 10 and 20% (v/v)) at three concentrations for pH values 
of 3.5,7 and 9.5, using HPLC with diode array detection. These samples were 
stored for 60 days for MDMA and 3-TFMPP and 28 days for mephedrone. Because 
of the formaldehyde, degradation products of N-methyl derivatives were 
detected, caused by the reaction of primary and secondary amine groups. These 
were unstable in formalin solutions and the degradation increased with increasing 
pH and formalin concentration. MDMA lost more in 5% formalin samples compared 
to 10 and 20% formalin samples, over a period of 60 days. 5% formalin samples of 
mephedrone and MDMA lost 82% and 25% respectively, over the period of this 
study. There was no degradation for 3-TFMPP after 24 hours, but 26% of the 
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concentration was observed on day 60. The degradation was 37% for mephedrone 
on day 28 and with pH 3.5 and 20% in formaldehyde [471].  
The reasons for the effect of formaldehyde on the degradation product pathways 
at different formalin concentration of SC was briefly discussed in [472-474]. In 
brief, the Eschweiler–Clarke reaction occurs when secondary amine groups present 
in mephedrone, for example reacts in formaldehyde. The iminium hydrogenate 
will then form the methylated amine products, and the mephedrone continuously 
degrades, due to the carbonyl group stabilising the iminium ion. 
Kerrigan and Glicksberg recently published three papers in 2017 evaluating the 
long-term stability of 22 cathinones over a period of six months using SPE and LC-
Q/TOF-MS in blood and urine at pH 4 and 8. The evaluation was based on 
temperature (-20°C, 4°C, 20°C, and 32°C) and concentration (100 ng mL-1 and 1000 
ng mL-1). There was no significant difference observed when the concentration 
changed in all compounds examined. The variation in degradation for cathinones 
were highly dependent on target analyte, pH and temperature. The cathinones 
were stable in the FZ over the period of the study. Some cathinones were 
undetectable after 24 hours of storage. In short, under all conditions tested, 
unconfirmed cathinones, ring-substituted drugs, followed by 
methylenedioxyphenol-group were the most unstable, and the pyrrolidone-group 
cathinones were the most stable [475-477].  
Al-Saffar et al. investigated buphedrone, mephedrone, methedrone, methylone, 
butylone, MDPV and naphyrone in urine [478].  The remaining drugs after a period 
of three months at FZ temperatures were 36.3% for buphedrone and between 62.1 
and 106% for secondary amines with ring substituents and 78-96% for tertiary 
amines. The drugs remaining at RF temperatures were 0.9% for buphedrone, 2-
15% for secondary amines with ring substituents and 85% and 30% for MDPV and 
naphyrone, respectively. All examined SC were undetected at RT, except MDPV 
which had 38% of the drug remaining.  
Miller et al. investigated the stability of 10 SC (cathinone, methcathinone, 
naphyrone, 4-methylethcathinone, mephedrone, MDPV, PVP, buphedrone, 
methylone and N-ethylcathinone) over a period of a month in oral fluid under the 
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preservation using Quantisal™ and Oral-Eze™, as compared with unpreserved oral 
fluid samples that were stored under RT, RF (4°C) and FZ (−20°C), using ultra HPLC–
MS-MS. All preserved and unpreserved samples that were kept at FZ temperatures 
were stable. At RT 71 to 100% of the samples were lost after one month, but at 
RF temperatures more than 88% was lost in unpreserved and Oral-Ez™ samples, 
whereas Quantisal™ oral fluid samples lost more than 34% [470].  
5.1.2 Amphetamine-type stimulants stability  
The long-term stability of amphetamine, methamphetamine, MDA, MDMA and 
other ephedrine derivatives were investigated in urine samples for two years by 
GC−MS. In this study, the work was carried out to evaluate sterilised and non-
sterilised urine specimens under refrigerator (4°C) and frozen conditions (−20°C). 
No significant degradation of the substances was observed at any examined 
condition over the two years [479]. Amphetamine and methamphetamine were 
similarly  stable under all examined conditions for a period of six [480] and 18 
months at 4–8°C [481].  
Peters et al. [482] measured the stability of amphetamine, methamphetamine, 
MDA, MDMA, MDEA, PMA, PMMA and other piperazine-derived designer substances 
in plasma. Stability was studied for three freeze/thaw cycles over three days, and 
no degradation was observed for any of the drugs. The samples were tested when 
left on the autosampler at RT for 32 hours, and no instability was observed.  
Clauwaert et al. [25] reported a comprehensive stability study of MDA, MDMA and 
MDEA in urine, serum, water and whole blood at temperatures of −20, 4, and 20°C 
for more than 21 weeks. No degradation was reported for all examined analytes 
under the above conditions. Nevertheless, interferences from the degraded blood 
matrix prevented quantification of MDA and MDEA after five and 13 weeks, 
respectively under low concentrations at the conditions of 20 and 4°C. 
Enantiomers of amphetamine, methamphetamine, MDA, MDMA and MDEA were 
stable in plasma over six months at frozen conditions and for the three 
freeze/thaw cycles [483, 484]. 
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In the long-term storage and stability of amphetamine and methamphetamine in 
blood lost 38% after three years and 77% after one year, throughout the five-year 
study, respectively. However, RSD was greater than 30%, and this might be the 
reason for the loss, instead of degradation [485]. MDMA, MDA, MDEA and MBDB 
((N-methyl-1-(3,4-methylenedioxyphenyl)-2-butamine) in oral fluid within 10 
weeks had lost 31% for MDA, 28% for MDMA, 38% for MDEA and 37% for MBDB [486]. 
5.1.3 Aim 
To examine the long-term stability of the 7 ATS and 22 SC from chapter 4 including 
metabolites and a variety of structure compounds in human urine over 381 days 
when the specimens were stored at three temperatures in ordinary light: RT, RF 
(4°C) and dark: FZ (−20°C). The assessment of which included:  
• To study the stability of RT, RF and FZ for all drugs examined in the 
period of 381 days at two concentrations 1 µg mL-1 and 0.5 µg mL-1. 
•  To study the relative stabilities for each class. 
• To investigate when SC will be totally undetectable.  
• To confirm the ability of ATS to remain stable, even when SC are degraded 
in the urine sample. 
• To assess autosampler stability over 72 hours.  
• To estimate the half-lives of 14 drugs. 
• To evaluate concentration and analyte dependence of selected SC.  
5.2 Method and Materials 
5.2.1 Chemicals and reagents  
All 29 standards, three ISD (amphetamine-d11, MDA-d5 and butylone-d3), PFPA, 
materials and chemicals were purchased from the supplier mentioned in sections 
3.2.1.1 and 4.2.1. 
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5.2.2 Sample preparation and storage 
1.85 mL was taken from each drug’s stock solution (100 µg mL-1) and spiked into 
fresh DFU in order to prepare 185 mL and to achieve the final concentration of 1 
µg mL-1. 0.925 mL was transferred from the 100 µg mL-1 of each drug’s stock 
solution and spiked to fresh DFU to obtain 185 mL for the final concentration 0.5 
µg mL-1. 185 µL was taken from the 100 µg mL-1 stock solution of each drug and 
spiked with fresh DFU to prepare 185 mL for the final concentration of 0.1 µg mL-
1. Each solution was inverted several times and shaken to make sure the spiked 
drug was homogeneously mixed with the drug-free urine.  
Aliquots of 1 mL of urine were added to 180 individual 1.5 mL Eppendorf 
microcentrifuge tubes with safe-locks to obtain information on the stability of 
concertation at 1 µg mL-1. A similar procedure was used to prepare the 0.5 and 
0.1 µg mL-1 concentrations. A total of 540 Eppendorf tubes (1 mL of each) were 
prepared within three hours.  
The samples were stored immediately after preparation at temperatures of RT, 
RF (4°C) and FZ (−20°C). The ambient (RT) and refrigerated samples were 
occasionally exposed to light. All spiked urine samples were exposed to light 
during routine laboratory work for sampling, preparation and analysis.  
The experimental design is briefly described in Figure 5-1. 
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Figure 5-1: Experimental design indicating the conditions under which ATS and SC stability 
was investigated 
5.2.3 Sample analysis 
Specimens were analysed on days 0, 1, 2, 3, 7, 14, 21, 28, 42, 77, 108, 137, 172, 
201, 319, 349 and 381. Testing occurred in three replicate samples in each 
concentration and condition with eight freshly prepared calibrator points and 
three QCs on each day of analysis. The calibration curves were plotted on each 
day with the calculation of accuracy and RSD for each concentration, QC and 
condition.  
5.2.4 Calibrators, QCs and sample preparation procedure 
Standards were freshly prepared on each day of the stability study. 100 µL was 
taken from each stock standard solution (100 µg mL-1) to prepare a 5 mL volume 
Drug-free urine
Low concentration 
100 ng mL-1  (n= 180)
Frozen (FZ)
-20°C.
Refrigerated 
4°C.
Room temp.
(RT)
Meduim concentration 
500 ng mL-1 (n= 180)
Frozen (FZ)
-20°C.
Refrigerated 
4°C.
Room temp.
(RT)
High concentration
1000 ng mL-1 (n= 180)
Frozen (FZ)
-20°C.
Refrigerated 
4°C.
Room temp.
(RT)
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of the final concentration of 2 µg mL-1. This mixture was diluted using DFU. The 
calibrator points were prepared using the method in chapter 4, section 4.2.5. 
QC3 and QC2 at 1 and 0.5 µg mL-1 were achieved by spiking 100 and 50 µL of 
working solution one (10 µg mL-1) into 1 mL of DFU, respectively. 100 µL of working 
solution two (1 µg mL-1) was added to 1 mL of DFU to prepare 0.1 µg mL-1. All the 
mention were prepared daily.  
5.2.5 Stability procedure 
On each test day, 1 mL of calibrators at concentrations of 0, 0.05, 0.1, 0.25, 0.5, 
0.75, 1 and 2 µg mL-1, QCs at 0.1, 0.5, and 1 µg mL-1, RT samples at 0.1, 0.5, and 
1 µg mL-1, RF samples at 0.1, 0.5, and 1 µg mL-1, FZ samples at 0.1, 0.5, and 1 µg 
mL-1 were added into 38 different culture tubes. The procedure from chapter 4 
was then followed using SPE, PFPA and GC−MS (see section 4.2.11 for the 
procedure). See Figure 5-2 for the laboratory preparation work on each day of 
the stability study.  
 
Figure 5-2: Laboratory preparation on the stability test days 
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5.2.6 Autosampler stability  
Autosampler stability was assessed to determine if samples could be left in the 
autosampler for 24 hours without the target analytes concentration decreasing. It 
was also important to know if there were any other effects on the results if the 
samples stayed in the auto sampler for more than 24, 48 and 72 hours. The method 
lasts 25 min for one sample, and knowing how many samples can be run through 
the batch before the degradation initiates would be vital. 
To examine the stability, the two QCs in urine were analysed at day zero for the 
evaluation of ATS and SC at concentrations of 500 and 1000 ng mL-1 in triplicate. 
The GC vials were at that time left on the autosampler and re-injected again after 
24, 48 and 72 hours.  
5.2.7 GC–MS conditions 
See chapter 4, section 4.2.15.  
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5.3 Results and Discussion 
Data stability was calculated using the standard design detailed by Hoffman et al. 
[20].  Accuracy parameter was selected to investigate stability. The studied 
compound was only considered unstable when its concentration was reduced by 
more than 20% of the initial concentration at day zero. The 20% bias was applied 
to avoid any confusion between the drug degradation and uncertainties. Single 
factor ANOVA was additionally used to determine the significant differences 
between tests (P = 0.05). The results in each concentration must be less than 20% 
of the RSD to be considered valid, otherwise it was reported as a Bad Response 
(B.R). The B.R can also mean that the relative ion ratios were less than 80% (Q. 
value) compared to the selected target ion.  
In a laboratory, urine specimens must be immediately stored at FZ or RF after 
analysis is completed. However, urine specimens were allowed to be left at RT for 
381 days for the purpose of assessing the stability. The stability study had several 
conditions and factors that may have affected the results, but all steps were taken 
to prevent this where possible.  
All tertiary amine substances presented high RSD in most stability study days. 
Therefore, they were excluded from the analysis. The concentration of 100 ng mL-
1 results were also excluded for the same reason.   
5.3.1 Freezer stability study at −20C 
All tested drug groups were stable on all examination days, even after 381 days 
when the samples were stored at −20°C.  
This is the first study of urine stability for cathinones over a long period of time 
under the stated conditions (see Table 5-2). The table shows that all drugs were 
stable on day 381, with similar stability findings on all other examined days.  
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Table 5-2: Freezer stability results on day 381 (n = 3) 
Day number Day 381 
Drug & Stability results Mean RSD Bias Mean RSD Bias 
(500 ng mL-1) (1000 ng mL-1) 
AMPHETAMINE 421 4.08% -16% 931 4.87% -6.9% 
METHAMPHETAMINE 488 1.27% -2.34% 951 2.94% -4.92% 
CATHINONE  600 16% 20% 1182 8.8% 18% 
FLEPHEDRONE 470 6.8% -6.0% 1119 11% 12% 
BUPHEDRINE  461 18% -7.8% 962 7.0% -3.79% 
METHCATHINONE 458 6.2% -8.5% 1094 12% 9.4% 
4 METHYLEPHEDRINE met. 512 12% 2.34% 971 3.89% -2.86% 
4-MEC metabolite  484 14% -3.27% 1056 4.49% 5.6% 
BUPHEDRONE 431 6.8% -14% 1054 8.4% 5.4% 
N-EC  457 15% -8.6% 990 7.3% -1.00% 
PMA  473 16% -5.4% 912 3.72% -8.8% 
MEPHEDRONE 433 17% -13% 984 6.4% -1.56% 
PENTEDRONE 404 12% -19% 997 5.6% -0.32% 
MDA 504 16% 0.85% 885 3.29% -11% 
4-MEC  497 13% -0.65% 950 9.1% -5.0% 
PMMA 536 17% 7.2% 966 3.60% -3.45% 
4-EMC  440 19% -12% 1003 11% 0.30% 
METHEDRONE 479 16% -4.25% 923 5.2% -7.7% 
MDMA 467 18% -6.6% 898 3.20% -10% 
MDEA 454 10% -9.2% 878 5.1% -12% 
PVP 489 13% -2.26% 911 4.11% -8.9% 
METHYLONE 479 17% -4.28% 933 5.9% -6.7% 
BUTYLONE 503 17% 0.62% 965 4.66% -3.52% 
ETHYLONE  482 18% -3.59% 904 5.1% -9.6% 
PYROVALERONE 518 16% 3.62% 911 4.30% -8.9% 
PENTYLONE 506 15% 1.17% 900 4.56% -10% 
MDPPP 512 11% 2.48% 1056 0.70% 5.6% 
MDPV 526 16% 5.1% 939 4.48% -6.1% 
NAPHYRONE 498 19% -0.39% 1048 7.8% 4.82% 
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5.3.2 Stability study at RT 
ALL ATS drugs were stable in urine at RT from the initial day until day 349. On day 
381, amphetamine and methamphetamine were stable, while the remaining ATS 
drug concentrations had decreased 24-44%. In general, most SC degraded after 
one day or two days, and the degradation was gradually increased to day 21 before 
being completely undetected on day 28 (see Table 5-3 for the results).  
More specifically, non-ring substitute cathinones required 24 hours (cathinone, 
methcathinone and N-EC), and 48 hours (buphedrone and pentedrone) to present 
a difference in the concentration (greater than 20%). All non-ring substitute drugs 
were undetected after 21 days, except for methcathinone, which only needed 14 
days to entirely disappear. 
Ring substituted compounds (flephedrone, mephedrone, 4-MEC, 4-EMC, 
methedrone) lost more than 19% concentration after 24 hours and were 
completely unobserved after 21 days, with the exception of methedrone which 
was undetected after 28 days.  
Methylenedioxy-substituted substances were stable from day zero to day three for 
butylone and pentylone, but methylone and ethylone lost more than 38% and 40% 
after 24 and 48 hours, respectively at 1 µg mL-1. These substances were 
undetected after 28 days.µ 
Cathinone metabolites (buphedrone-ephedrine, 4-methylephedrine, 4-MEC 
metabolite) were all stable after 24 hours, except for 4-MEC metabolite which 
decreased by 39% after a day at 1 µg mL-1. Concentrations fluctuated above the 
acceptable range of RSD and relative ion ratios from day 21 to 319. It was difficult 
to determine if this was from the breakdown of the products themselves or from 
the breakdown of other compound products. Pyrrolidine-type substances (tertiary 
amines, PVP, pyrovalerone, MDPPP, MDPV and naphyrone) achieved similarly poor 
responses in specimens with above 20% RSD from day 2 to 381. These drugs were 
underivatised and had one dominant mass spectra; the residual ions were less than 
8%. Hence, the residual ions were unstable to be used as qualitative ions for 
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interpretation. Therefore, the stability results for this group were unknown, 
except for the first 24 hours when the drugs were stable.  
5.3.3 Stability study at 4°C (refrigerator) 
The ATS substances were stable in urine at RF over all examined days. Cathinones 
were only stable for 14 days excluding N-EC and the selected metabolites, which 
degraded after 48 hours. This group was primarily undetected after 77 days for N-
EC and flephedrone, but diminished entirely after 349 days for all SC. See for 
Table 5-4 the results.  
Non-ring substitute cathinones were stable from day zero into day 14, except for 
N-EC which was stable in days zero and one, but then the degraded from day 21. 
By day 108, 137, 42, 172 and 77, cathinone, methcathinone, N-EC, buphedrone 
and pentedrone were undetectable, respectively. Ring substituted substances 
were stable until day 14, except flephedrone which only lasted three days. The 
breakdown products were observed and increased from day 21 to day 77 for 
mephedrone, and up to day 319 for 4-EMC and methedrone before totally 
disappearing. The RSD and the ion ratios of 4-MEC compound were more than 20% 
from day 21 to 381.  
Methylenedioxy-substituted drugs were stable from day zero to day 14, but 
degraded from day 21 to 319, and were undetected from day 349 until the last 
day of the study.  
SC metabolites were all stable for 24 hours before being degraded on day two, the 
uncertainties were above the acceptable recommendation. On most investigation 
days, tertiary amine substance results provided poor responses with similar errors.  
The GC−MS was occasionally operated in full scan mode instead of SIM to look for 
breakdown products that could be identified. Unfortunately, the baseline of the 
GC−MS was high to catch peaks, and the ions were only determinable when the 
target quantitative and qualitative ions were selected and extracted.  
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Table 5-3: Linearity and accuracy (bias) at RT for concentrations of 500 and 1000 ng mL-1 with stability condition for selected compounds. 
ST: the drug is stable, B.R: bad response, ND: the compound is undetected, UnST: the substance is unstable, but it can be detected. (n= 3) 
Days & Drugs Condition Amphetamine Methamphetamine PMA  MDA PMMA MDMA MDE Cathinone Methcathinone N-EC Bupherone  Pentedrone Flephedrone Mephedrone 4-MEC 4-EMC Methedrone   Methylone Butylone Ethylone  Pentylone Buph-ephedrine 4-Methylephedrine 4-MEC metabolite
R
2 1 1 0.999 0.999 0.997 0.999 0.999 0.999 1 0.998 0.999 0.999 1 0.999 0.994 0.999 0.999 0.999 1 0.998 0.999 0.999 0.998 0.998
500 ng/mL -4% -4% -3% -7% -2% -4% 15% 13% 7% 16% 13% 13% 8% 14% 2% -12% -5% -1% -4% 5% -4% 0% 10% 14%
1000 ng/mL 0% -4% 14% -7% 2% -1% 8% 4% 4% 16% 7% 13% 0% 6% 4% -6% -6% -10% -1% 6% -1% -8% -5% 0%
Stability ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST
R
2 0.997 0.999 0.999 0.998 0.997 0.999 0.99 0.995 0.999 0.999 0.995 0.995 0.999 0.998 0.99 0.995 0.997 0.997 0.999 0.998 0.998 1 0.999 0.995
500 ng/mL -11% -1% -6% -10% -14% -8% 0% -20% -22% -10% -7% -12% -17% -12% -4% -21% -19% -16% -8% 14% -11% -7% -5% -9%
1000 ng/mL -5% -13% 15% -11% -18% -8% 9% -21% -34% -25% -15% -14% -35% -19% -27% -35% -33% -38% -8% -12% -9% -20% -2% -39%
Stability ST ST ST ST ST ST ST UnST UnST UnST ST ST UnST ST UnST UnST UnST UnST ST ST ST ST ST UnST
R
2 1 0.999 1 1 0.999 0.999 0.998 0.998 0.999 0.994 1 0.998 0.999 0.998 0.994 1 1 1 1 0.999 1 1 0.999 0.997
500 ng/mL -7% -8% -13% -3% -14% -13% -18% -26% -44% -39% -11% -23% -41% -17% -22% -36% -18% -14% -10% -23% -14% -5% -17% -13%
1000 ng/mL -4% -19% -2% -12% -14% -19% B.R -32% -49% -56% -24% -28% -55% -25% -40% -34% -22% -23% -12% -40% -15% -7% -32% -27%
Stability ST ST ST ST ST ST ST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST ST UnST ST ST UnST UnST
R
2 0.998 0.999 0.999 1 0.999 0.999 0.998 0.998 0.999 0.993 0.999 0.999 1 0.999 0.998 1 1 1 1 0.998 1 0.999 0.999 0.999
500 ng/mL 1% 4% -2% -8% -9% -19% B.R -41% -57% -56% -28% -35% -54% -27% -36% -34% -19% -23% -15% -35% -15% -13% -23% -44%
1000 ng/mL 2% -18% -7% -10% -17% -16% B.R -53% -69% -71% -42% -50% -71% -43% -42% -43% -24% -30% -18% -43% -19% -15% -26% -49%
Stability ST ST ST ST ST ST B.R UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST ST UnST ST ST UnST UnST
R
2 0.999 0.996 0.998 1 0.998 0.992 0.996 0.998 0.999 0.993 0.999 0.998 0.999 0.998 0.992 0.999 0.998 0.998 0.998 0.99 0.999 0.999 0.999 0.994
500 ng/mL -8% -13% -4% -9% B.R B.R B.R -68% -85% -84% -52% -64% -86% -62% -65% -65% -39% -45% -26% -54% -29% -4% -4% -16%
1000 ng/mL 0% -9% -10% -13% -15% -11% B.R -81% -95% -92% -69% -83% -96% -76% -57% -78% -46% -55% -33% -53% -41% -15% -36% -38%
Stability ST ST ST ST ST ST B.R UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST ST UnST UnST
R
2 1 1 0.997 0.999 0.999 0.997 0.995 0.997 1 0.995 0.999 0.998 0.999 0.998 0.997 1 0.999 1 1 0.997 0.999 0.998 0.997 0.981
500 ng/mL -3% -4% 4% -10% -9% 0% 0% -90% B.R -44% -76% -87% -95% -83% -63% -86% -59% -68% -39% -58% -48% -20% -41% -40%
1000 ng/mL 0% -5% -3% -12% 2% 5% 15% -95% ND -72% -90% -96% ND -93% -72% -95% -74% -82% -51% -68% -63% -18% -30% B.R
Stability ST ST ST ST ST ST ST UnST ND UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST UnST
R
2 0.999 0.999 0.999 0.999 0.997 0.999 0.993 1 0.998 0.998 0.999 0.999 0.999 0.998 0.997 0.997 0.999 0.999 1 0.994 0.999 0.998 0.998 0.998
500 ng/mL -4% -8% 14% -1% B.R 13% 15% ND ND ND ND ND ND ND ND ND -74% -79% -50% -67% -58% B.R B.R B.R
1000 ng/mL -1% -12% 3% -8% 5% 5% 8% ND ND ND ND ND ND ND ND ND -92% -96% -70% -90% -83% B.R B.R B.R
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND ND ND UnST UnST UnST UnST UnST B.R B.R B.R
R2 0.999 0.999 0.997 1 0.999 0.995 0.999 0.999 0.993 0.999 0.994 0.996 0.999 0.996 0.999 0.999 0.999 0.999 0.999 0.998 0.998 0.992 0.993 0.992
500 ng/mL -6% -7% 10% -9% -17% 12% 6% ND ND ND ND ND ND ND ND ND ND ND ND ND ND 13% B.R B.R
1000 ng/mL -3% -7% 11% -6% 14% -5% 3% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND ND ND ND ND ND ND ND ST B.R B.R
R
2 0.998 0.997 0.994 0.995 0.998 0.998 0.993 0.994 0.997 0.967 0.995 0.998 0.998 0.998 0.995 0.997 0.998 0.999 0.998 0.991 0.999 0.998 0.993 0.996
500 ng/mL -14% -9% 10% -3% -12% -2% 2% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
1000 ng/mL -11% -6% 1% -17% -7% 3% 9% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
R
2 1 0.999 0.998 1 1 0.999 0.998 0.998 0.997 0.998 0.997 0.996 0.998 0.996 0.999 0.999 0.999 1 1 1 0.999 1 0.997 0.999
500 ng/mL -8% -12% 2% -7% -8% 9% 16% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
1000 ng/mL 2% -7% 5% -8% 6% 7% 15% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
R
2 1 1 0.995 0.999 0.998 0.999 0.999 0.997 0.992 0.994 0.998 0.996 0.999 0.994 0.995 0.999 0.999 0.999 0.999 0.999 1 0.998 0.994 0.997
500 ng/mL -4% 16% 8% -16% -12% -16% -11% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
1000 ng/mL -3% 8% 10% -15% -7% -9% -8% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
R
2 0.999 0.999 0.999 0.998 0.999 0.999 0.99 0.997 0.994 0.997 0.997 0.992 0.997 0.995 1 0.999 0.995 0.993 0.999 0.991 0.998 0.995 0.998 0.997
500 ng/mL -15% B.R 3% -15% -18% -23% -11% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
1000 ng/mL 3% -9% -12% -17% 9% -2% -4% ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
R
2 1 0.999 0.983 0.992 0.999 0.997 0.979 0.999 1 0.995 1 0.992 0.992 0.999 0.983 0.962 0.997 0.996 0.995 0.964 0.992 0.994 0.999 0.98
500 ng/mL -10% -1% -15% -3% -12% -7% B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
1000 ng/mL -10% -13% -13% 7% -13% -7% B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
Stability ST ST ST ST ST ST B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
R
2 1 0.997 0.992 0.998 0.993 1 0.915 0.989 0.995 0.991 0.998 0.99 1 0.981 0.992 0.996 1 1 1 0.987 0.999 0.997 0.995 0.993
500 ng/mL -7% -5% -17% -13% 25% -9% B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
1000 ng/mL -6% -11% 6% -17% 12% -11% B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
Stability ST ST ST ST ST ST B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R B.R
R
2 0.998 0.997 0.997 0.998 0.998 0.995 0.99 0.995 0.999 0.972 0.995 0.996 0.993 0.994 0.96 0.969 0.956 0.977 0.998 0.971 0.983 0.997 0.964 0.963
500 ng/mL -10% B.R -14% -13% B.R B.R B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R
1000 ng/mL -4% B.R 17% -12% -18% B.R B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R
Stability ST B.R ST ST ST B.R B.R ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND B.R B.R
R
2 0.999 0.998 0.999 0.998 0.999 0.998 0.998 0.995 1 0.999 1 0.999 0.999 0.998 0.998 0.997 0.996 0.998 0.998 0.999 0.998 0.999 0.999 1
500 ng/mL -8% -14% -3% B.R 2% -1% 9% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
1000 ng/mL -15% -16% 8% 7% 10% 8% 4% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
R
2 1 1 1 0.999 1 1 1 0.999 0.999 1 0.999 0.999 0.999 1 1 1 1 1 0.999 1 0.999 1 1 0.999
500 ng/mL -19% 10% -32% -26% -24% -32% -44% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
1000 ng/mL -16% 0% -26% -28% -18% -30% -30% ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Stability ST ST UnST UnST UnST UnST UnST ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
A) Stability study at RT, 0.5 and 1 ug/mL 
Day 349
Day 381
Day 172  
Day 201  
Day 319
Day 77  
Day 108  
Day 137  
Day 21  
Day 28  
Day 42  
Day 3  
Day 7  
Day 14  
Cathinone metabolites
Day 0  
Day 1  
Day 2  
Group name ATS Non-ring substitute Ring substituted Methylenedioxy-substituted
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Table 5-4: Accuracy (bias) at RF for concentrations of 500 and 1000 ng mL-1 with stability conditions for selected compounds. 
ST: the drug is stable, B.R: Bad response, ND: the compound is undetected, UnST: the substance is unstable, but it can be detected. (n= 3) 
Days & Drugs Condition Amphetamine Methamphetamine PMA  MDA PMMA MDMA MDE Cathinone Methcathinone N-EC Bupherone  Pentedrone Flephedrone Mephedrone 4-MEC 4-EMC Methedrone   Methylone Butylone Ethylone  Pentylone Buph-ephedrine 4-Methylephedrine 4-MEC metabolite
500 ng/mL -4% -2% -7% -7% 3% 3% -7% 12% 6% 0% 12% 14% 6% 15% -7% -12% -1% -2% -5% 38% -6% 1% 18% 17%
1000 ng/mL -1% -8% 14% -6% 1% 0% 7% 11% 7% 17% 11% 16% 4% 18% -6% -6% -4% -12% 0% 14% -1% -4% 0% 9%
Stability ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST
500 ng/mL -6% -7% 17% -10% -17% -11% -13% -11% -5% -6% -1% -5% -3% -5% -10% -13% -16% -13% -7% 5% -8% -11% -15% 3%
1000 ng/mL -3% -6% 1% -11% -15% -3% -3% -11% -6% 0% -8% -5% -8% -14% -11% -19% -19% -4% -6% -7% -7% -19% -17% 5%
Stability ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST ST
500 ng/mL -8% -10% -18% -12% B.R -16% B.R -19% -14% -42% -14% -21% -11% -22% -12% -8% -10% -11% -9% B.R -10% -24% -29% -49%
1000 ng/mL -6% -13% -4% -13% -17% -19% B.R -17% -11% -43% -19% -17% -14% -13% -13% 10% 5% 5% -6% -19% -7% -20% -23% B.R
Stability ST ST ST ST ST ST B.R ST ST UnST ST ST ST ST ST ST ST ST ST ST ST UnST UnST UnST
500 ng/mL 2% -13% -2% -8% B.R -12% B.R -6% -6% -34% -10% -10% 3% 0% -8% -2% -3% -4% -7% B.R 0% -16% -28% -60%
1000 ng/mL 6% -17% -3% -8% B.R -14% B.R -12% -6% -29% -11% -6% -5% 1% -8% -3% -4% -5% -4% -18% -4% -24% -30% B.R
Stability ST ST ST ST B.R ST B.R ST ST UnST ST ST ST ST ST ST ST ST ST ST ST UnST UnST UnST
500 ng/mL -7% -14% -11% -10% B.R -16% B.R -14% -17% -27% -9% -13% -12% -8% -10% -7% -6% -4% -9% -19% -8% -24% -42% -57%
1000 ng/mL 1% -18% -11% -10% B.R -7% B.R -15% -20% -72% -11% -15% -21% -14% -10% 8% 9% -1% -5% -14% 0% -18% -56% B.R
Stability ST ST ST ST B.R ST B.R ST ST UnST ST ST UnST ST ST ST ST ST ST ST ST UnST UnST UnST
500 ng/mL 3% 0% 3% -2% -7% -7% -11% -14% -5% -24% -5% -8% -17% -12% -2% -13% -3% -3% -3% -11% -2% B.R B.R B.R
1000 ng/mL 5% -4% 2% -7% 1% -1% -2% -17% -14% -24% -9% -11% -26% -12% -7% -12% -3% -4% -2% B.R -4% B.R B.R B.R
Stability ST ST ST ST ST ST ST ST ST UnST ST ST UnST ST ST ST ST ST ST ST ST B.R B.R B.R
500 ng/mL 1% B.R 7% -5% B.R 25% B.R -76% -53% -45% -39% -49% -39% -20% B.R -40% -32% -35% -47% -34% -10% B.R B.R B.R
1000 ng/mL 3% -18% -3% -2% B.R -9% B.R -70% -36% -83% -44% -53% -65% -59% B.R -51% -34% -55% -24% -81% -24% B.R B.R B.R
Stability ST ST ST ST B.R ST B.R UnST UnST UnST UnST UnST UnST UnST B.R UnST UnST UnST UnST UnST UnST B.R B.R B.R
500 ng/mL -4% -7% -18% -4% -7% -10% -12% -41% -20% -53% -22% -36% -64% -39% B.R -40% -19% -20% -7% -12% -17% B.R B.R B.R
1000 ng/mL -1% -8% -13% -7% B.R -11% B.R -51% -17% -61% -28% -40% -70% -42% B.R -43% -21% -26% -7% -21% -16% B.R B.R B.R
Stability ST ST ST ST ST ST ST UnST UnST UnST UnST UnST UnST UnST B.R UnST UnST UnST ST UnST ST B.R B.R B.R
500 ng/mL -12% -8% B.R -17% -11% -19% -13% -49% 9% -52% -28% -36% -76% -32% B.R -67% -40% -40% -21% -25% -28% 8% B.R B.R
1000 ng/mL -9% -15% -14% -15% B.R -15% B.R -61% -27% -75% -54% -66% -88% -59% B.R -76% -54% -58% -30% -53% -38% -33% -17% -24%
Stability ST ST ST ST ST ST ST UnST UnST UnST UnST UnST UnST UnST B.R UnST UnST UnST UnST UnST UnST UnST UnST UnST
500 ng/mL -3% 2% -13% -4% -6% -11% B.R -78% B.R ND -59% -77% ND -75% B.R -76% -46% -51% -18% -52% -32% B.R B.R B.R
1000 ng/mL -1% -5% B.R -8% -5% -10% B.R -85% B.R ND -67% -83% ND -81% B.R -81% -49% -58% -20% -55% -36% B.R B.R B.R
Stability ST ST ST ST ST ST B.R UnST B.R ND UnST UnST ND UnST B.R UnST UnST UnST UnST UnST UnST B.R B.R B.R
500 ng/mL B.R B.R B.R B.R B.R B.R B.R -88% 2% ND B.R ND ND ND B.R B.R B.R B.R B.R B.R B.R B.R B.R B.R
1000 ng/mL -3% -10% B.R B.R B.R B.R B.R -95% -46% ND -91% ND ND ND B.R -87% -84% -87% -65% -83% -71% -52% -46% -54%
Stability ST ST B.R B.R B.R B.R B.R UnST UnST ND UnST ND ND ND B.R UnST UnST UnST UnST UnST UnST UnST UnST UnST
500 ng/mL -8% -1% 5% -10% B.R 10% -2% ND -90% ND -62% ND ND ND B.R -67% -49% -58% -36% -92% -47% -51% B.R -72%
1000 ng/mL -2% -5% -12% -11% 11% 3% B.R ND -94% ND -76% ND ND ND B.R -84% -65% -73% -40% -78% -55% -43% B.R -51%
Stability ST ST ST ST ST ST ST ND UnST ND UnST ND ND ND B.R UnST UnST UnST UnST UnST UnST UnST B.R UnST
500 ng/mL -9% -2% B.R 11% -10% 1% B.R ND ND ND -88% ND ND ND B.R ND -66% -73% -36% -83% -49% B.R B.R B.R
1000 ng/mL -4% -7% B.R 14% 0% 18% 5% ND ND ND -94% ND ND ND B.R ND -76% -85% -51% -84% -66% B.R B.R B.R
Stability ST ST B.R ST ST ST ST ND ND ND UnST ND ND ND B.R UnST UnST UnST UnST UnST UnST B.R B.R B.R
500 ng/mL 0% -7% -18% -3% 13% -2% B.R ND ND ND ND ND ND ND B.R -89% -75% -83% -50% -79% -63% B.R B.R B.R
1000 ng/mL 1% -14% B.R -19% B.R -5% B.R ND ND ND ND ND ND ND B.R -95% -87% -91% -61% -79% -72% B.R B.R B.R
Stability ST ST ST ST ST ST B.R ND ND ND ND ND ND ND B.R UnST UnST UnST UnST UnST UnST B.R B.R B.R
500 ng/mL -1% 1% B.R -10% B.R B.R B.R ND ND ND ND ND ND ND B.R -72% -86% -83% -73% B.R -66% -84% B.R B.R
1000 ng/mL 4% -6% B.R -4% -17% B.R B.R ND ND ND ND ND ND ND B.R -86% -91% -91% -75% -85% -90% -91% B.R B.R
Stability ST ST B.R ST ST B.R B.R ND ND ND ND ND ND ND B.R UnST UnST UnST UnST UnST UnST UnST B.R B.R
500 ng/mL -18% -11% -11% -3% -7% -7% -5% ND ND ND ND ND ND ND B.R ND ND ND ND ND ND ND ND ND
1000 ng/mL -9% -8% 9% 8% 9% 13% 13% ND ND ND ND ND ND ND B.R ND ND ND ND ND ND ND ND ND
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND B.R ND ND ND ND ND ND ND ND ND
500 ng/mL -13% -2% -12% -3% -9% -9% -10% ND ND ND ND ND ND ND B.R ND ND ND ND ND ND ND ND ND
1000 ng/mL -6% 5% -10% -15% -6% -7% -8% ND ND ND ND ND ND ND B.R ND ND ND ND ND ND ND ND ND
Stability ST ST ST ST ST ST ST ND ND ND ND ND ND ND B.R ND ND ND ND ND ND ND ND ND
  Day 381
  Day 7  
A) Stability study at RF, 0.5 and 1 ug/mL 
Day 21  
Day 28  
Day 42  
Day 77  
Day 108  
Day 137  
Day 0  
Day 1  
Day 2  
Day 3
Day 14  
Day 172
Day 201  
Day 319
Day 349
Methylenedioxy-substituted Cathinone metabolitesGroup name ATS Non-ring substitute Ring substituted
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5.3.4 Autosampler Stability 
The results of autosampler stability for the 29 substances at 0.5 and 1 µg mL-1 on 
days zero through three in triplicate urine samples are shown in Table 5-5. All 
tested analytes were less than or equal the acceptable range of ±20% for the 
accuracy and RSD.  
Therefore, the data proved that the ATS and SC with ISD are stable when left in 
the autosampler for at least three days after extraction. Additionally, the data 
showed that most SC lost more than 10% but less than 20% in concentration on day 
three, which indicates that these compounds could be become unstable after this 
day.  
5.3.5 Concentration reliance 
Concentration reliance was evaluated by associating the remaining percentage of 
the target ion at 500 ng mL-1 and 1000 ng mL-1. One-way ANOVA was applied to 
compare the average concentration of each test day at each concentration and 
temperature. The statistical work was completed for each substance alone in each 
condition. No concentration reliance was observed in the stability study for any 
condition (P = 0.05) for all valid samples.  
The ANOVA result was true for most values, but not all, because some data 
achieved bad response (B.R). Therefore, the concentration reliance was 
additionally assessed by trendline accuracy (%) results; these results show that 
most substances were following approximately the similar trendline for both 
concentrations on all stability test days with the similar degradation (see the 
results that were mentioned earlier on Table 5-3 and Table 5-4).  
Figure 5-3 and Figure 5-4 illustrate that trendline changes are comparable for 
both concentrations. Overall, no significant difference was observed in the 
stability work between the two concentrations examined (500 ng mL-1 and 1000 
ng mL-1) using single factor ANOVA study. 
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Table 5-5: Autosampler stability study. Triplicate urine samples in each concentration of 0.5 and 1 µg mL-1 repeated after 24, 48 and 72 hours with calculation 
of R2, mean (n= 3), SD, RSD and accuracy (bias).  
Autosampler_day 0 Amphetamine Methamphetamine Cathinone FlephedroneBuph-ephedrine metabolite Methcathinone 4-Methyl ephedrine metabolite 4-M-N-E-norephedrine Buphedrone N-Ethyle cathinone PMA Mephedrone Pentedrone MDA 4-MEC PMMA 4-EMC Methedrone MDMA MDE Methylone Butylone Ethylone Pentylone
R2 1 1 0.999 0.999 1 0.999 1 0.999 0.999 1 1 1 0.999 0.999 1 1 1 1 1 1 1 0.999 1 0.999
500 ng/mL 438 481 652 506 468 479 471 495 454 476 425 444 431 446 422 439 444 429 408 415 426 453 421 420
500 ng/mL 404 493 490 444 374 426 482 412 398 380 436 352 350 469 534 548 353 441 427 440 439 452 442 533
500 ng/mL 422 490 657 460 541 468 582 544 443 516 558 502 432 598 534 621 522 567 566 507 571 604 583 565
The average 421 488 600 470 461 458 512 484 431 457 473 433 404 504 497 536 440 479 467 454 479 503 482 506
SD 17 6 95 32 84 28 61 66 29 70 74 76 47 82 65 92 84 76 86 47 80 88 88 76
RSD 4.1% 1.3% 15.8% 6.8% 18.2% 6.2% 11.9% 13.7% 6.8% 15.2% 15.7% 17.5% 11.6% 16.2% 13.0% 17.2% 19.2% 15.9% 18.4% 10.5% 16.7% 17.4% 18.3% 15.0%
Accuracy -15.7% -2.3% 19.9% -6.0% -7.8% -8.5% 2.3% -3.3% -13.7% -8.6% -5.4% -13.4% -19.2% 0.8% -0.6% 7.2% -12.0% -4.3% -6.6% -9.2% -4.3% 0.6% -3.6% 1.2%
1000 ng/mL 941 924 1209 1149 995 1121 979 1063 1058 966 910 987 985 872 939 957 1025 913 875 840 923 957 886 888
1000 ng/mL 882 948 1067 980 884 955 931 1006 963 933 880 920 948 865 870 936 885 882 889 867 885 924 869 866
1000 ng/mL 971 980 1270 1229 1007 1205 1005 1100 1141 1071 947 1046 1058 919 1042 1004 1099 976 930 927 993 1013 956 945
The average 931 951 1182 1119 962 1094 971 1056 1054 990 912 984 997 885 950 966 1003 923 898 878 933 965 904 900
SD 45 28 104 127 68 127 38 47 89 72 34 63 56 29 87 35 109 48 29 45 55 45 46 41
RSD 4.9% 2.9% 8.8% 11.4% 7.0% 11.6% 3.9% 4.5% 8.4% 7.3% 3.7% 6.4% 5.6% 3.3% 9.1% 3.6% 10.8% 5.2% 3.2% 5.1% 5.9% 4.7% 5.1% 4.6%
Accuracy -6.9% -4.9% 18.2% 11.9% -3.8% 9.4% -2.9% 5.6% 5.4% -1.0% -8.8% -1.6% -0.3% -11.5% -5.0% -3.4% 0.3% -7.7% -10.2% -12.2% -6.7% -3.5% -9.6% -10.0%
Autosampler_24h
500 ng/mL 441 487 544 505 480 485 507 561 473 474 422 426 464 449 430 463 467 432 424 426 432 476 435 434
500 ng/mL 407 523 563 440 386 422 509 462 405 373 433 335 362 458 440 465 348 441 434 450 442 474 434 442
500 ng/mL 426 502 622 458 546 466 614 590 448 501 556 492 465 586 549 575 516 566 579 623 579 640 589 576
The average 424 504 576 468 470 458 543 538 442 449 470 418 430 498 473 501 444 480 479 500 484 530 486 484
SD 17 18 41 34 80 32 62 67 35 67 74 79 59 76 66 64 86 75 87 107 82 96 89 80
RSD 4.0% 3.5% 7.0% 7.2% 17.1% 7.0% 11.3% 12.4% 7.8% 14.9% 15.8% 18.9% 13.7% 15.4% 13.9% 12.8% 19.5% 15.7% 18.2% 21.5% 17.0% 18.0% 18.3% 16.5%
Accuracy -15.1% 0.8% 15.3% -6.5% -5.9% -8.5% 8.6% 7.5% -11.6% -10.1% -5.9% -16.5% -13.9% -0.5% -5.3% 0.2% -11.2% -4.1% -4.2% -0.1% -3.1% 6.0% -2.8% -3.2%
1000 ng/mL 938 924 1186 1153 1004 1190 1000 1085 1080 1023 884 940 998 845 929 933 930 895 876 842 897 992 867 877
1000 ng/mL 889 974 1168 987 893 937 964 1041 1005 907 873 890 982 859 903 920 883 891 903 892 903 994 900 885
1000 ng/mL 966 983 1137 1243 1013 1308 1016 1115 1166 1100 941 1017 1075 912 1010 984 1001 968 940 942 986 1066 974 957
The average 931 960 1164 1128 970 1145 993 1080 1084 1010 900 949 1019 872 948 946 938 918 906 892 929 1017 914 906
SD 39 32 25 130 67 189 27 37 81 97 37 64 50 35 56 34 59 43 32 50 49 42 55 44
RSD 4.2% 3.3% 2.1% 11.5% 6.9% 16.5% 2.7% 3.4% 7.5% 9.6% 4.1% 6.8% 4.9% 4.0% 5.9% 3.6% 6.3% 4.7% 3.5% 5.6% 5.3% 4.1% 6.0% 4.9%
Accuracy -6.9% -4.0% 16.4% 12.8% -3.0% 14.5% -0.7% 8.0% 8.4% 1.0% -10.0% -5.1% 1.9% -12.8% -5.2% -5.4% -6.2% -8.2% -9.4% -10.8% -7.1% 1.7% -8.6% -9.4%
Autosampler_48h
500 ng/mL 439 487 636 512 479 499 499 554 464 454 414 419 450 442 400 444 430 421 416 425 426 493 416 422
500 ng/mL 405 521 577 442 382 435 500 453 396 372 424 330 380 454 444 451 438 431 431 446 438 487 443 432
500 ng/mL 434 516 551 468 553 457 607 578 446 506 554 481 460 591 574 570 516 564 586 534 581 667 498 574
The average 426 508 588 474 471 464 535 528 435 444 464 410 430 495 472 488 461 472 478 468 482 549 452 476
SD 18 18 43 35 86 32 62 66 36 68 79 76 44 83 91 71 47 80 94 58 86 102 42 85
RSD 4.2% 3.6% 7.4% 7.5% 18.2% 7.0% 11.6% 12.5% 8.2% 15.3% 16.9% 18.6% 10.2% 16.7% 19.2% 14.5% 10.3% 16.8% 19.6% 12.3% 17.8% 18.6% 9.3% 17.8%
Accuracy -14.9% 1.6% 17.6% -5.2% -5.8% -7.3% 7.1% 5.7% -12.9% -11.2% -7.2% -18.0% -14.0% -0.9% -5.5% -2.3% -7.8% -5.6% -4.5% -6.4% -3.6% 9.8% -9.5% -4.8%
1000 ng/mL 960 985 1061 1265 1019 1231 990 1077 1154 1055 927 977 1102 917 942 957 980 948 942 947 968 1063 945 939
1000 ng/mL 885 947 1087 1008 898 973 945 1008 1000 894 859 849 954 874 851 912 864 873 900 907 888 998 885 872
1000 ng/mL 913 908 1092 1157 994 1102 948 1016 1044 917 854 889 1012 869 882 890 905 868 865 843 876 989 844 849
The average 919 947 1080 1143 970 1102 961 1034 1066 956 880 905 1022 886 892 920 916 896 902 899 911 1017 891 887
SD 38 39 17 129 64 129 25 38 80 87 41 66 75 26 46 34 59 45 39 52 50 40 51 47
RSD 4.2% 4.1% 1.6% 11.3% 6.6% 11.7% 2.7% 3.7% 7.5% 9.1% 4.6% 7.2% 7.3% 3.0% 5.2% 3.7% 6.4% 5.0% 4.3% 5.8% 5.5% 3.9% 5.7% 5.3%
Accuracy -8.1% -5.3% 8.0% 14.3% -3.0% 10.2% -3.9% 3.4% 6.6% -4.4% -12.0% -9.5% 2.2% -11.4% -10.8% -8.0% -8.4% -10.4% -9.8% -10.1% -8.9% 1.7% -10.9% -11.3%
Autosampler_72h
500 ng/mL 414 474 601 455 525 424 554 518 422 470 518 442 442 565 499 468 487 532 484 525 546 555 472 542
500 ng/mL 473 455 591 412 355 392 461 408 359 412 397 397 343 420 397 420 415 403 412 430 410 463 408 407
500 ng/mL 409 456 562 480 447 453 452 507 421 382 383 379 428 412 379 415 403 387 395 405 395 465 385 392
The average 432 461 585 449 442 423 489 477 400 421 433 406 404 466 425 434 435 441 430 453 450 494 422 447
SD 36 11 20 34 85 30 57 61 36 44 74 32 54 86 65 29 46 79 47 63 83 52 45 83
RSD 8.3% 2.3% 3.5% 7.7% 19.3% 7.2% 11.6% 12.7% 8.9% 10.5% 17.2% 8.0% 13.2% 18.5% 15.2% 6.6% 10.5% 18.0% 11.0% 14.0% 18.4% 10.6% 10.7% 18.5%
Accuracy -13.6% -7.7% 17.0% -10.2% -11.6% -15.4% -2.2% -4.5% -19.9% -15.7% -13.4% -18.8% -19.2% -6.9% -15.0% -13.1% -13.0% -11.9% -14.0% -9.3% -9.9% -1.2% -15.7% -10.6%
1000 ng/mL 919 929 1015 1207 972 1094 903 972 1066 907 883 899 1080 883 961 912 926 892 915 923 902 1041 902 877
1000 ng/mL 845 877 1048 975 852 864 862 906 919 774 822 784 941 857 852 857 817 817 894 884 819 969 831 812
1000 ng/mL 843 837 1093 1074 934 939 839 890 940 799 794 791 1012 796 860 825 818 785 819 795 786 918 778 770
The average 869 881 1052 1085 919 966 868 923 975 827 833 825 1011 845 891 864 853 831 876 867 836 976 837 820
SD 43 46 39 117 61 117 32 43 80 71 45 65 70 45 61 44 63 55 50 66 60 62 62 54
RSD 5.0% 5.2% 3.8% 10.7% 6.6% 12.2% 3.7% 4.7% 8.2% 8.6% 5.4% 7.8% 6.9% 5.3% 6.9% 5.1% 7.3% 6.6% 5.8% 7.6% 7.2% 6.3% 7.4% 6.6%
Accuracy -13.1% -11.9% 5.2% 8.5% -8.1% -3.4% -13.2% -7.7% -2.5% -17.3% -16.7% -17.5% 1.1% -15.5% -10.9% -13.6% -14.7% -16.9% -12.4% -13.3% -16.4% -2.4% -16.3% -18.0%
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Figure 5-3: The degradation of selected ATS and SC at 500 and 1000 ng mL-1 at RT (n=3) 
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Figure 5-4: The degradation example for selected ATS and SC at 500 ng mL-1 and 1000 ng mL-1 at RF (n=3)
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5.3.6 Half-life estimation 
Half-lives of each unstable drug were estimated in each condition based on the 
concentration average of triplicate measurements at a specific time using the 
following equation:  
Equation 5-1: Half-life equation  
 𝒕 𝟏
𝟐⁄
=
𝑳𝒏𝟐
𝜸
 
where Ln2 = 0.693, 𝜸 is the constant rate ( 𝜸 = In (the concentration of analyte 
after specific time) − In (the initial concentration) ÷ (− the specific time)), 𝒕 1
2⁄
is 
the half-life. For example, the initial concentration for the cathinone compound 
was 500 ng mL-1 (true value), the concentration of cathinone at RT after 14 days 
was 51 ng mL-1, and the calculation can be applied as follows: 
𝛾 = 𝐼𝑛 (51) − 𝐼𝑛 (500)  ÷ (−14) = 0.163   
So t 1
2⁄
=
0.693
0.163
=  4.24 𝑑𝑎𝑦𝑠. 
The results are shown in Table 5-6. The half-lives of the 14 cathinones 
demonstrate the significant differences between ambient temperature and 
refrigerator conditions, as well as the analyte and concentration-dependent 
variables. In this study the metabolites and tertiary amines groups were rejected, 
due to reasons stated in the previous sections.  
The half-lives at RT for non-ring substitute, ring substituted and methylenedioxy-
substituted cathinones in urine ranged from 1.78 to 6.9, 1.50 to 11 and 4.62 to 17 
days respectively; and at RF 19 to 56, 16 to 39 (not including methedrone) and 94 
to 169, respectively. The 4-MEC results were not known, due to high variation 
errors. 
It should be noted that the constant rate had substantial estimation variation 
between the stability days, and little variation within stability days (RSD≤20%). In 
addition, the analyte dependence was determined by referencing the above 
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graphs and tables. As a result, it can be concluded that the uncertainties 
originated from several issues rather than instrument error. Consequently, the 
large variation errors in the constant rate were due to the effects of several 
factors such as light, pH, store condition and pre-sample preparation. 
The samples were left covered at RT or RF but were not completely in the dark. 
The lights in the room were switched on and off on different occasions; this was 
similarly true for RF, as the refrigerator door was intermittently opened by other 
students. This procedure was designed to emulate real laboratory conditions.  
Even though several studies proved that SC were significantly more stable in acidic 
urine [17, 21-23, 26, 30], this project was proposed to examine human urine 
samples at an average of healthy people pH (4.5-8).  
The store condition also impacted such as humidity and temperature changes. The 
temperature in the room and refrigerator slightly fluctuated throughout the day. 
The interval time for sampling was slightly different for each stability day. Hence, 
these factors may contribute to increasing error variation in the constant rate. 
5.3.7 Interferences and breakdown products  
The products that resulted from SC degradation did not interfere the reliability of 
the quantification of the analytes, except for tertiary amines and metabolites. 
The breakdown products may be the reason for the increasing statistical variability 
of these compounds. The project was carried out using a mixture rather than each 
drug alone, and it was difficult to study the breakdown products in scan mode.  
The scan mode was inadequate for interpreting the behaviour of the product, due 
to the complexity of the mixture and the background noise. No new endogenous 
interferences in blank urine were observed over the period of the study under the 
described conditions.   
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Table 5-6: Half-life estimation of 14 cathinones in urine in days (d) at RT and RF 
Synthetic cathinones RT RF 
500 ng mL-1   1000 ng mL-1  500 ng mL-1 1000 ng mL-1 
CATHINONE  4.24 d 3.25 d 36 d 28 d 
METHCATHINONE 2.56 d 1.78 d 19 d 21 d 
N-EC  2.67 d 1.93 24 d 21 d 
BUPHEDRONE 6.9 d 4.23 d 56 d 43 d 
PENTEDRONE 4.78 d 3.03 d 36 d 30 d 
FLEPHEDRONE 2.48 d 1.50 d 20 d 16 d 
MEPHEDRONE 5.5 d 3.56 d 39 d 33 d 
4-MEC 9.2 d 7.7 d Not known Not known 
4-EMC 4.95 d 3.24 d 27 d 38 d 
METHEDRONE 11 d 5.8 d 113 d 92 d 
METHYLONE 9.1 d 4.62 119 d 94 d 
BUTYLONE 23 d 12 d 169 d 161 d 
ETHYLONE  13 d 6.4 d 89 d 116 d 
PENTYLONE 17 d 7.1 d 129 d 109 d 
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5.4 Conclusion 
Urine specimens must be protected from heat promptly after being collected and 
kept, where possible, under freezing temperatures. Otherwise, cathinones may 
gradually degrade until lost. ATS and SC in urine were assessed to measure 
decrease half-life, concentration, group and temperature stability. Long term 
stability lasted 381 days without degradation at −20°C was shown for ATS and SC. 
The ATS group was also stable at RF and RT throughout 349 days. 
Most SC at RT had decreased concentrations of more than 20% after 24 or 48 hours, 
before completely disappearing in less than a month. Most SC at RF were unstable 
on day 21, after which the concentration of each drug was gradually decreased 
until undetected between the days 77 and 349. The last day (381) of the stability 
study was completed to confirm that all SC were undetected at RF.  
The autosampler study has proven the stability of ATS and SC within 72 hours. The 
stability variations between and within SC groups were slightly different, 
particularly at RF.  No significant difference in the results was noted for the 
concentrations of 500 ng mL-1 and 1000 ng mL-1. No concentration-dependent 
variations were observed for all unstable SC drugs using one-way analysis of 
variance. Half-lives in 14 SC were estimated for each drug alone and within the 
groups. The analyte dependence was clearly observed for all examined cathinones 
using the half-life equation. The factors affecting the uncertainties were briefly 
discussed. In this project, human drug-free urine was used rather than commercial 
DFU, which had many advantages. Stability results for the metabolites and tertiary 
groups were rejected due to the reasons discussed above.  
Urine positive samples are typically stored in the Freezer for at least one year. 
These tests might be repeated due to legal requirements, and this is the first work 
proving the stability of all examined substances in urine without the necessity for 
preservations. Additionally, this is the first work that demonstrates that ATS 
substances do not interfere with the breakdown products of SC under all studied 
conditions in urine specimens over a year.   
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6. Determination of amphetamine-type stimulants and 
synthetic cathinones in urine using solid phase 
microextraction in tips and gas chromatography-mass 
spectrometry  
6.1 Introduction 
SPME was developed in 1989 as an extraction method at the University of Waterloo 
(Ontario, Canada) with a number of advantages compared to traditional sampling 
techniques [487], including a reduced volume of sample, a shorter preparation 
time, a lower solvent volume required and an increased LOD [488]. When SPME 
was first discovered, coatings were mostly applied to natural and hydrophobic 
substances [289, 489]. Currently, innovative coatings have been developed to 
extract additional polar analytes with charged particles and molecules [490, 491]. 
The application of SPME is published on a consistent basis, which covers a wide 
range of coatings. The recent techniques involving sorbents and coatings are 
chemical grafting, sol-gel technology, electrospinning, liquid-phase deposition, 
hydrothermal methods, dipping and physical agglutinating and electrochemical 
methods [492].  
The unique feature of SMPE is the ability of the system to yield similar quantities 
even when the sampling is repeated. This is because the reaction occurs based on 
equilibrium extraction with a small quantity of analytes (named negligible 
depletion) between the analyte and stationary phase. This is the ideal 
characteristic for identification of forensic toxicology drugs in matrices; by 
repeating every time without reducing the concentration of analytes [493-495].  
At the present time, SPME has confirmed the validity of various bioanalytical and 
forensic toxicology examinations, involving in vivo and in vitro sampling for a 
number of diverse forensic matrix investigations [493, 496]. The comparison 
between the SPME in tips with other extraction methods is illustrated in Table 
6-1.  
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Table 6-1: Comparison of SPME tips, SPME-TFME, SPE, SPME-traditional fibre and LLE 
Extraction 
type & 
feature 
SPME-tips 
[497] 
SPME-TFME 
[497] 
SPME-
traditional 
fibre 
LLE SPE 
Steps Pre- 
treatment, 
two steps, 
extraction 
and 
desorption 
Two steps, 
extraction 
and 
desorption 
Pre- 
treatment, 
dilution for 
complex 
sample  
multi-stage 
operations, 
time-
consuming, 
labour-
intensive 
multi-stage 
operations, 
time-
consuming, 
clotting, 
percolation 
Volume Small sample 
volume 
Large sample 
volume to 
improve 
sensitivity 
Large sample 
volume to 
improve 
sensitivity 
Large sample 
volume to 
improve 
sensitivity 
Large sample 
volume to 
improve 
sensitivity  
Cost Disposable, 
Lower cost 
per sample 
Reusable, 
expensive 
Reusable, 
expensive, 
fragile 
Waste 
disposal of 
solvents 
Disposable, 
waste disposal 
of solvents 
Handling Pipettor, 
robotic liquid 
handling 
system 
Require 
dedicated 
commercial 
TFME robotic 
station     
Manual and 
Automated 
Manual  Manual and 
Automated 
Theory Non- 
exhaustive 
system 
Non- 
exhaustive 
system 
Non- 
exhaustive 
system 
Exhaustive 
system 
Exhaustive 
system 
Sampling 
repetitions  
The sampling 
can be 
repeated 
The sampling 
can be 
repeated 
Remeasure 
the same 
sample 
No No 
Abbreviations: SPME-tips (solid-phase microextraction in tips), SPME-TFME (thin-film microextraction), SPE (solid-phase 
extraction), LLE (liquid-liquid extraction).  
6.1.1 General principle of SPME  
This work will focus on a liquid matrix and polymer coating fibres with a direct 
immersion mode, because only those were included in the thesis. An 
understanding of SPME theory provides direction for evolving and optimising this 
method [489, 498].  
Extraction equilibrium happens between the sample and the fibre coating. The 
equilibrium reaction occurs during the adsorption and desorption of analyte by the 
fibre polymer coating with the consequent increase or decrease of the 
concentration depending on, for example the material used and the thickness of 
the fibre coating. The time required for the extraction is based on the distribution 
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coefficient. The higher the distribution coefficient ratio, the better extraction for 
the analytes with higher precision results. SPME extraction is considered complete 
when extraction equilibrium is reached between the analyte in the matrix and the 
fibre coating, which means that further extraction time will not increase the 
amount of analyte extracted. 
The distribution equilibrium ratio is reached faster when the M.W and bp. of the 
analyte are high. Selectivity can be achieved by altering the type of polymer or 
the thickness of the coating to be compatible with the properties of the target 
analyte. Volatile substances match well with a thicker coating, but semi-volatile 
compounds have a preference for a thin coating polymer. The amount of analyte 
distributed between the coating fibre (for example PDMS) and the matrix (for 
example urine) during the extraction stage is dictated by Equation 6-1:  
Equation 6-1: The amount of analyte distributed between PDMS and urine  
 Kfs = (Cfibre ÷ Csample) 
where Kfs is the distribution constant between the fibre coating and the sample, 
and C is the equilibrium concentration of the analyte in both the fibre and the 
sample. It can be concluded from the equation that the distribution constant (Kfs) 
can be affected by temperature, pH, salts, ionic strength, coating type, solvents 
and agitation speed.  
The final concentration of analyte increases after the extraction processes by 
increasing the volume of the sample and coating, see Equation 6-2:  
Equation 6-2: The final amount (mass) of analyte adsorbed by coating (n)  
n = (Kfs Vf Vs Ci) ÷ (Kfs Vf + Vs) 
where Vf = volume of fibre coating, Vs = volume of sample and Ci = initial 
concentration. 
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The above equation indicates that a directly proportional association (linear 
relationship) between the amount of analyte extracted and the initial 
concentration of analyte after equilibrium is reached in the matrix.  
When the sample volume is very large, thermodynamic theory can be used to 
estimate the extraction amount of analyte by using the following Equation 6-3:  
Equation 6-3: Thermodynamic theory 
 n = Kfs Ve Cs 
where Ve = volume of extraction and Cs = concentration of analyte. [489, 498, 499]    
6.1.2 Literature review for ATS and SC applied to SPME fibre in tips  
Numerous studies have been published addressing the practicality of SPME for the 
examination of amphetamine and related substances in a biological matrix in [500-
509], and more recently in [510-515]. The compounds were specifically 
determined in urine coupled with SPME-GC−MS [506, 516-524]. The application of 
SPME for SC were reviewed in section 2.5.4. However, the literature shows that 
the new trends of SPME fibre tips are very limited. Google Scholar, PubMed and 
Science Direct were used to search the following terms: “solid phase 
microextraction” and “tip”, “tips”, “in tip”, “in tips”, “pipette tips”, “well”, 
“well plate”, “96 well plate” or “pipette in tips”. Twenty relevant articles were 
identified based on the above key words (see Table 6-2). Most of the coating fibres 
were manufactured in-house and were used in tip with a syringe. A comprehensive 
review for the multi-well-plate format of SPME tips was published elsewhere 
[497].  
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Table 6-2: General application of SPME in tips 
Name of drugs Matrix Fibre coating type Instrumentation name Year Ref. 
Iminodiacetic acid Natural water Monolithic chelating ICP-MS 2010 [525] 
Pesticide residues Cucumber Polytetrafluoroethylene (PTFE) GC–MS 2012 [526] 
A peroxisome proliferator activated receptor 
modulator drug compound  
Human plasma PDMS-DVB SPME automation (96-well) 
coupled with HPLC–MS-MS 
2014 [527] 
Ultra-trace perfluorinated compounds Whole blood, water 
and milk  
Wooden-tip Ambient mass spectrometry 2014 [528] 
Enkephalins Human cerebrospinal 
fluid 
Imprinted polymer HPLC–ultraviolet (UV) 2015 [529] 
Benzoylecgonine and cocaethylene, norfentanyl, and 
methadone and its metabolite EDDP (2‐ethylidene‐1, 
5‐dimethyl‐3, 3‐diphenylpyrrolidine) 
Urine SPME LC tips (C18) LC-MS-MS (96-well array- 
automation) 
2015 [530] 
Copper Serum Carbon cloth Micro sampling flame atomic 
absorption spectrometry 
2015 [531] 
MDPV, buphedrone, flephedrone, butylone, ethylone, 
mephedrone, methylone and methedrone 
Serum and plasma  SPME LC tips (C18) LC-MS (96-well array- 
automation)  
2015 [532] 
Cadmium Water and WB Modified magnetic nanoparticles 
of iron oxide Triton X114 
Flame atomic absorption 
technique 
2015 [533] 
Metoprolol, propranolol, carbamazepine and 
diazepam 
Dried blood SPME LC tips (C18) LC-MS-MS (96-well array- 
automation) 
2016 [534] 
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Arsenic speciation Water Polymer, polystyrene 
polydimethyl siloxane 
Electrothermal atomic 
absorption spectroscopy (ET-
AAS) 
2016 [535] 
Mefenamic acid Urine A carbon nanotube–zinc sulfide  HPLC 2016 [536] 
Dithizone–mercury Water Carbon xerogel A Shimadzu UV–vis 
spectrophotometer 
2016 [537] 
Gallic acid Orange juice samples Molecularly imprinted silica 
monolithic 
HPLC analysis 2017 [538] 
Alkaloids flavonoids Urine, feces and cell 
culture fluid samples 
Sulfonated carbon nanotube-
polymer 
Scanning electron 
microscopy (SEM) images 
2017 [539] 
Silver-APDC (ammonium pyrollidine dithiocarbamate) Fresh and waste 
water samples 
Carbon cloth Electrothermal atomic 
absorption spectroscopy (ET-
AAS) 
2017 [540] 
Bisphenol A Urine Molecularly imprinted polymers GC–MS 2017 [541] 
Vanadium species Water and food 
samples 
Immobilized with 
tetraethylenepentamine 
Atomic absorption 
spectrometer 
2018 [542] 
Inorganic antimony (Sb) Environmental and 
food samples 
Polystyrene oleic acid imidazole 
polymer 
Atomic absorption 
spectrometer 
2018 [543] 
Antidepressants Urine Poly (ethylene dimethacrylate) HP 1100 liquid 
chromatograph 
2018 [544] 
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6.1.3 Aims  
Because of an increased prevalence in the misuse of ATS and cathinones in specific 
geographical areas, more methods must be developed to provide quantification 
and green analytical chemistry, while adhering to the validation guidelines for 
obtaining a new forensic toxicology sample investigation technique. In addition, 
no previous work was found on SPME in tips to extract ATS and SC drugs. 
Therefore, the aims of the study are as follows: 
• To develop and validate a method for the simultaneous detection and 
quantification of amphetamine, methamphetamine, PMA, MDMA, 
mephedrone, buphedrone ephedrine metabolite, 4-methylephedrine 
(mephedrone metabolite) and pentylone in a human urine specimen, using 
SPME in tips followed by GC−MS analysis. 
• To apply a clean, simple, fast, convenient, cheap, sensitive, selective 
sample preparation method with a microlitre scale while considering the 
need to reduce solvents, chemicals, reagents, waste, energy and 
environment impacts using SPME in tips and adhering to guidelines for 
method validation. 
• To assess the new SPME pipette tips with fibres of C18, C18/SCX and 
PDMS/DVB.  
• To compare this method with the SPE method discussed in chapter 4.  
• To evaluate the method using five criteria (environment, safety, energy, 
health and waste) for the assessment of green analytical chemistry.  
• To apply this method for quantification of real human urine samples 
collected from Saudi Arabia.  
Chapter 6—159 
 
6.2 Materials and methods 
6.2.1 Chemicals and reagents  
All nine reference standard substances at a concentration of 1 mg mL-1, three ISD 
and PFPA were purchased from the supplier mentioned in section 3.2.1.1. 
The substances were four ATS of amphetamine, methamphetamine, PMA, 
MDMA, five SC of cathinone, mephedrone, buphedrine, 4-methylephedrine, 
pentylone, three ISD of amphetamine-d11 (1 mg mL-1), cathinone-d5 (0.1 mg 
mL-1), pentylone-d3 (0.1 mg mL-1). 
Pipette tips of PDMS-DVB (IonSense® PDMS/DVB SPME-in Tips) and C18 (IonSense® 
C18 SPME-in Tips) coating fibres, vial kits in the size of 0.3 mL (certified vial kit, 
low adsorption (LA) QsertVial™ volume 0.3 mL, QsertVial, clear glass vial, natural 
PTFE/silicone septa (with slit), thread 9 mm), 1.2 mL (certified vial kit, low 
adsorption (LA) MRQ30 CD™ vial volume 1.2 mL, MRQ30 Vial, clear glass vial, 
natural PTFE/silicone septa (with slit), thread 9 mm, pkg of 100), 0.7 mL (crimp 
top microvial, requiring a 8 mm seal volume 0.7 mL, amber glass vial, O.D. × H 
7 mm × 40 mm , flat bottom, pkg of 100) and formic acid (FA) were obtained from 
Sigma-Aldrich, Gillingham, UK. The new pipette SPME tips were coated with fibres 
of mixed mode (C18-SCX) and were provided by Sigma Aldrich, due to 
unavailability on the market. 
Microcentrifuge tubes, Eppendorf® (1.5 mL), acetonitrile, acetone, 2-propanol,  
sodium hydroxide (NaOH) and sodium chloride (NaCl) were purchased from 
VWR International Ltd (Lutterworth, UK). Deionised water was generated 
from an Ultrapure water purification system (Merck Direct QR 3UV water 
deionizer). Other materials and grade chemicals were obtained from the supplier 
mentioned in section 3.2.1.1. 
6.2.2 Drug-free urine (DFU) 
Urine samples were obtained from healthy volunteers under ethical approval 
statement. All specimens were tested using scan and SIM mode to confirm 
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the absence of drugs in the urine using the procedure demonstrated in 
chapter 4. All DFU were stored at 4°C in the RF.  
6.2.3 Ethics statement  
All procedures, written informed consent from all subjects and applications 
within this study were completed based on the guidelines obtained from the 
College of MVLS Ethics Committee for Non-Clinical Research Involving 
Human Subjects at the University of Glasgow.The protocol was reviewed and 
approved by the MVLS College Ethics Committee, University of Glasgow 
(200160055) (See Appendix 2). The urine samples that were collected in 
Saudi Arabia (SA) were also ethically approved by the Research Committee 
at Security Forces Hospital (SFH), Riyadh, SA (16-190-24) (See Appendix 3). 
Both University of Glasgow and SFH committees reviewed the research 
proposal and agreed that there was no objection on ethical grounds.  
Drug-Free Urine (DFU) samples were collected under an ethical approval 
procedure. The procedure was reviewed and approved by the MVLS College 
Ethics Committee, University of Glasgow (200160020). 
6.2.4 Preparation of drug standards 
Standards at a concentration of 1 mg mL-1 for all eight drugs (amphetamine, 
methamphetamine, PMA, MDMA, mephedrone, buphedrine, 4-
methylephedrine and pentylone) were diluted in MeOH to prepare a stock 
solution of 100 µg mL-1 (See section 4.2.3 for the procedure used for 
preparation).  
6.2.5 Preparation of ISD  
ISD of amphetamine-d11 at 1 mg mL-1 were diluted to 100 µg mL-1. The 
amphetamine-d11 of 100 µg mL-1, cathinone-d5 (100 µg mL-1) and pentylone-
d3 (100 µg mL-1) were diluted to 10 µg mL-1 as a mixture. See section 4.2.3 
and 4.2.4 for the full procedure used for the preparation.  
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6.2.6 Preparation of working solutions 
The mixture working solutions of eight drugs were diluted using DFU to reach 
2 μg mL-1 for the validation work; and MeOH to reach 10 μg mL-1 for the 
development work. The stock standards mentioned above were similarly 
prepared following the procedure stated in section 3.2.1.12 and 4.2.5. 
6.2.7 Laboratory preparation for the method development work  
Pipette tips of SPME were evaluted for three types of fibres (PDMS, C18 and 
mixed mode) in DFU using the following parameters: size of vials, sample 
volume, pH of buffer, addition of salts, addition of derivatisation reagent, 
ionic strength, solvent type and volume, extraction time, agitation speed in 
the period of extraction stage, desorption time, agitation speed in the 
period of desorption stage and finally increasing the temperature before the 
extraction stage. Each parameter was assessed alone as a single factor while 
the other factors were kept constant.  
The parameters above were optimised and absolute recoveries were 
calculated [545] . During the optimisation of analytes 1 mL of urine was used 
1 µg mL-1. 50 µL of amphetamine-d11 at a concentration of 10 µg mL-1 was 
added to each evaluated sample prior the evaporation stage. 
Duplicate tubes of unextracted MeOH contain a mixture of the eight 
substances (final concentration= 1 µg mL-1) with amphetamine-d11 (final 
concentration= 0.5 µg mL-1). They were prepared each day and analysed 
together with the samples to increase the accuracy of the results during the 
development work.  
The calculation recovery method was mentioned in chapter 3, section 
3.2.2.6. The evaluation rule was very simple: the uppermost percentage 
recovery achieved was considered the best results in each evaluated 
parameter. The parameters were developed until the highest recovery and 
sensitivity possible for the instrument was achieved. 
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The method development processing stages for optimisation of each 
parameter followed the procedures used in most articles published for 
general SPME method development. The design protocol that was discussed 
in the hand book sample preparation, hand book of solid phase 
microextraction and the book of solid phase microextraction method 
development was followed more specifically [202, 499, 546].  
6.2.7.1 pH   
The investigation began by evaluating three fibres using urine samples 
adjusted to a pH of three, five, seven, nine and 11. A triplicate pH buffered 
of 1 mL urine samples with 100 µL of drug mixtures (10 µg mL-1) was tested. 
The total number of samples was 47 (3 (repetition) × 3 (fibres) × 5 (pH)) + 2 
unextracted tubes). The preparation method of each selected pH value was 
calibrated as shown in Table 6-3.  
The introductory procedure is described as follows. The three types of 
fibres were conditioned for 20 minutes in MeOH and distilled water (50:50). 
900 µL of adjusted pH urine and 100 µL of drug mixtures in MeOH (10 µg mL-
1) were added to 1.2 vials. The fibres were then inserted for extraction with 
an agitation speed of 1000 rpm for 30 minutes. After, the fibres were 
inserted in the vials of 0.3 mL which had 100 µL of 0.5 mL of (NH4OH (28% 
solution, v/v) + 99.5 mL of MeOH) + 50 µL of ISD amphetamine-d11 for the 
desorption step with an agitation speed of 1000 rpm for 30 minutes. After 
this, 10 µL of acidified MeOH was added (1 % HCL + MeOH). The samples 
were gently evaporated using a hot block with nitrogen gas at 33°C. 50 µL 
of PFPA:EtOAc (2:1) was added, the tubes were capped and mixed for 3-5 
seconds and then left for 20 minutes at 60°C for completion of the reaction. 
The specimens were evaporated again at RT and reconstituted by adding 50 
µL of EtOAc. Finally, the contents were injected into GC−MS for analysis. It 
should be noted that the optimum results from each step were used in the 
next step, and so forth.  
  
Chapter 6—163 
 
Table 6-3: An example preparation method for adjusting the selected pH values in urine 
samples using pH electrodes.  
Note: phosphate buffer solution was also prepared and investigated based on the desired pH. 
pH The preparation method 
3 Formic acid was added to 25 mL DFU until the desired pH was reached. 
5 Formic acid + 0.1 M HCL were added to 25 mL DFU until the desired pH was reached. 
7 The original urine was below 7, so 25% (w/v) NaOH was added to 25 mL DFU until the 
desired pH was reached. 
9 25% (w/v) NaOH was added to 25 mL DFU until the desired pH was reached. 
11 25% (w/v) NaOH was added to 25 mL DFU until the desired pH was reached. 
6.2.7.2 Ionic strength and salts additive  
The introductory procedure above was applied to evaluate the ionic strength 
and salts additive. Examples of laboratory work days were: 
A 1 mL duplicate of the drug urine samples mixture was tested including 100 
µL of 5%, 10% and 25% (w/v) NaOH and KOH in each vial (total of samples = 
36 samples + 2 unextracted); ((3 fibres) × (2 duplicate) × (3 NaOH))  ((3 
fibres) × (2 duplicate) × (3 KOH)). 
Duplicate vials of 0.1, 0.25, 0.5, 0.75 and 1 g of NaCl were investigated 
separately (total of samples = 30 samples + 2 unextracted); ((3 fibres) × (2 
duplicate) × (5 NaCl)). 
In another separate study, 100 µL of 5%, 10% and 25% w/v NaOH was added 
together with 0.1, 0.25, 0.5, 0.75 and 1 g of NaCl ((3 fibres) × (2 duplicate) 
× (3 NaOH) × (5 NaCl) = 90 samples + 2 unextracted). This procedure was 
repeated again on the following two days for clarification of the results.  
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6.2.7.3 Temperature 
Three fibres in tips were examined in triplicate using the temperatures of 
60°C and room temperature before the extraction step. 
6.2.7.4  Vial types 
1.2 mL kits (Figure 6-1) and 1.5 mL Eppendorf vials were evaluated using 
duplicate specimens for each fibre. The linearity study was used for the 
assessment of the two vials at 50, 100, 250, 500, 750, 1000, 2000 ng mL-1 
(duplicate specimens, total samples = 84 (2 (duplicate) × 7 (points) × 3 
(fibres) × 2 (vials)).  
 
Figure 6-1: 1.2 mL vial kit used during the development stage.  
6.2.7.5 Derivatisation reagent 
The PFPA derivatisation reagent was used for the assessment. Duplicate 
specimens containing the PFPA derivative were added prior, throughout and 
after the extraction stage. The PFPA was also added after the evaporation 
step.  
During pre-extraction derivatisation, the 50 µL of PFPA was added to the 
sample containing the mixture of eight drugs and left for 15 minutes to 
Chapter 6—165 
 
react. The extraction and desorption steps then took place after the 
compounds were derivatised. 
Throughout extraction and derivatisation, which is also named simultaneous 
extraction and derivatisation, 50 µL of PFPA was added to the three types 
of fibre coatings which were then exposed to the mixture in the urine 
samples to permit derivatisation and extraction processes to continuously 
occur in the fibre coatings.  
The 50 µL of PFPA was also added to the vial in desorption step (after the 
extraction stage).  
6.2.7.6 Sample volume 
Volumes of 1000, 500 and 100 µL urine samples at 1 µg mL-1 were measured 
with three replicated vials at each volume. 100, 50 and 10 µL of (10 µg mL-
1) the drug mixtures were added to 1000, 500 and 100 µL urine samples, 
respectively. The introductory procedure was applied using the optimum 
results obtained from the above sections.  
6.2.7.7 Type of solvents in desorption stage 
The evaluation of solvent types for the assessment of the desorption phase 
was applied to NH4OH:MeOH (0.5:99.5, (v/v)), MeOH, EtOAc, IPA, 
NH4OH:MeOH (2:98 (v/v)), DCM:IPA: NH4OH (78:20:2, (v/v/v)), acetonitrile, 
and acetone: water (20:80 (v/v)). The urine samples were triplicated on two 
different test days (samples per day = 3 (replicate) × 3 (fibres) × 8 (solvents) 
= 72 + 2 (unextracted)).  
6.2.7.8 Extraction time and agitation speed 
On the first test day, triplicate spiked DFU specimens were tested for the 
assessment of agitation speed using durations of 15, 30, 60 and 120 minutes 
at a speed of 1000 rpm (all fibres were involved = 36 + 2 unextracted 
samples). On the second test day, durations of 5, 15, 30 and 60 minutes 
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were used with an agitation speed of 1500 rpm (12 (PDMS) + 8 (C18 and 
mixed mode) fibres + 2 unextracted samples). On the third test day, times 
of 30 and 60, 90, 120 and 180 minutes with an agitation speed of 2000 rpm 
were used (15 (PDMS) + 10 (C18 and mixed mode) fibres + 2 unextracted 
samples). The PDMS/DVB fibre tips only were triplicated on the second and 
third test days. The optimum procedure was used during and between the 
processing work for each fibre. 
6.2.7.9 Desorption time and agitation speed 
Triplicate urine specimens for PDMS/DVB and duplicate urine samples for 
mixed mode and C18 fibres were applied and repeated on three test days. 
On the first day, the shaker for agitation was set to 1000 rpm for 15, 30, 45, 
60 and 90 minutes (total of samples = 37 (3 (triplicate) × 1 (rpm) × 5 (times) 
 (10 for mixed mode)  (10 for C18)  2 unextracted). 
On the second day, the samples were assessed at a speed of 1500 rpm and 
times of 20, 30, 40 and 50 minutes (total of samples = 30 (3 (triplicate) × 1 
(rpm) × 4 (times)  (8 for mixed mode)  (8 for C18)  2 unextracted). On 
the third day, a speed of 2000 rpm and times of 1, 5, 10 and 20 minutes 
were used (total of samples = 30 (3 (triplicate) × 1 (rpm) × 4 (times)  (8 for 
mixed mode)  (8 for C18)  2 unextracted).  
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6.2.8 Lab preparation for the method validation 
The new method was fully validated using the detection and quantification 
of the eight target analytes in urine. The validation guideline was Scientific 
Working Group for Forensic Toxicology (SWGTOX) [3]. The validation 
parameters were linearity, LOD, LLOQ, interferences, selectivity, carryover, 
accuracy and precision. 
The optimised procedure was used as the sample preparation method for 
the determination of the following method validation parameters.  
6.2.8.1 Linearity method 
A mixture of all drugs tested was diluted using DFU to obtain 2 μg mL-1 (this 
was used as a highest point concentration for calibration assessment). The 
concentration points of 50, 100, 250, 500, 750 and 1000 ng mL-1 were freshly 
prepared using a technique similar to that in section 4.2.5. Calibration 
curves for each substance in the mixtures were plotted using a best fit 
straight-line method to calculate the linear regression (R2) of the target ion 
substances with respect to the target ion ISD compounds using the procedure 
previously mentioned in chapter 3 with Equation 3−2. Linearity was 
measured by repeating eight samples four times each day to obtain eight 
concentration points including the DFU in each calibration curve. This 
procedure was repeated on five consecutive days to plot 20 calibration 
curves in total for each substance. The accuracy (bias) and RSD were 
calculated and should be between ± 20% error for each concentration point. 
6.2.8.2 Accuracy and precision methods 
Three QCs at concentrations of 250, 850 and 1500 ng mL-1 were prepared 
using a protocol similar to that detailed in section 4.2.7. The QCs were 
tested by replicating the samples four times every day on five consecutive 
days. These samples were analysed on the same days as linearity study 
mentioned above. Bias (%) was calculated using the grand average 
calculated concentration of Equation 3−5. Within-run and between-run 
precision were calculated using Equation 4−2 and Equation 4−3. After 
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calculation, each analyte must be within ±20% (bias) to the true 
concentration value analysed in order to consider the method valid for the 
bias study. Each analyte must be less than or equal 20% error for the RSD to 
consider the method valid for the precision study.  
6.2.8.3 LOD and LLOQ methods 
The preparation was completed following the procedure configured in section 
4.2.9. The outcome of LOD and LOQ were known using a signal-to-noise (S/N) 
ratio obtained from the instrument software explained in sections 3.2.2.4 
and 4.2.9. The drug mixtures in the DFU specimens were repeated ten times in 
two days including five in each day at concentrations of 200, 100, 50, 25, 10, 5 
and 1 ng mL-1. The LLOQ was evaluated using the linearity points by 
calculating the average concentration of each point with ≤20% and ±≤20% 
error of RSD and accuracy, respectively.  
6.2.8.4 Interferences and selectivity methods 
The method of interference studies was given in section 4.2.14, where it 
was assessed by using the instrument chromatogram to observe if there were 
peaks that interfere with the target analyte peaks. This was achieved using 
ten different DFU samples without the addition of an ISD via the SIM mode.  
The selectivity study was completed by injecting DFU samples that 
contained twenty-one similar chemical structure drugs to those intended to 
be checked in order to complete the validation work. Those drugs are 
cathinone, 4-methyl-N-ethyl-norephedrine, N-ethylecathinone, 
methcathinone, PMA, MDEA, methedrone, methylone, pentedrone, 
flephedrone, MDPPP, butylone, pyrovalerone, MDPV, ethylone, MDA, 
bupherone, PMMA, 4-EMC , α-PVP and naphyrone at 2 µg mL-1. 
6.2.8.5 Carryover   
Carryover was investigated by examining DFU specimen results after the 
sample was injected after the target analytes had a concentration of 2 µg 
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mL-1. This procedure was used as a routine in each day of the validation 
work. 
6.2.9 Application of the method  
After the method was validated, it was applied to three positive real urine 
specimens that were collected from SA. These samples were confirmed as 
positive using this method and the SPE method stated in chapter 4. This 
application was completed to verify the robustness of the method for real-
life urine samples.  
Three positive samples were extracted and analysed using the optimised 
methods of PDMS/DVB SPME fibre in tips and GC−MS as stated previously in 
this chapter. The samples were repeated three times for each specimen to 
compare SPE and SPME. Two procedures were applied as follows. 
Triplicate of the three urine samples were extracted and analysed by SPE 
and SPME coupled with GC−MS with the calibrator points and QCs using the 
procedures stated in chapter 4 and 6, respectively. After the completion of 
the analysis, the concentration result for each sample was reported for 
comparison purposes only. 
6.2.10 Green analytical chemistry method  
In general, there are five criteria that should be assessed for the evaluation 
of GAC: environment, safety, energy, health and waste [547-549]. Based on 
the above, SPME in tips, SPE and LLE procedures were compared and 
discussed in chapters 6, 5 and 4, respectively. The GAC criteria were 
evaluated for the analysis of ATS and SC during sample preparation stages 
only. The explanation of the method used here for the assessment of GAC 
was recently published in 2018 in a paper by Płotka-Wasylka [188].  
6.2.11 Fragmentation patterns and retention time (tR)   
The interpretation of the results was by the retention time (tR) of each 
target analyte compound with at least three fragmentation ions including 
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their relative ion intensities ratio (%). tR should not fluctuate more than ±1%. 
The relative abundance ions ratio should not be greater than ±10% for ions 
with the relative intensities > 50%.  
6.2.12 GC−MS method 
This method was completed using the procedure described in section 
3.2.2.12 with the exception of oven temperature programme; 70°C to 200°C 
at a rate of 11°C/minute (hold for 4 minutes), and 200°C to 280°C at a rate 
of 10°C/minutes (hold for 1 minute). 
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6.3 Results and discussion 
6.3.1 Unextracted responses of the mixture of eight drugs in GC−MS 
The methods demonstrated in chapter 4 were applied to the eight target 
analyte drugs using PFPA and unextracted tubes. The tR of the eight drugs 
with ions ratio were identified. After the method provided good responses 
and peaks with adequate separation, development work for the evaluation 
of the SMPE tips was initiated. See Figure 6-2. 
 
Figure 6-2: Unextracted separation chromatogram peaks for eight SC and ATS substances at 2 
µg mL-1 
1. Amphetamine (8.20) 
2. Methamphetamine (9.51) 
3. Buphedrone ephedrine (9.75)   
4. Mephedrone metabolite (10.14) 
5. PMA (10.85) 
6. Mephedrone (11.21) 
7. MDMA (13.34) 
8. Pentylone (16.48) 
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6.3.2 Method development  
The SPME procedure is uncomplicated and comprises the performance of 
two stages: the absorption stage (partitioning of target analytes between 
the urine sample and the polymeric fibre coating in tips) and the desorption 
stage (desorption of the extracted compounds using back extraction 
solvents). Several parameters characteristically must be optimised with the 
purpose of reaching high sensitively, selectivity, recovery, repeatability and 
reproducibility.  
The extraction of analytes can be increased by optimising and altering the 
method development parameters within the sample conditions [359]. 
Method development strategy was followed as detailed in Figure 6-3. The 
plan was designing such that the procedure would be modified to the 
optimum results in each step. This plan was used to save time, material, 
money, as well as accomplishing the above goals.  
The retention time (tR) with ion ratio (%) for each drug was determined and 
reported (see Table 6-4). The results presented successful separations and 
detections for PMDS/DVB-SPME fibre in tips.  
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Figure 6-3: Optimisation processing stages in this thesis for the SPME method development 
work 
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Table 6-4: Retention time (tR) and ion fragmentation (m/z) with ratio (%), the target ions 
in bold, the continuing ions were used for confirmation with their ratio (%).   
Drug name tR m/z Ratio 
(%) 
Drug name tR m/z Ratio 
(%) 
Amphetamine-d11 8.422 194 100 4-Methylephedrine 
(mephedrone 
metabolite) 
10.158 204 100 
128 72 119 13 
98 33 160 20 
308 3 
Amphetamine 8.486 190 100 PMA 10.854 121 100 
118 79 148 42 
91 36 190 5 
65 9 311 7 
Methamphetamine 9.505 204 100 Mephedrone 11.215 119 100 
160 31 204 25 
118 24 91 20 
91 14 160 14 
Pentylone-d3 16.339 193 100 MDMA 13.315 204 100 
235 86 162 73 
149 380 135 43 
339 12 
Buphedrine 
(buphedrone 
metabolite) 
9.770 218 100 Pentylone 16.442 149 100 
119 12 190 22 
308 3 232 19 
160 18 381 5 
Chapter 6—175 
 
6.3.2.1 Step 1: Selection of the fibre coating 
During SPME method development, the appropriate selection of coated materials 
is crucial. SPME coated fibres have been reviewed elsewhere [492, 550, 551]. 
The selection of the fibre coating should be as the first step in SPME method 
development [289, 552]. Each fibre coating type with unique thickness, length, 
polarity and volatility of the fibre delivers different reactions and mechanisms in 
each analyte and in each matrix. The extraction efficiency is reliant on the 
distribution coefficient between type of sample, analyte and the fibre coating 
[289]. The distribution coefficient of the target analyte penetrates (absorption) 
the volume of polymer coating within a specified time. Enhancing the penetration 
of the entire analyte into the fibre depends on the compatibility of the polarity of 
the coating fibre and analyte, called “like dissolves like” (see Figure 6-4  for 
general selection guide associated to ATS and SC) [546, 553-555]. 
 
Figure 6-4: Estimation guide for the selection of fibre coating [546] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polarity low high 
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Since ATS and SC are polar and semi-volatile compounds, affinities are high in the 
polar and semi-volatile fibre coating, such as PDMS-DVB (bipolar), PA, C18 and 
C18-SCX [553-555]. In general, nonpolar substances have high affinity to 
adsorption on nonpolar coated fibres; the thicker the fibre coating, the higher the 
capacity to extract the volume of organic compounds. Conversely, a lower film 
thickness allows the compound to be effortlessly desorbed in the bound phase, 
specifically at higher temperatures with higher boiling points. This is because the 
diffusion of the compounds over a smaller thickness coating occurs much easier 
than the diffusion in a thicker coating [518]. However, the non-polar PDMS 
provides excellent extraction for amphetamines. This is because of the effects of 
other factors such as the thickness of the coating and the molecular mass of the 
analyte [500-502, 518, 546]. Generally, a thicker coating fibre needs a longer 
extraction time, but the recoveries are higher [358]. Additional discussion on the 
selection of coating fibres in SPME was reviewed by Graham et al. [556].  
From the above discussion, it is evident that selecting the right fibre without 
investigating the affinity and behavior of the coating fibre with the target analytes 
is complex, particularly in the case of mixtures or new materials. The new fibre 
tips that were evaluated were slightly different in physiochemical properties, such 
as the size and length of the coating fibres. Therefore, it is very important to 
assess the sensitivity of these fibres. Unfortunately, the fibre tips on the market 
are accessible from a single source (Supelco) with availability of only two coated 
fibres PDMS/DVB and C18. The coated fibres of C18-SCX were kindly donated by 
Sigma Aldrich, because the product is still under investigation (not available on 
the market).  
PDMS-DVB was designed for the extraction neutral fractions of the analytes with 
medium to high polarity and semi-volatile to volatile compounds, such as 
amphetamines [552, 557]. Several articles carefully chose PDMS/DVB as the fibre 
for the extraction of amphetamines [522, 555, 558] and cathinones [413]. For 
example, PDMS/DVB, PDMS, CAR/PDMS and CW/TPR were tested for amphetamine 
and methamphetamine in serum using LC MS, and the conclusion was that the 
PDMS/DVB was the favoured extraction fibre in terms of extraction efficiency, 
response and sensitivity [559]. Therefore, as expected, the results show that the 
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PDMS/DVB provides high sensitivity with great responses in GC−MS compared to 
the other tested fibre coating tips (see Figure 6-5 for drug separation peaks in 
chromatograph). 
C18 provided great separation characteristics and it is extensively used in 
chromatography or SPE as a stationary phase for medium and non-polar substances 
[560]. However, it had very poor responses in this study under all examined drugs 
and under all developing processing stages.  
The mixed mode SPME-C18/SCX, which is a mixture of ion strong cationic 
exchange and hydrophobic coating phases, was introduced for the improvement 
of the extraction efficiency [561, 562]. It was used for the extraction of normal 
and charged fractions of the target analytes. It has high affinity for the extraction 
of ATS because the natural and ionic fractions of ATS can be absorbed on the fibre 
coating. Good responses were not found within this study. Additionally, accuracy 
and precision, recoveries or even good selectivity for all drugs tested under all the 
developing processing stages using C18/SCX were not adequate [511, 515, 561]. 
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.  
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Figure 6-5: A) SIM chromatogram for eight stimulant drugs: SPME-PDMS/DVB fibre tips and 
PFPA derivative; this is after the optimum conditions were applied at a concentration of 1 µg 
mL-1 in a urine sample. 
  
Amphetamine d11: (8.14) 
1. Amphetamine (8.200) 
2. Methamphetamine (9.505) 
3. Buphedrone ephedrine (9.770)   
4. Mephedrone metabolite (10.158) 
5. PMA (10.861) 
6. Mephedrone (11.215) 
7. MDMA (13.316) 
8. Pentylone (16.452) 
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6.3.2.2 Step 2: Extraction mode 
There are two commonly used SPME extraction methods: direct immersion 
and headspace. Even though the headspace mode is more suitable for 
complex, high to medium volatility and low to medium polarity samples and 
analytes, it cannot be utilised for SPME in tips because the headspace mode 
requires high temperature to enable evaporation. This step cannot be 
achieved for the fibre in tips because high temperatures cannot be 
withstood. Therefore, the direct immersion only was used for the following 
method development steps.  
6.3.2.3 Step 3: Instrumentation 
GC−MS is the most common technique used extensively for a wide range of 
mixture drugs of interest; for example, the quantitative analysis of ATS and 
SC in forensic toxicology laboratories.   
6.3.2.4 Step 4: Agitation methods 
The agitation mechanism is a very important parameter for the development of 
SPME. The effectiveness of the agitation method determines equilibration time of 
the aqueous specimen. This is significant in order to yield efficient extraction 
based on kinetic theory [489]. Suitable agitation techniques accelerate the 
transfer of mass analytes from the sample to the fibre coating providing shorter 
equilibrium reaction time and greater extraction of the analytes [359, 563]. 
For a liquid matrix such as urine, the most widespread agitation methods used 
within the literature for SPME were a shaking (vortex/ moving vial), magnetic 
stirring (a stirring bar in the vial), sonicating and fibre moving. All methods 
required temperature to reach equilibrium, with the exception of the shaker 
[546].  
The most effective technique is direct sonication, which provides extraction times 
as short as 30 seconds [361]. However, it heats the sample, which in some cases 
destroys the fibre, and may also destroy the analytes [564]. Triplicate urine 
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samples were examined at RT and 60°C for 10 minutes using the direct sonication 
method throughout the extraction stage. The results were poor for all fibres in all 
investigated samples. Stirring bar and fibre movement techniques also require 
sufficient space in the vail and high temperatures, thus were not evaluated within 
this development study.  
In-tip SPME (automation) fixed with a Tomtec Quadra 96 workstation significantly 
decreased agitation by simply operating aspiration and dispense functions through 
several cycles in the system [565]. 
As a result, the single remaining method that can be safely and effectively 
performed is a shaker vortex (IKA VIBRAX VXR shaker). Therefore, this technique 
was applied to the following steps.  
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.  
6.3.2.5 Step 5: pH evaluation   
The pH of the sample is vital. For slightly basic compounds, such as amines, 
the undissociated form must be maintained [566]. It is also very important 
that the analytes are completely transformed into natural form, because 
SPME can extract only natural compounds [363]. Therefore, the requirement 
of pH values to be adjusted is key to increasing sensitivity. Low pH values 
improve recoveries for acidic species, while high pH values improve the 
extraction efficiency of basic compounds. Basic molecules are protonated 
at low pH values, and acidic molecules are ionised at high pH values. The 
optimum pH for extraction is within the stability range of the fibre coatings 
and the target analytes [546, 561].  
The sample pH is theoretically described by the extraction equilibrium and 
acid–base equilibrium [567]. For ATS and SC (amphetamines pKa (8.8-10.4) 
[568], cathinones pka (7.4 and 9.5) [569]), the value of pH > 10 is essential, 
because of the high value of ATS and SC acid dissociation constants. Basic 
pH values enhance the recovery of basic analytes [570]. Overall, it is 
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expected that to deliver an efficient extraction, it is essential to make the 
contents 2 or 3 units above or below the pKa of the analyte of interest [571, 
572] . 
The three repeated specimens in each fibre coating in tip were adjusted to 
pH values of 3, 5, 7, 9 and 11. Poor responses and detections were observed 
for C18 and C18/SCX modes for all pH values, whereas PDMS/DVB was the 
only fibre that provided great responses and detections with good recovery 
for a pH value of 11 (see Figure 6-6). It can be noted that the PDMS/DVB pH 
results here is compatible with the evidence of the discussion above. 
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.         
 
Figure 6-6: The pH buffering results of an averaged triplicate in PDMS/DVB-SPME tips in urine 
at 1 µg mL-1  
6.3.2.6 Step 6: Ionic strength and salts additive 
The addition of inorganic salts increases the ionic strength of the matrix. 
Organic substances then become less soluble and the partition coefficients 
are achieved [564]. The distribution constant increases when salts are 
added. For example, with the addition of NaOH or NaCl, the aqueous 
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solubility of most compounds decreases and causes the target analytes to 
be distributed faster from the matrix to the fibre coating, as a result the 
extraction efficiency is improved [289]. The effect of the additive salts 
varies according to the nature of the targeted analytes and the matrices. 
The addition of salts can boost or diminish the amount of analytes extracted, 
depending on concentrations, therefore, it is important that the parameter 
be experimentally investigated [218, 546].  
The results showed that the two coating fibres (C18 and C18/SCX) provided 
poor responses and detections in the experiment and similar results were 
achieved in the following sections.  
The recovery of PDMS/DVB fibre coating improved when 10% NaOH and 0.5 
NaCl were mixed with the contents of the samples. (see Figure 6-7, Figure 
6-8 and Figure 6-9 for the example recovery results). Accordingly, the 10% 
NaOH and 0.5 NaCl were selected as the optimum conditions for the 
evaluation of the ionic strength and salts additive. 
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.  
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Figure 6-7: Example average recovery (%) (n=3) results for evaluation of the effects of the 
ionic strength with addition of salts applied to PDMS/DVB-SPME tips in selected drugs in urine 
at 1 µg mL-1  
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Figure 6-8: Comparison of average recovery (%) results (n=3) for assessment of the effect of ionic strength and additive of salts on PDMS/DVB-SPME tips on 
two different days (A and B)
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Figure 6-9: Percentage of average recovery example results (n=3) when only additive salts 
were applied to selected compounds on PDMS/DVB-SPME tips in urine at 1 µg mL-1 
6.3.2.7 Step 7: Temperature 
The assessment of temperature during the extraction stage was an essential 
parameter to obtain high recovery, specifically in the headspace mode. Increasing 
the temperature in the tested vial increases the following: analyte diffusion 
coefficient, extraction rate, mass analyte to be transferred into the coating and 
shorter equilibrium time. The higher the temperature is, the lower the distribution 
constant in the sample matrix fibre coating, which leads to reduced sensitivity 
and recovery at equilibrium [546]. In general, higher temperatures should be 
applied to high molecular weight and less volatile substances [573].   
The effect of temperature on methamphetamine compounds and recovery for 
SPME was evaluated for four temperatures (22, 40, 60 and 73°C). It was concluded 
that the highest recovery was achieved when the temperature was lowest, yet the 
extraction time was the longest [552]. In addition, it should be noted that 
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extremely high temperature damages the fibre coating and consequently 
eliminates the capability to absorb the analytes, causing the target analytes to be 
degraded  [574]. 
Even though Supelco was introduced, the fibre in tips was not recommended for 
increased temperature conditions, because it was developed for ambient 
temperature. Three fibres in tips on triplicate samples were evaluated in each 
fibre using pre-equilibrium temperatures of 60°C and RT. Poor detections and 
recoveries were achieved in most tested drugs for the samples that were set at 
60°C, while the RT samples provided better detections and recoveries. 
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.    
6.3.2.8 Step 8: Type of vials  
The 1.2 mL vial kit that was purchased from Supelco was expensive, while the 1.5 
mL microcentrifuge Eppendorf vial (conical bottom) was very inexpensive. The 
silicone septa (with slit), which was created specifically for SPME fibre in tips, 
cannot fulfil with the requirements for high agitation speeds in a shaker, as the 
tips had fallen when the shaker was set to 2000 rpm or more. This situation rarely 
occurred with Eppendorf vials.  
These vials were investigated using linearity and recovery parameters. The results 
are illustrated in Figure 6-10 showing that the linearity study was slightly better 
using Eppendorf vials, whereas the opposite was true for the recovery results. 
Since the Eppendorf has more advantages than kit vial and since they both 
provided similar results, the Eppendorf was selected for future work. 
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.  
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Figure 6-10: A) the comparison of the average recovery (%) (n=2) results for amphetamine 
and methamphetamine, B) the average linearity (R2) (n=2) using PDMS/DVB-SPME tips 
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6.3.2.9 Step 9: Derivatisation reagent 
The derivatisation agents were discussed in section 3.1.2. The reagents 
were normally used for the development assessment of SPME when added 
before, within or after the extraction stage. For example, when exposed to 
the fibre coating during the extraction step or prior, the extraction 
efficiency and the distribution constant (partition ratio) for the less volatile 
compounds will increase. This approach is commonly applied to the 
headspace mode to increase the volatility [556]. However, the four 
strategies were assessed, mentioned in section 6.2.7.5.  
The results presented poor responses and detection for all drugs examined with 
the exception of adding PFPA after the evaporation step (see Figure 6-11).  
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.  
 
Figure 6-11: The average recovery results (%) for selected drugs when PFPA was added after 
the evaporation step in urine PDMS/DVB-SPME tips (n=2) 
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6.3.2.10 Step 10: Sample volume 
From Equation 6-2, the amount of target analyte adsorbed increases when the 
sample volume size increases. Increasing the distribution constant (Kfs) can be 
accomplished by increasing the volume of the sample, which increases the amount 
the extracted analytes [202, 546]. However, the current scope limits the volume 
of the sample to maximum of 1 mL. This is to match the size of the sample vial 
and the vortex shaker, because the tips of SPME were introduced to fit with 
specific sizes of vials. In addition, reducing the sample volume is always preferable 
for the analysis of forensic investigation matrices due to availability constraints, 
minimising waste and eliminating contamination.  
As expected, the recovery results (%) shows that a volume of 1 mL provided high 
extraction efficiency compared with lower urine sample volumes. See Figure 6-12 
for the results.  
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.  
 
Figure 6-12: The average recovery results (%) of sample volumes 0.1, 0.5 and 1 mL on 
PDMS/DVB-SPME in tips for selected drugs using triplicate urine specimens (n=3) 
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6.3.2.11 Step 11: Type of solvents  
Desorption is a very important stage, where the target analytes are desorbed from 
the coating fibres into the separation and detection system for the analysis. The 
desorption of analytes can occur directly during the static mobile phase or 
dynamically with another suitable solvent in the HPLC or LC interface using the 
SPME desorption chamber [202, 499, 546]. In tube SPME, the desorption is 
performed directly within the mobile phase in the extraction capillary over a 
specified time. In GC, the desorption occurs thermally in the injector port [388]. 
In tips SPME, the desorption stage occurs using either the direct desorption 
technique or a desorption solvent followed by evaporation, derivatisation and 
reconstitution [202]. Clearly, the desorption solvent followed by evaporation, 
derivatisation and reconstitution is one approach that can be utilised in GC, 
because the direct desorption technique is used in LC, HPLC or GC for automation. 
Therefore, the reversed-phase solvent is the only approach that can be used in 
this manual process in tips SPME coupled with GC−MS.  
In this work, the amount of solvent was not evaluated, since it is recommended 
that the solvent should be kept at a minimum. This is to reduce its effects during 
the desorption step, because it can decrease the sensitivity and increase the 
chance that the analytes are desorbed into the wall of the vial [202]. For these 
reasons, a 0.3 mL certified glass vial kit, with low absorption and a septum cap 
with slit were operated during the desorption stage to reduce the possibility of 
the analytes desorbed into the wall of the vial or into the septum. 
The 60 µL of solvent was sufficient to fully cover the fibre coating in tip; therefore, 
this volume was applied throughout the project. 
The example results of tested drugs and solvents are shown in Figure 6-13 and in 
Table 6-5 for day one, and Figure 6-14 with Table 6-6 for day two. The recovery 
results of mephedrone were above 20% RSD on both days, the buphedrine 
(buphedrone metabolites) was above 20% on day two, which is unacceptable, and 
the remaining recovery drug results were below 20%. 
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According to single factor ANOVA illustrated in Table 6-7, there were no 
significant differences between the mean recoveries in each drug and solvent 
tested with the exception of buphedrine, which means that there was no 
difference in the recovery results when different solvents were used. 
Consequently, MeOH was selected as the optimum solvent to be used for the 
experiments and investigations. Due to the better performance, the SPME-
PDMS/DVB fibre was chosen as the best option.  
 
Figure 6-13: The average recovery results (%) of triplicate urine PDMS/DVB-SPME tips for the 
evaluation of solvent type on day one 
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Table 6-5: This table demonstrates the mean of all recoveries under all solvents in each 
selected drug with SD, RSD and confidence limit 95%.  
The values here were calculated from the above figure.  
Drug Name Amphetamine Methamphetamine PMA Mephedrone MDMA Pentylone 
Mean of 
recoveries % with 
Confidence limit 
(95%) 
20 ± 2.13 41 ± 4.44 13 ± 
1.36 
9.0 ± 3.18 27 ± 
2.73 
11 ± 1.52 
SD 2.55 5.3 1.62 3.80 3.26 1.81 
RSD 13% 13% 13% 42% 12% 17% 
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Figure 6-14: The average recovery results (%) of triplicate urine PDMS/DVB-SPME tips for the 
evaluation of solvent type on day two 
Table 6-6: The mean of all recoveries under all solvents in each drug with SD, RSD and 
confidence limit 95% 
The values here were calculated from the above figure. 
Drug name Amphetamine Methamphetamine Buphedrine PMA Mephedrone Pentylone 
Mean of 
recoveries % 
with Confidence 
limit (95%) 
28 ± 5.4 55 ± 10 53 ± 29 21 ± 
3.83 
10 ± 2.92 28 ± 5.8 
SD 4.44 8.2 23 3.08 2.35 4.71 
RSD 16% 15% 44% 15% 23% 17% 
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Table 6-7: Single factor ANOVA applied to selected solvents and drugs on day two for study 
the solvent type 
ANOVA: Single factor P-value Differences 
Compound name P <0.05 Yes/No 
Amphetamine 0.40 NO 
Methamphetamine 0.17 NO 
Buphedrine  0.045 Yes 
PMA 0.64 NO 
Mephedrone 0.15 NO 
Pentylone 0.23 NO 
 
6.3.2.12 Step 12: Extraction time and agitation speed 
Extraction time required to reach equilibrium for SPME can be decreased using an 
appropriate agitation method. For in tip SPME, the appropriate agitation method 
was a shaker, which was discussed in section (6.3.2.4). Once the equilibrium time 
reached, the error of extracted analytes decreases when repeatability is ensured 
[289]. Sensitivity increases when the equilibrium time point is achieved [202, 546].  
The results show (see Figure 6-15) that on day one and at a speed of 1000 rpm, 
the highest recoveries were accomplished after 2 hours, however, the equilibrium 
time point might arise after this time. Therefore, the samples were repeated using 
different durations and speeds. On day two, as in Figure 6-16 (A), similar results 
to day one were observed, but at a different speed (1500 rpm). The equilibrium 
time point was observed on day two in Figure 6-16 (B). This point was achieved 
after 1 hour and when the speed was 2000 rpm. It can be concluded from the 
figures that a speed of 2000 rpm provided the highest recoveries for all drugs 
tested. The maximum speed that could be practically obtained was 2000 rpm, 
because when the shaker was set to 2500 rpm the tips came off of the vials. The 
optimum conditions in this step are 2000 rpm after 1 hour, this is based on the 
parameters, materials and techniques that were used in the experiments. Due to 
the better performance, the SPME-PDMS/DVB fibre was chosen as the best option.   
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Figure 6-15: The average recovery results (%) on day one for the assessment of extraction 
reaction time in triplicate urine PDMS/DVB SPME tips at a speed of 100 (n= 3)
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Figure 6-16: Examples of the average recovery results (%) for the estimation of extraction reaction time in triplicate urine PDMS/DVB SPME tips. 
 A) The results at 1500 rpm on day two B) The results at 2000 rpm on day three
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6.3.2.13 Step 13: Desorption time and agitation speed  
To reduce the extraction time required, the desorption time and agitation speed 
were varied in the development protocol. The general rule was that the maximum 
recovery achieved is equal to the maximum analytes that desorbed at that time 
and speed.  
On days one and two, the recovery results in Figure 6-17 and Figure 6-18 show 
that the analytes were fully desorbed during all investigated times. To confirm 
the above conclusion, a single factor ANOVA was performed to study the effect of 
agitation time on the recovery results. By observing the results in Table 6-8, there 
was no significant difference when the time was modified. This conclusion is valid 
based on the methods and materials that were used in the laboratory experiments. 
Based on the recovery results for the evaluation of agitation speed, it is clear that 
a speed of 1500 rpm provided higher recoveries than 1000 rpm.  
On day three (see Figure 6-19), because the analytes were fully desorbed during 
all times investigated on days one and two, the following times were set for the 
shaker to determine when the analytes were fully desorbed: 1, 5, 10 and 20. The 
recovery results show that the analytes were completely desorbed, however the 
RSD (%) indicated that only the 10 minute duration was valid for all drugs 
examined. The 5 minute RSD was valid except for mephedrone. The 1 minute 
duration was above 20% of RSD for most drugs. The 20 minute RSD was greater 
than 10% for most compounds, and the error increased after 20 minutes. This may 
result from the effect of speed in the shaker that damaged the fibre in tips. By 
observing the methamphetamine recovery results in all graphs (Figure 6-17 and 
Figure 6-18) on all experimental days, it can be concluded that the 2000 rpm 
speed provided the maximum recovery results. Therefore, the optimum results 
that were selected for PDMS SPME in tips were using a 10 minute duration and 
2000 rpm.  
Due to the better performance, the SPME-PDMS/DVB fibre was chosen as the best 
option.  
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Figure 6-17: Average recovery results (%) at 1000 RPM on day one for selected ATS and SC 
using triplicate urine specimens and PDMS/DVB SPME tips. 
 
Figure 6-18: Average recovery results (%) at 1500 RPM on day two for selected ATS and SC 
using triplicate urine specimens and PDMS/DVB SPME tips. 
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Table 6-8: Single factor ANOVA applied to selected drugs on day two to study the effect of 
agitation time 
ANOVA: Single Factor P-value Differences 
Compound name P <0.05 Yes/No 
Amphetamine 0.85 NO 
Methamphetamine 0.98 NO 
Buphedrine  0.53 NO 
PMA 0.54 NO 
Mephedrone 0.92 NO 
Pentylone 0.66 NO 
 
199 
 
 
 
Figure 6-19: The left graph shows the time effect on day 3 for selected drugs using triplicate urine specimens and PDMS/DVB SPME tips based on the average 
recoveries (%), the right graph is the RSD for each length of time the drugs were tested. 
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6.3.2.14 The optimum procedure results 
The optimised procedure was determined from the results of the previous 
development processing. The optimum procedure was then selected for the 
assessment of validation parameters.  
The PDMS/DVB fibre provided the best recoveries, responses with the least 
error in accuracy and precision, and for that reason, only the optimum 
procedure of the PDMS/DVB fibre will be presented in the results and 
discussion sections. The procedure is detailed below.  
Condition step: The SPME pipette tips coated by PDMS-DVB fibre were 
inserted into small glass tubes that contained MeOH: d. water (50:50 (v/v)). 
The fibres were conditioned for 10-20 minutes.      
Sampling step: 1 mL mixtures of the eight target analytes in DFU, 100 µL 
ISD (amphetamine-d11 and pentylone-d5), 100 µL of 10 % (w/v) NaOH and 0.5 
g NaCl at a pH of 12.6 were aliquoted, added and mixed using 1.5 mL 
Eppendorf microcentrifuge tubes (safe-lock). The tubes were then pierced 
using small needle to permit the tips to enter. The tips were inserted and 
secured into the contents, ensuring that the tips would not escape during 
the shaking step.  
Extraction step: The tubes with tips were put into a vortex shaker for 
agitation and extraction for one hour at a speed of 2000 rpm.  
Desorption step: The tips were taken out of the Eppendorf tubes and 
transferred to 0.3 mL vials for desorption using 65 µL of MeOH. A speed of 
2000 rpm for 10 minutes in a shaker was used for agitation. 
Evaporation step: The samples were transferred to the hot block for 
evaporation, and 10 µL of 0.1 HCl with MeOH (1:9) was added to all vials. 
The vials were left at RT until fully dry under gentle evaporation using 
nitrogen gas (approximately 2 minutes). 
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Derivatisation step: The 0.3 mL vials were derivatised using 50 µL of PFPA: 
EtOAc (2:1); immediately mixed, vortexed, capped and left on the hot block 
for incubation at 60° for 15 minutes.  
Evaporation step again: The vials were again placed on the hot block for 
evaporation at RT. Two to three minutes was sufficient for completion. 
Reconstitution step: Vials reconstituted by adding 50 µL of EtOAc. 
Analysis step: The 0.3 mL vials were placed on the GC-autosampler for 
analysis in GC−MS. See Figure 6-20. 
The laboratory work was carried out to increase the recoveries (%) of the 
drugs and the three fibres in tips-SPME (C18, C18-SCX and PDMS/DVB) using 
the strategies from the method development processing stages. After the 
recoveries were calculated over the processing stages, it was concluded that 
the PDMS/DVB fibre in tips provided the greatest recovery (2-80%), followed 
by the fibres of C18 (0.1-10%) and C18-SCX (0.1-10%). The optimum recovery 
results for the developed method parameters are summarised in Table 6-9.  
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Figure 6-20 demonstrates the optimum procedure for PDMS/DVB-SPME fibre tips applied 
to mixtures of selected ATS and SC in DFU samples. 
10 % NaOH, pH 12.6 and 0.5 g 
NaCl 
PDMS/DVB Tips, condition 
using MeOH and d. water 
(50:50) 
 
Urine + mixture of ATS 
and SCs + ISDs   
 
The length of 
PDMS/DVB is 1 cm  
2000 rpm 
 
GC-MS   
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6.3.3 Method validation 
After the method development work, it is necessary to prove the validity of 
this method. The new method was also evaluated through validation 
parameters to verify limitations, problems or disadvantages of the tips. The 
final optimum method development parameters were used for the 
assessment of the method validation in PDMS/DVB fibre only.  
6.3.3.1 Linearity results  
The unweighted linear calibration model was used for all drugs tested. The 
average R2 was calculated from 20 calibration curves for each drug. The R2 
was greater than 0.992 for all analytes.  
The concentration in each point was also calculated to study the LLOQ using 
RSD (%) and bias (%). Each point should be within ±20% to be considered valid. The 
LLOQ was ≥100 ng mL-1 for all target analytes. See Table 6-10 for the linearity 
results with the average accuracy of the selected points as an example for 
the evaluation of LLOQ. 
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Table 6-9: The optimum conditions of the method development parameters, for the 
evaluation of three fibres in SPME tips  
The products were decided according to the most significant recovery (%) for the eight ATS 
and SC substances at 1 µg mL-1 in urine specimen. *Invalid equates to ≥ 20% error of RSD (%) 
and/or accuracy (± %) in each parameter, fibre and drug alone.   
Parameters vs Fibre 
coating type 
PDMS/DVB C18 C18/SCX 
Vial type 1.2 mL kit and 1.5 mL 
Eppendorf vials 
1.2 mL kit and 1.5 
mL Eppendorf vials 
1.2 mL kit and 1.5 
mL Eppendorf vials 
Agitation method Orbital shaker Orbital shaker Orbital shaker 
pH evaluation ≥11, the highest 
recoveries were at pH 
12.60  
pH 2.80 pH 3.30 
Ionic strength (w/v) 10% NaOH + 0.5 g 
NaCl (pH 12.60)   
100 µL formic acid 100 µL formic acid + 
100 µL 0.1 HCl (pH3) 
Salts & acid additives NaOH + NaCl Formic acid  Formic acid + HCl 
Temperature RT RT RT 
Vials type validity Both Eppendorf vials 
and vial kits were 
valid  
Invalid* Invalid 
PFPA-derivatisation 
and analyte studies 
After drying  After drying After drying 
Sample volume 1 mL  Invalid Invalid 
Solvent type All 8 solvents were 
valid 
Invalid Invalid 
Extraction time ≥1 hour Invalid Invalid 
Extraction speed 2000 RPM Invalid Invalid 
Desorption time 10 min Invalid Invalid 
Desorption speed 2000 RPM Invalid Invalid 
Linearity 0.920-999 Invalid Invalid 
Recovery 2-80% 0.1-10% 0.1-10% 
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Table 6-10: Linearity (R2) and LLOQ studies 
The average of each accuracy concentration point was used to evaluate the LLOQ.  
Drug name (R2) 
n= 20 
LLOQ study Drug name (R2) LLOQ study 
ng 
mL-1 
Grand mean 
of accuracy 
(error ± %) 
ng 
mL-1 
Grand mean 
of accuracy 
(error ± %) 
Amphetamine 0.999 100 -4.67% PMA 0.997 100 19% 
500 -1.49% 500 1.07% 
2000 0.54% 2000 0.27% 
Methamphetamine 0.997 100 -2.10% Mephedrone 0.994 100 13% 
500 -3.87% 500 1.46% 
2000 -1.61% 2000 -0.06% 
Buphedrine 
(buphedrone 
metabolite) 
0.994 100 -12% MDMA 0.995 100 8.9% 
500 3.57% 500 -5.5% 
2000 -0.35% 2000 1.48% 
4-Methylephedrine  
(mephedrone 
metabolite) 
0.992 100 0.72% Pentylone  0.999 100 14% 
500 -0.55% 500 2.00% 
2000 2.72% 2000 0.56% 
6.3.3.2 Accuracy and precision results  
The accuracy (%) and RSD (%) within and between run were successfully 
provided within an acceptable range. The error values were lower than or 
equal 15% for both. See Table 6-11 below for the results.  
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Table 6-11: Bias and RSD results  
Drug name Conc. (ng mL-1) Intra−day RSD Inter−day RSD Bias 
Amphetamine 250 3.78% 2.34% 1.17% 
850 6.3% 2.20% 0.91% 
1500 2.61% 1.97% -0.66% 
Methamphetamine 250 7.9% 3.40% -0.08% 
850 10% 3.48% 2.77% 
1500 8.7% 4.16% -0.30% 
Buphedrine 
(buphedrone metabolite) 
250 13% 5.7% 6.2% 
850 7.9% 4.30% -1.82% 
1500 9.7% 5.8% -2.30% 
4-Methylephedrine  
(mephedrone metabolite) 
250 13% 11% 2.95% 
850 9.9% 3.56% -4.16% 
1500 12% 7.0% -5.4% 
PMA 250 13% 4.28% -0.34% 
850 9.8% 1.65% 3.04% 
1500 8.3% 3.52% -1.56% 
Mephedrone 250 11% 6.1% 6.6% 
850 13% 2.62% -3.72% 
1500 15% 2.73% -6.9% 
MDMA 250 12% 6.3% -2.15% 
850 12% 4.30% -1.10% 
1500 9.4% 5.6% -0.25% 
Pentylone  250 5.8% 5.5% 2.78% 
850 7.4% 2.20% -0.24% 
1500 2.70% 1.35% -0.99% 
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6.3.3.3 LOD and LLOQ   
The LOD results were between 5 and 25 ng mL-1 for all the analytes. The 
LLOQ results were between 25 and 100 ng mL-1 for all the drugs investigated. 
The LOD and LLOQ for each drug is shown in Table 6-12. The results show 
the reliability of the method to quantify all selected drugs of ATS and SC. 
This statement is true if the concentration of each drug is truly above the 
value of the LLOQ quoted in the table below.  
Table 6-12: Signal-to-noise ratio for LOD and LLOQ  
Compound name LOD 
 (ng mL-1) 
LLOQ 
 (ng mL-1) 
Compound name LOD 
 (ng mL-1) 
LLOQ 
 (ng mL-1) 
Amphetamine 5 25 PMA 5 25 
Methamphetamine 5 25 Mephedrone 25 100 
Buphedrine 5 25 MDMA 10 50 
4-Methylephedrine  10 100 Pentylone  5 25 
6.3.3.4 Interferences and selectivity  
There were no observations of peaks from an endogenous study of all blank 
urine samples that interfere with the tR of the eight ATS and SC substances 
using the SIM mode. See Figure 6-21 for an example of the interference 
chromatogram peaks in blank urine with no addition of ISD.   
The selectivity exogenous study of 21 drugs outlined in section  6.2.8.4 
indicated that no peak was observed that affected the interpretation of the 
eight drugs of interest in the SIM mode.  
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Figure 6-21: An example of a SIM Chromatogram for an endogennous interferences study 
using a blank urine specimen without the addition of ISD 
6.3.3.5 Carryover   
The stimulant analytes of interest were not detected in a sample of urine 
when this sample was run after the 2 µg mL-1 of the eight drugs. Carryover 
was not seen within days of the validation work. No peak had similar tR with 
ion relative ratios of the eight drugs tested (see the example of carryover 
result (Figure 6-22)). 
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Figure 6-22: An example of a carryover study using a DFU sample 
6.3.4 The comparison study between the SPME in tips and SPE  
The PDMS/DVB, SPME in tips and SPE methods were applied for the 
confirmation of three positives of the cathinone compound. The positive 
confirmatory results obtained from the real human urine case samples were 
evidence that the SPME and SPE methods have the ability to detect and 
quantify similar stimulant compounds; in this instance: the cathinone drug. 
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Repeatability and reproducibility of the two techniques with excellent 
results for selectivity and sensitivity were successfully validated using the 
detection of real human urine specimens. See the Table 6-13 for the 
comparison outcomes. 
Table 6-13: The comparison study of three positives of the cathinone compound in 
real human urine samples  
(This was applied to SPE and SPME tips using GC−MS. The samples were collected from 
Saudi Arabia under the acceptance approval of ethics). 
Specimen vs. 
the results 
The mean conc. of SPE 
with RSD% (ng mL-1)   
The mean conc. of PDMS/DVB-SPME in 
tips with RSD% (ng mL-1) 
Urine 
specimen 1 
802 (3.99) 806 (9.4) 
Urine 
specimen 2 
1209 (3.89) 1201 (8.2) 
Urine 
specimen 3 
227 (13) 285 (18) 
6.3.5 Green analytical methodology 
The evaluation of green analytical methodology is complex and contains 
many criteria with several diversities of analytes and associated systems 
that must be assessed. Under certain circumstances, it is difficult to 
determine the ideal green analytical chemistry (GAC) for the protocol, since 
method validation parameters are also difficult to attain without the use of 
hazardous and harmful materials. In the SPME procedure, the solvents, 
chemicals and reagents were reduced to minimize hazards, while also 
fulfilling the requirements for achieving method validation.  
The fundamental background of GAC for sample preparation techniques and 
separation chromatography methods was reviewed by Armenta et al. and 
Galuszka et al. [548, 575] and discussed in [576]. The results for the 
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comparison study of the three sample preparation methods are 
demonstrated in Table 6-14.    
It can be concluded from the comparison study that the total amount of 
chemicals consumed per specimen using the SPME in tips procedure declined 
by 95% and 67% compared to SPE and LLE, respectively (95% = ((0.725 ÷ 13.6) 
× 100 = 5.3% – 100)), (67% = ((0.725 ÷ 2.18) × 100 = 34% – 100)).  
For the energy rate study, the uncertainty values were too high to be 
assessed in the procedure. Therefore, the comparison study for the energy 
rate is invalid for all sample preparation methods.  
The SPME in tips procedure decreased waste by 91% and 49% compared to 
SPE and LLE, respectively per sample (91% = ((1.6 ÷ 18) × 100 = 8.8% – 100)), 
(49% = ((1.6 ÷ 3.16) × 100 = 51% – 100). The number of wasted tubes and 
vials in each sample were: two (Eppendorf and vial Kit), four (culture tube, 
SPE cartridge, glass tube and GC vial) and three (culture tube, glass tube 
and GC vial) for SPME in tips, SPE and LLE, respectively. Hence, SPME in tips 
used less consumables by 50% and 33% compared to SPE and LLE, 
respectively.       
For the health rate study, the extraction method of SPME in tips reduced 
the total health harm by 33% and 7% caused by using SPE and LLE procedures 
(33% = ((3 (NaOH)  1 (NaCl)  1 (MeOH)  3 (HCl)  3 (PFPA)  2 (EtOAc) ) ÷ 
(1 (phosphate buffer) + 3 (acetic acid)  1 (MeOH)  2 (DCM)  2 (IPA)  3 
(NH4OH)  3 (HCl) + 3 (PFPA)  + 2 (EtOAc)) × 100 = 67% – 100)), (7% = ((3 
(NaOH)  1 (NaCl)  1 (MeOH)  3 (HCl)  3 (PFPA)  2 (EtOAc) ) ÷ (3 (NaOH) 
+ 2 (DCM)  3 (HCl)  1 (MeOH)  3 (PFPA)  2 (EtOAc)) × 100 = 93% – 100). 
This calculation was only valid when the amount of chemicals consumed was 
neglected in the calculation. Accordingly, it is clear that the LLE may cause 
more health impacts than the SPME for labourers, because the labourer is 
consuming and handling larger amounts of chemicals when using the LLE 
procedure.  
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For the safety rate study, the method of SPME in tips cut the flammability 
to 50% and 14% of SPE and LLE levels, respectively (50% = (3 (MeOH) + 3 
(EtOAc) ÷ (2 (acetic acid) + 3 (MeOH) + 1 (DCM) + 3 (IPA) + 3 (EtOAc) × 100 
= 50% – 100), (14% = (3 (MeOH) + 3 (EtOAc) ÷ (1 (DCM) + 3 (MeOH) + 3 (EtOAc)) 
× 100 = 86% – 100). Similarly, the flammability is increased with a higher 
amount of chemicals consumed, which is true when using SPE or LLE 
procedures.  
For the environmental rate study, all sample preparation methods have a 
similar impact on the environment. Less than 50 g of exhausted consumed 
chemicals are produced. Hence, no evidence was observed to confirm any 
differences between the methods.     
Overall, according to the above results and discussion, the SPME in tips 
provided the lowest penalty with minimal impact based on the criteria of 
assessment as compared to SPE and LLE.  
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Table 6-14: The comparison study for the assessment of green analytical chemistry applied to three procedures of SPME in tips, SPE and LLE  
a) Energy ranking: 1= ≤ 0.1 kWh, for example, wet chemistry and very tiny solvents used in evaporation stage; 2= ≤1.5 and >0. 1 kWh, moderate solvents used in evaporation 
stage and GC was applied. 3= >1.5 kWh, high volume of solvents used in evaporation stage and GC−MS were applied.  
b) Waste ranking: 1= full waste per sample ≤50 g. 2= full waste ≤250 and >50 g. 3= full waste >250 g. 
c) Health ranking: NFPA (National Fire Protection Association) score is 0 or 1= slightly toxic and irritant; NFPA 2 or 3= moderately toxic and temporary incapacitation; NFPA= 4 
serious injury and exposure.  
d) Safety ranking: NFPA score 0 or 1= instability score, no special hazards, flammable; 2 or 3= instability score, a special hazard is used, flammable; 4= instability score and 
flammable. 
e) Environmental ranking: 1 = <50 g; 2= ≥50 g and ≤250 g; 3 = >250 g.  
Method & 
criteria  
Chemicals used per sample Energy ratea (kWh) Waste rateb Health 
ratec 
Safety rated Environmental 
ratee 
Chemicals 
amount/ 
sample 
NFBA 
health 
rating 
NFBA 
flammability 
rating 
NFBA 
reactivity 
rating 
SPME procedure 
in tips used in 
this chapter 
• 100 µL of 10% 
NaOH 
3 0 0 3 
• The time required for 
evaporation was roughly 5 
min and the volume was 75 
µL/sample 
• Agitation speed was 2000 
rpm and total time was 70 
min 
• GC−MS 
 
1 
The volume of waste 
per sample was 1.6 
mL (urine and 
chemicals) 
3 
 
0 
(Flammable) 
1 
• 0.5 g NaCl 1 0 0 
• 65 µL of 
MeOH 
1 3 0 
• 10 µL of 
acidified 
methanol (1:9) 
3:1 0:3 0:0 
• 50 µL of PFPA 
and EtOAc (2:1) 
3:2 0:3 0:0 
Total amount of the chemicals consumed = 725 
µL/sample. 
SPE (see chapter 
4 for the 
procedure)  
• 4 mL of 0.10 
M phosphate 
buffer- pH 6 
1 0 0 3 
• The time required for 
evaporation was (30-40 
1 
The volume of waste 
per sample was 18 
3 0 
(Flammable) 
1 
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• 1 mL of 100 
mM acetic acid 
3 2 0 min) and the volume was 
2.6 mL/sample 
• SPE Vacuum was used for 
5 min 
• Centrifuged for 10 min at 
3000 rpm 
• GC−MS 
 
mL (urine and 
chemicals) 
• 5 mL of MeOH 1 3 0 
• 3 mL of DCM: 
IPA: NH4OH 
(78: 20: 2) 
2: 2: 3 1: 3: 0 0: 0: 0 
• 10 µL of 
acidified 
methanol (1:9) 
3:1 0:3 0:0 
• 50 µL of PFPA 
and EtOAc (2:1) 
3:2 0:3 0:0 
Total amount of the chemicals consumed = 13.6 
mL/sample. 
LLE (see chapter 
3 for the 
procedure)  
• 0.1 mL of 25% 
NaOH 
3 0 0 3 
• The time required for 
evaporation was roughly 35 
min and the volume was 
about 2 mL/sample 
• Centrifuged for 10 min at 
2500 rpm 
• GC−MS 
1 
The volume of waste 
per sample was 3.16 
mL (urine and 
chemicals) 
3 0 
(Flammable) 
1 
• 2mL DCM 2 1 0 
• 25 µL of 
acidified 
methanol (1:9) 
3:1 0:3 0:0 
• 50 µL of PFPA 
and EtOAc (2:1) 
3:2 0:3 0:0 
Total amount of the chemicals consumed = 2.18 
mL/sample. 
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6.4 Conclusion 
SPME in tips provided an efficient, clean, convenient, simple, reliable, 
robust and inexpensive method for the extraction of ATS and SC compounds 
in urine samples using GC−MS. The technique was developed manually 
through multiple steps, followed by validation work using the selected 
parameters. The results of the method development showed that the 
detection and determination of ATS and SC achieved excellent repeatability 
and reproducibility using only 60 µL of MeOH. No other chemicals were used 
except the additive of salts. Moreover, the advantage of using PDMS/DVB-
SPME in tips is that the equilibrium between the analytes and the stationary 
phase arose in one step. One other step was desorption, and no further steps 
were applied. This increases safety and decreases handling for the 
technicians. Further benefits of this system include improvements in the 
economy and environment with less spending on vials, solvents and 
chemicals.  
This procedure used the least solvents and chemicals to meet the 
requirements of GAC. It had minimal effects with the lowest negative impact 
on health, waste and safety in relation to LLE and SPE. This method is 
desirable in forensic toxicology laboratories for the investigation of 
stimulant drugs in biological samples, such as urine. The optimum procedure 
involving PDMS/DVB-SPME in tips followed by PFPA derivative presented an 
effective extraction protocol, followed by GC−MS analysis. The extraction 
efficiency with a full validation of the technique was completed for the 
extraction and quantification of four compounds of ATS and four compounds 
of SC. The tips coupled with GC−MS were able to quantify the analytes even 
at low specimen volume and concentrations. The time required for the 
sample preparation procedure was 2.5 hours (this is as an average of 25 tube 
samples). 
The validation parameters provided excellent repeatability and 
reproducibility with lower than 15% error in accordance to RSD and bias 
studies. Similar results were observed for the linearity, sensitivity and 
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selectivity. The LLOQ was sufficient to quantify the following drugs: 
amphetamine, methamphetamine, PMA, MDMA, mephedrone, buphedrine, 
4-methylephedrine and pentylone at concentrations of at least 100 ng mL-1. 
The real human urine specimens confirmed a positive of three cathinone 
substances by using these tips and SPE for a comparison study. Both 
extraction methods confirmed the results within the acceptance range of 
errors lower than 20% RSD. The collected samples from Saudi Arabia 
demonstrated the validity and the suitability of the SPME in tips method for 
routine analysis of toxicology forensic specimens for the screening and 
confirmation of the eight drugs tested.  
The SPME in tips was developed and validated to enable this procedure to 
be used worldwide to increase the availability of green analytical 
methodologies. The GC−MS provided an excellent peak shape and responses 
for the eight stimulant drugs in 25 minutes using the PFPA derivatives. 
Additionally, the GC conditions of the chromatogram allowed the separation 
of two metabolites in human urine samples named buphedrone ephedrine 
metabolite and mephedrone metabolite. The GC−MS was desirable and 
preferable for investigating routine specimens in many forensic toxicology 
laboratories. 
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7. Drug of abuse and synthetic cathinones in Saudi Arabia  
7.1 Introduction  
The information obtained from the data collected in prevalence studies were very 
useful to the medical and forensic communities. The data aided improvements in 
the quality of patient service, which helped physicians in Emergency Departments 
to investigate when dangerous levels of toxins were present. The data also assisted 
in recognising SC misuse trends and addressing sale, trade and supply of them. 
Moreover, the data may direct the precedencies for national care programmes 
regarding this subject. There are many ways of collecting the data for the 
prevalence study. For instance, collecting the biological samples to detect a drug 
of abuse is the one of most commonly used methods for studying prevalence in a 
defined population and region. Accordingly, the prevalence studies using the 
analysis of biological samples for the detection of illicit drugs of abuse and NPS 
have increased over the last few years, taking the place of questionnaires, 
interviews and supplements [406, 577-580]. 
These data, however, can be affected by many factors. One of the greatest 
limitations is collecting data samples from small sample population sizes. Other 
factors include self-data reporting, type of matrix and drugs, time of drug 
consumption, stability of drugs and drug concentration. Usage of self-reporting 
decreases the trustworthiness of a prevalence study. Furthermore, the 
information attained from the analysis of a survey is frequently insufficient to 
accomplish all objectives. For instance, within a survey it is very challenging to 
investigate all SC that may have been consumed. However, the one tool regularly 
used in a prevalence study is collecting biological specimens to investigate the 
types and concentrations of SC in the body [578]. Therefore, examination of 
biological matrices is an essential practice in forensic toxicology when determining 
whether a person has taken a substance during a specific time period.  This will 
influence a person’s behavior, which is relevant, for example, in medico–legal 
cases. In this project, urine specimens were used to estimate the prevalence of 
SC use in Saudi Arabia. 
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In spite of the proposals from several sources, [31] suggested that the misuse of 
NPS involving SC was prevalent around the globe, though no data currently exists 
on internet or literature that provides information on SC use in Saudi Arabia. In 
many countries, SC substances have been legally controlled in order to reduce the 
flow. In Saudi Arabia, the General Directorate of Narcotics Control (GDNC) of the 
Saudi Interior Ministry in cooperation with the Saudi Food and Drug Authority 
(SFDA) regulate and implement the legislation on narcotic drugs, medical devices, 
chemicals and biological substances. The GDNC (105 branches) with the help of 
the National Committee for Combating Drugs (Nebras) launch several educational 
(lectures, workshops, and training) and prevention programs to raise awareness 
on the harmful effects of illegal substances. One program also purported to reveal 
the substance traffickers’ techniques and was entitled “The serious scourge and 
keeping society safe” [581].  
181 million Captagon fenethylline tablets, 2.206 tons of cathinone, 61 tons of 
cannabis and 222 kg of heroin have been detained with total value of over £3 
billion in Saudi Arabia between 2010 and 2012. This represents 10% of the entire 
quantity of illegal drugs smuggled into the kingdom. It is estimated that roughly 
60% of crimes were drug-related, resulting in the arrest of 119 people for drug 
offences.  The most common drugs were Captagon tablets, khat, heroin and 
hashish. Saudi Arabia accounts for 30% of all worldwide amphetamine seizures. 
Captagon is very widespread amongst scholars, particularly before exams, as it is 
thought to boost performance. It is used by staff that have strenuous jobs, such 
as drivers and labourers [582].  
However, the appearance of NPS involving SC was not considered by the 
government of Saudi Arabia in the same way as traditional illicit substances.  
The narcotic substances in Saudi Arabia (SA) are controlled based on the United 
Nations Conventions on drugs (1961, 1971, 1972 and 1988) and the International 
Narcotics Control Board [583-585]. Schedules of the Convention on Psychotropic 
Substances of 1971, updated on 18 October 2017 list the following controlled drugs 
of SC (these are the only SC drugs included in this thesis): cathinone, 
methcathinone, pentedrone, 4-MEC, mephedrone, ethylone, methylone, MDPV, 
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pyrovalerone and α-PVP. Other parent cathinone drugs that are still not 
specifically listed in SA include flephedrone, buphedrone, N-EC, methedrone, 
butylone, 4-EMC, pentylone, MDPPP and naphyrone. However, SA has covered any 
narcotic and psychotropic drugs that are not taken under medical supervision 
[586].  
It is important to comprehend the prevalence of illegal substance use globally. 
The actual prevalence of illegal substance use in Saudi Arabia is unidentified 
because of the lack of epidemiological population reports or studies [587-589]. 
Nonetheless, it can be estimated by using authorised statistics and data of drugs, 
crime, death and seizures.  
For many years, amphetamines dominated synthetic drug markets in the Middle 
East [590]. More than 56% of global seizures of amphetamines were in the Middle 
East and South-West Asia, consisting of 12 tons in 2012 alone [578]. Fenethylline 
(7-(2-a-methylphenyl-aminoethyl)-theophylline), well known as Captagon (‘Abu 
Hilalain’) is a hugely abused substance in Saudi Arabia, making up 40% of the 
total of illegally consumed substances in the kingdom. It is primarily used by 
juvenile and young people between 12 and 22 years old, as well as in militant 
groups [591]. Fenethylline is mixture of amphetamine and theophylline, with a 
formal name of amphetaminoethyltheophylline. It was synthesized in 1961 and 
was used for the treatment of  hyperactivity disorders, depression and narcolepsy 
under medical supervision until 1986 [591, 592].  
Drug use amongst Saudi adolescents is a rising concern, and drug smuggling 
remains a problem along the security border areas. On a weekly basis the 
newspapers and Saudi Press Agency [245] announce large drug seizures, which 
constantly contain fenethylline, cannabis or alcohol. For instance, five million 
Captagon tablets and 350 grams of cannabis was found at the Halet Ammar 
customs checkpoint on 12 March 2018 [593, 594]. Principal punishment for 
narcotics smuggling is commonly imposed, and according to media broadcasting, 
63 individuals were executed for drug smuggling in 2015 [595]. In the same year, 
methamphetamine was being injected rather than smoked and first appeared in 
youth at a hospital in Jeddah city in the western region. ATS was found to be used 
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on a daily basis in the eastern provinces and resulted in 1000 confirmed problem 
drug users which is more than double the number of opiate users (450 cases). The 
number of people treated for ATS drug abuse was greater than 50% of total number 
of people treated for all types of illegal drug use in the country. 5200 people 
visited the emergency-room due to drug abuse, and the highest mortality rates 
were due to the use of opiates in 2015 [596]. Greater than 60% of all crime in SA 
is associated directly or indirectly with the use of illicit drugs between 2010-2012 
[582, 597].  
In spite of illicit drugs being strongly prohibited under the Islam religion and the 
social stigma, many Saudi people are addicted to illegal substances and alcohol. 
There are five cities in five different regions of Saudi Arabia where drugs are more 
accessible: central (the capital Riyadh), south (Jizan), western (Jeddah), east 
(Dammam), northwestern (Tabuk). Alcohol can be easily smuggled through the 
bridge between Bahrain and Dammam. Dammam and Jeddah have ports that 
increase the availability of drugs. Jizan is a well-known hub for the use of khat 
(prevalence = 21.4% [598]). No prevalence studies of the epidemiological 
population have estimated the prevalence of substance abuse in Saudi Arabia. 
However, there were several studies investigating the prevalence of drug abuse 
patients in treatment.  
All these are indicators of the size of the illegal drug abuse problem within the 
population of Saudi Arabia.  
Drug abuse has been recognised as a public health issue. The Saudi government 
constructed three specialised hospitals for drug abuse treatment in three different 
regions of Saudi Arabia: Riyadh, Jeddah and Dammam, treating both male and 
female patients.  
In central Saudi Arabia, Al-Nahedh determined that 29.5 years was the average 
patient age in Al Amal hospital (Al-Amal means “hope” in Arabic) in Riyadh. This 
hospital has treated drug abuse patients since 1998, with an average of abuse 
duration of 9.5 years. The mean age of first exposure to substance use was 19 
years. The sample size was 160, using a questionnaire survey. Alcohol was used by 
23.75% of patients, with other drugs including sedatives (23.12%), heroin (18.75%), 
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cannabis (10.63%), glue sniffing (9.38%) and 14.38% of patients used a combination 
of two or more drugs [599]. 423 patients (based on clinic epidemiological 
information within the Al-Qassim region) reported that alcohol was the most used 
substance at 52%, followed by amphetamines (25%), heroin (7%) and cannabis (4%) 
in 2000 [600].  
In western Saudi Arabia, 799 patients were surveyed in a voluntary detoxification 
unit within drug treatment services of Al-Amal hospital, Jeddah. This study was 
carried out in 1996 and 1997 with 68% of participants under 35 years of age. 97% 
of participants were tobacco smokers and 55% commenced smoking prior the age 
of 15. 64% started taking drugs prior to the age of 25, and 34% had been on the 
drugs for less than five years. 87% abused alcohol or heroin, with 33% and 66% of 
patients initiating use prior the age of 20 and 25, respectively [601]. At the same 
hospital, another study was conducted by questionnaire including 101 patients 
between July and August, 2002.  The average age of the patients was 29.6 years, 
with 65% having used two substances or more. 2% patients had used cocaine, 8% 
benzodiazepines, 25% heroin, 61% cannabis, 72% amphetamine and 89% had 
smoked tobacco [602]. Osman reported in same region of Jeddah that heroin (43%) 
and alcohol (16%) were the most common drugs abused over the course of one 
year. This study was undertaken in a psychiatric hospital with 485 patients in 1992 
[603]. Heroin and alcohol were also found to be the most commonly abused drugs 
in 2000 (799 patients) and 2001 (302 patients) in Jeddah, at 70% and 68% for heroin 
and 18% and 21% for alcohol, respectively. 116 patients in Al-Amal were 
investigated by the psychiatric team in 1995. The findings showed that 84% of the 
patients abused heroin, 31% alcohol, 26% cannabis and 10% used stimulants [604].   
The high percentage of heroin abuse may reflect the highly addictive nature of 
the substance. Osman in 2003 documented 67 serious medical complications that 
resulted from heroin addiction in Jeddah, with two deaths during the treatment 
of 48 patients [605]. Therefore, the percentage of use in these studies does not 
reflect the actual prevalence of drug use in Saudi Arabia, but instead is only a 
measure of the prevalence of Saudi patients already in addiction treatment 
settings. 
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In the south and south west regions, a study was aimed at measuring the 
prevalence of chewing Khat (cathinone, cathine, cathidine, eduline and ephedrine 
[73, 606]) amongst 10,000 students (15 and 25 years old) at college and secondary 
school in May 2006 in the Jazan region using a self-administered questionnaire. 
The prevalence of khat was 21%. The findings also showed that the Khat use was 
significantly different depending on gender, age and education [598].  
A study of prohibited compounds (doping) was assessed by Al Ghobain et al. The 
prevalence was 4.3% among 1142 male sport players, using systematic random 
sampling techniques in 18 cities across all regions in Saudi Arabia in 2016 [607]. 
A study was conducted with 143,833 patients that visited the Emergency 
department in the University hospital in Dammam. 5574 were admitted and 253 
(4.5%) were drug-related cases. From the 253 admissions, 19.8% patients suffered 
from overdose toxicity, 11.5% were drug-interactions, 10.3% were accidental or 
suicidal drug ingestions, 7.1% were drug abuse (opiates (morphine and heroin), 
cannabis, benzodiazepines, clozapine, amphetamine and alcohol) and 3.2% were 
allergic reactions. 26.5% patients stayed in the hospital for 7-102 days and 4% died 
[608].  
In Saudi Arabia, new employees in selective positions and sectors must undergo 
laboratory tests, such as drug abuse testing. This workplace testing is similarly 
carried out for military staff when a promotion is received. Job applicants in 
military, transport and medicine sectors are also required to comply with 
workplace drug abuse testing. Random workplace drug abuse testing is also carried 
out during selection of military staff in certain situations. Forensic toxicology 
laboratories are used to investigate these drugs. Forensic toxicologists must detect 
and report the results of examined abused drugs using screening and confirmatory 
methods of human specimens, such as urine, following specific guidelines; i.e. 
Substance Abuse and Mental Health Service Administration [195] or European 
Workplace Drug Testing Society (EWDTS) guidelines [609, 610]. There are hundreds 
of laboratories for drug testing distributed across the country for the detection 
and screening of amphetamines, cannabinoids, opiates, barbiturates, cocaine, 
benzodiazepines, alcohol and methadone. Thousands of urine samples are 
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investigated every day. Ministries of Interior and Health select specific 
laboratories to carry out the examination of positive samples for confirmation. 
However, no prevalence or statistical information were found from all these 
examined samples; this may be due to ethical or confidential considerations. 
To estimate the prevalence of the selected SC within workplace drug abuse testing 
in Saudi Arabia, a study was performed in participation with the Security Forces 
Hospital (SFH) in Riyadh City, Saudi Arabia. This study is exclusive, as no previous 
publications have investigated SC amongst Saudi citizen to assess the incidence. 
Urine specimens were collected from workers or random people that visited SFH 
over a period of a month. The urine matrix was preferred because it is easy to 
collect with less contaminants than other matrices. It can also deliver evidence of 
parent drugs and metabolites even in low concentrations. Certain substances 
remain in the body for several days after the drugs are taken and can still be 
detected in urine.  
7.1.1 Aim 
It is important to determine the range of substances that have an effect on a 
specific population. The purpose of the study was to estimate the prevalence rate 
of SC use in specific population in Riyadh City in Saudi people within a month 
period by examining urine specimens collected in July 2017. This study 
correspondingly provided exclusive information on SC, which could help to better 
understand the estimation prevalence rate of SC in the new region of Saudi Arabia. 
The prevalence study was conducted in Riyadh City at Security Forces Hospital 
(SFH), which is one of the largest health care providers in Saudi Arabia. 
7.1.2 Ethical approval 
Procedures in this project complied with the guidelines written by the College of 
MVLS Ethics Committee for Non-Clinical Research Involving Human Subjects at the 
University of Glasgow (See Appendix 2). All procedures were approved by the 
Research Committee at SFH in Riyadh City in Saudi Arabia (See Appendix 3). The 
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committees individually reviewed the proposed research study and agreed that 
there is no objection on ethical grounds.  
For the ethical approval, three forms were submitted consisting of the application 
form, the participant information sheet (Appendix 4) and the consent form 
(Appendix 5).  
7.1.3 Study design 
Participants were both male and female Saudi citizens. Urine collection was 
undertaken by the toxicology department in SFH in order to provide urine 
specimens for drug abuse testing. The urine samples were collected for the study 
was over a month-long period (every official work day in July 2017 (10-12 am). 
Participation in the study was voluntary. If the donor accepted, the information 
sheet was provided. Most volunteer participants were submitted to regular urine 
drug abuse screening to complete requirements for specific jobs or promotions. 
Participants were completely informed concerning the objective of the study and 
were permitted to withdraw from the study at any time without objection. After 
a volunteer read the information sheet and approved donation, the consent form 
was read and signed. Any individual below the age of 18 was rejected from this 
study. An empty plastic container was given to the donor to collect a urine 
specimen. Urine collection was performed by the researcher (author) under the 
supervision of a urine collection employee from the SFH administration. 
Consent and the urine specimens were collected at the same time. Each urine 
specimen had a distinct number and the consent form was signed by the 
participant at the time of the urine collection. The consent form was separated 
from the urine specimen to ensure anonymity; i.e. there was no labelled number 
on the consent forms to link to the urine sample. This procedure yielded 
completely anonymous urine specimens, which at no point could be associated to 
any person. 273 individuals agreed to participate and provided urine samples. 
Therefore, each urine container had a unique number from 1 to 273. Each 
participant provided a single urine sample on a single occasion. Each urine 
specimen contained approximately 10-20 mL. The participant was given 5 minutes 
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to donate the specimen. The location was appropriate for the collection of urine 
samples and the system respected SAMHSA guidelines. The study design within the 
stage of urine collection is summarised in Figure 7-1. 
 
Figure 7-1: The study design in the urine collection stage 
In the toxicology laboratory, a total of 273 urine specimens were collected, 
securely saved in the toxicology laboratory and stored at −20°C in the freezer while 
awaiting shipment. The toxicology laboratory at SFH had accreditation with the 
Standards Council of Canada, which indicated capability, robustness and 
competence of the laboratory. Human urine specimens were chilled during 
transportation and were delivered to the Forensic Medicine and Science (FMS) 
department at the University of Glasgow by FedEx within two days. The condition 
The researcher met the participant at SFH in Riyadh, Saudi Arabia and asked if he/she 
would like to take part in the study by donating a urine specimen 
Yes, the researcher provided the Participant Information 
Sheet to read
No
Thank you
Yes, the researcher provided the 
consent form to read and sign
Yes
The participant was given the urine 
container to donate
No consent given 
Thank you
No
Thank you
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of the specimens was confirmed directly by the author after receipt and the 
specimens were kept at −20°C, pending analysis.   
7.2 Method and materials 
Since the profile of using synthetic cathinones in Saudi Arabia is unknown, the 
selected drugs were those that were prevalent in other populations, such as in the 
UK and the USA. The chemical structures of the selected substances are illustrated 
in Table 2-2. The policy and procedure of this work were completed according to 
those used in the toxicology department of SFH. Each sample was analysed after 
few days from the completion of urine collection using GC−MS in the Forensic 
Medicine and Science (FMS) laboratory at the University of Glasgow to detect SC 
compounds. In the forensic toxicology laboratory, all 273 samples were prepared 
and analysed by aliquoting 1 mL urine sample then using the procedure of SPE, 
evaporation, PFPA, evaporation again and reconstitution, following the method 
and materials of chapter 4. A calibrator, three QCs, a DFU and 39 specimens were 
analysed each day, over seven working laboratory days. There was a one-day gap 
in between each working day, because each batch required more than 45 hours of 
run time. In each sample, the SIM mode was used to investigate the target 
cathinones (cathinone, flephedrone, buphedrone-ephedrine (metabolite), 
methcathinone, 4-methyl ephedrine (metabolite), 4-methyl-N-ethyl-
norephedrine, buphedrone, N-ethyle cathinone, mephedrone, pentedrone, 4-MEC, 
4-EMC, methedrone, α-PVP, methylone, butylone, ethylone, pyrovalerone, 
pentylone, MDPPP, MDPV and naphyrone) , while general cathinones with 
metabolites were investigated using the scan mode. See Table 7-1 for the drug 
selection ions with their ISD.   
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Table 7-1: Drugs analysed with their ions during the analysis of Saudi samples. Quantification 
ions in bold. The other related ions were selected as qualifier ions with their ratios (%). 
Drug name tR m/z Ratio 
(%) 
Drug name tR m/z Ratio (%) 
AMPHETAMINE-d11 8.422 194 100 PMMA 12.408 121 100 
128 72 204 
148 
159 
102 
98 33 
160 42 
CATHINONE 9.937 105 100 4−EMC 12.472 133 100 
77 79 204 
160 
20 
10 51 36 
190 9.2 
FLEPHEDRONE 10.024 204 100 METHEDRONE 13.330 135 100 
123 59 77 8.0 
95 19 160 6.1 
91 14 204 9.1 
BUPHEDRINE 10.030 218 100 PVP 14.384 126 100 
119 12 77 6.1 
308 2.6 105 3.2 
METHCATHINONE 10.316 105 100 METHYLONE 14.716 149 100 
204 102 204 19 
160 36 160 11 
4−METHYLEPHEDRINE  10.403 204 100 BUTYLONE 15.667 218 100 
119 13 149 480 
160 18 160 35 
308 2.60 367 20 
4−M−N−E−NOREPHEDRINE  10.706 218 100 ETHYLONE 15.923 190 100 
119 20 149 655 
190 22 218 198 
322 2.50 367 22 
BUPHEDRONE 10.905 218 100 PYROVALERONE 16.564 126 100 
105 51 91 4 
77 21  
160 23 
N−EC 11.091 218 100 PENTYLONE-d3 16.941 193 100 
105 45 235 86 
190 40 149 380 
77 23   
PMA 11.110 121 100 PENTYLONE 16.946 149 100 
148 42 190 22 
190 5 232 19 
311 7.4 381 5 
MEPHEDRONE 11.482 119 100 MDPPP 18.703 98 100 
 
204 25 149 10 
91 20 
160 14 
PENTEDRONE 11.668 232 100 MDPV 20.539 126 100  
190 59 
105 45 
337 3.90 
4−MEC 12.220 119 100 NAPHYRONE 22.667 126 100 
218 37 
190 30 
91 17 
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7.3 Results and Discussion 
The 273 collected urine specimens were investigated using GC−MS. The compound 
of cathinone was positive in three urine samples (1.01%). The comparison 
concentration study was discussed in chapter 6 for the three positive samples using 
two different sample preparation methods. No other cathinone substances or 
metabolites were found for all examined samples, particularly the following drugs 
and metabolites: cathinone, flephedrone, buphedrone-ephedrine (metabolite), 
methcathinone, 4-methyl ephedrine (metabolite), 4-methyl-N-ethyl-
norephedrine, buphedrone, N-ethyle cathinone, mephedrone, pentedrone, 4-MEC, 
4-EMC, methedrone, α-PVP, methylone, butylone, ethylone, pyrovalerone, 
pentylone, MDPPP, MDPV and naphyrone. However, other SC or metabolites that 
are not listed above may have been present in the specimens at low 
concentrations. Other exogenous or endogenous substances in the matrix could 
have detected and interfered with the SC in scan mode, therefore the method 
cannot identify all SC. The method was only robust for investigating the selected 
22 SC drugs, as other SC lacked reference standards. Hence, the data were 
interpreted with caution.   
Even though the result of the prevalence study for the cathinone compound was 
1.01%, this study had several limitations. The first one was the small sample size 
of only 273 samples. The plan was to collect as many urine samples as possible 
within one month, and though more samples were sought, some volunteers refused 
to participate. The people that may take SC or other substances could refuse to 
donate, due to the sensitivity of the subject. As a result of ethical practices, it 
was not possible to include routine workplace testing without the agreement of 
organisations and participants. These large samples could provide much better 
understanding of SC prevalence. No information was ethically accepted to identify 
age, sex or other positive results other than the drugs related to SC compounds.  
Furthermore, the study was completed within a single society in Riyadh City that 
may restrict the demonstrative. The stability issue was another concern, because 
transportation of urine specimens overseas may have affected the findings even 
though samples were kept in the freezer condition throughout. Therefore, the 
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study might not reflect the SC prevalence a in large population such as Saudi 
Arabia. The government in cooperation with institutions are able to investigate 
thousands of biological samples in many cities across Saudi Arabia and could 
determine the actual figure for SC prevalence. Even though the results show low 
prevalence of SC use in Saudi Arabia, this study was the first attempt to investigate 
the issue. A prospective population-based study is recommended in order to fully 
investigate and understand the progression of drug involvement in Saudi Arabia. 
The documentation of factors that lead to substance is necessary to aid in 
treatment and rehabilitative measurements.  
7.4 Conclusion 
273 human urine specimens were collected in July 2017 and investigated for the 
purpose of studying the prevalence of SC in Riyadh City, Saudi Arabia. The 22 SC 
with metabolites that were analysed using the SIM mode in GC−MS were: 
cathinone, methcathinone, buphedrone metabolite, flephedrone, mephedrone 
metabolite, 4−MEC metabolite, buphedrone, N−ethylcathinone, mephedrone, 
pentedrone, methedrone, methylone, butylone, ethylone, pyrovalerone, 4−EMC, 
4-MEC, α−PVP, pentylone, MDPPP, naphyrone and MDPV. The cathinone compound 
was confirmed positive in three cases with a prevalence of 1.01%. No other SC 
drugs or metabolites were observed, even under scan mode.  
Since no information or previous study described the presence of SC in the 
Kingdom of Saudi Arabia, this study was carried out. The finding provides an 
estimation of the prevalence of SC. Even though the study has several limitations, 
such as a small population size within one province, this is the first study 
investigating the issue. 
Legislators, government and forensic scientist communities must monitor the 
global illicit drug marketplace in order to ascertain that the appropriate laws, 
schemes, prevention programs and forensic laboratories are in place. As new 
substances emerge in the drug-user market, toxicologists must act rapidly and 
identify the biomarkers through in vitro examinations. Standard suppliers must 
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synthesise certified reference standards to detect NPS. At present, forensic 
laboratories have expanded regarding these substances. 
It is suggested that the “Early Warning System” applied in the Europe Union should 
follow in Saudi Arabia. This can enhance measures to fight criminal drugs, 
expressly NPS, beyond simply sharing information on the appearance of NPS.   
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8. Conclusions  
In chapter 3, the project was conducted to investigate illicit drugs, such as ATS 
and ALS, in urine samples using GC−MS. GC−MS was initially developed to increase 
the sensitivity and selectivity of the method using nine new recreational 
cathinones (butylone, ethylone, flephedrone, MDPV, mephedrone, methedrone, 
methylone, pentedrone and pyrovalerone) and six derivatisation reagents (PFPA, 
TFA, CLF2AA, HFBA, AA and PA). The technique was optimised by modifying the 
temperatures of the injector port and the oven until the necessary separation and 
detection were observed with excellent peak shape. Next, the derivatisation was 
optimised using incubation time and temperature. The optimum procedure was 
selected based on the maximum peak area values. The optimum time was 20−25 
minutes for most derivative SC under all reagents. The temperature that provided 
a better response in cathinones was 70°C for the high M.W and BP reagents. The 
comparison of the acylation agents inspected a number of parameters, including 
ion number, relative ion ratios, quantity of unique ions, peak area, recovery, LOD, 
linearity, precision, accuracy and interferences. All reagents provided good 
fragmentation with high sensitivity and repeatability, and PFPA was found to be 
the best. PFPA was then further studied in whole blood using validation 
parameters. The sensitivity of GC−MS was also elevated by using acidified 
methanol. One internal standard was adequate to cover all derivative SC. LLE and 
SPE had good recoveries for the analysed substances. Butyric anhydride was 
unsuitable to be used for SC. The tertiary amines were underivatised. The 
fragmentation patterns of derivative CLF2AA cathinones were presented for the 
first time.    
In chapter 4, after the development work was completed, the method was 
validated using SWGTOX guidelines for urine samples. 20 out of 29 stimulant drugs 
were successfully validated. The nine remaining substances were valid at high 
concentrations. The SPE drug recoveries were between 80-120% for most 
substances. No carryover or interferences were observed that affected the 
interpretation of the results. The LOD and LLOQ were between 0.5−10 and 5−50 
ng mL-1, respectively using the S/N technique. The LLOQ was between 50−500 ng 
mL-1 for all studied substances using the accuracy parameter in the linearity 
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calibration points. The bias and precision were lower than 20% for all valid drugs. 
The novelty of the work included the validation of the selected PFPA (ATS and 
ALS) derivatives using GC−MS in a single procedure. Therefore, it is recommended 
that this method is used in forensic toxicology laboratories to decrease the time, 
cost and efforts for stimulant drug testing.        
In chapter 5, after the methods were validated, the stability work was 
accomplished. no study had previously been published documenting the stability 
of SC for longer than six months, therefore this study was conducted to determine 
the stability of ATS and SC for more than a year in urine samples. This chapter was 
also conducting for the importance of the stability for the overseas samples that 
were collected in SA. All stimulant substances for ATS and ALS were stable over 
the entire period of study at iced temperature (−20°C). Samples at refrigerator 
temperature (4°C) were stable for ATS and SC substances until day 349 and 14, 
respectively. The valid SC substances were undetected between day 77 and 349 
at the refrigerator condition. Specimens at RT were unstable after 349 days and 
after 24−48 hours for ATS and SC, respectively. All valid ALS compounds were 
undetected in less than a month. All stimulants were stable within three days in 
an autosampler. No concentration-dependence was observed for all analysed drugs 
at concentrations of 1 and 0.5 µg mL-1, but the stability differences between and 
within SC classes were diverse. The half-lives of 14 SC were briefly estimated and 
discussed. The recommendation is to keep all urine samples immediately after 
collection in freezer conditions, otherwise, the cathinones promptly start 
degrading.  
In chapter 6, the automation of SPME in tips coupled with GC−MS was developed 
manually to provide an effective, clean, easy, inexpensive and fast method to 
quantify new stimulants in urine samples. After the completion of development 
work using several parameters such as pH, sample volume, solvent type, 
extraction time, etc., the optimum procedure was determined. The validation 
parameters were used on the selected compund cathinones using SWGTOX 
guidelines. The RSD and accuracy were less than 15% error for all analysed 
compounds. The technique quantified all examined substances at ≥100 ng mL-1 
with LOD between 5−25 ng mL-1. The R2 was greater than 0.992 for all analytes. 
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Three fibre tips were evaluated, and the PDMS/DVB fibre was favoured based 
on recovery results. All chemicals that were added in the extraction stage used 60 
µL of MeOH and salts. The SPME in tips offered minimum impacts on health, waste 
and safety as compared with LLE and SPE procedures. The real positive human 
urine samples were investigated, and the results were compared by applying the 
two extraction methods. The results showed that by using both SPME and SPE, the 
cathinone compound was identified and quantified in all tested specimens in 
GC−MS. 
In chapter 7, the prevalence of cathinones was studied using 273 urine samples 
collected in Riyadh City, Saudi Arabia in July 2017. This was the first prevalence 
study that attempted to investigate SC using biological samples in specific 
population in Riyadh City in Saud Arabia. The cathinone compound prevalence was 
1.01%. No other cathinones were identified. Consideration of the prevalence of 
NPS, such as SC, can deliver important information to the government, the justice 
system and the forensic community. More prevalence studies should be introduced 
using greater populations and other drugs in Saudi Arabia.  
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9. Future work  
Proposals for future work:  
• Although GC−MS is dominant in most forensic toxicology laboratories, the 
work here for investigating SC and SPME in tips could be also carried out 
using more modern and sensitive instrumentation, such as LC−MS-MS. 
• Screening instrumentation methods such as UPLC−quadrupole time of flight 
(UHPLC-TOF) could be used to detect numerous new recreational drugs.   
• The work here was completed using a single procedure in urine samples, 
but the mixtures of SC and ATS could be also determined using a single 
procedure in other matrices, such as saliva and hair.  
• More metabolite SC drugs could be evaluated and investigated in urine.   
• More stimulants drugs could be evaluated and validated to cover wider 
range using GC−MS.  
• Despite the fact the SPME in tips was proven as a powerful extraction 
method, the technique could be developed using other materials and 
methods to extract more drug mixtures. 
• Research could be focused on developing microextraction methods to meet 
the GAC.  
• Three SPME fibre tips were evaluated here, but other material fibres could 
be industrialised for the purpose.    
• Six derivatisation reagents were researched to increase the sensitivity and 
selectivity of GC−MS, but more agents could be evaluated and investigated.    
• These techniques could also be applied to more case specimens to ensure 
the applicability of the methods to “real-life” circumstances. 
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• The stability of SC could be carried out using various matrices and 
conditions by experimenting with each drug alone rather than a mixture. 
This will be beneficial for studying the breakdown products in each SC 
compound using the scan method.    
• The prevalence study could be carried out on regular basis (such as each 
year) to determine the trends of illicit drug use, such as SC. 
• Further parameters could be collected for the purpose of the prevalence 
study, such a higher sample size, various regions and populations, data 
concerning sex and age or dissimilar biological samples in order to produce 
a thorough understanding of SC users.  
• A combination of several tools and surveys could be used to improve the 
understanding of NPS use, such as SC using data from questionnaires, 
seizures, dark website market, deaths and drug abuse testing of selected 
populations (prisons, schools, sports) and general populations (countries, 
cities, ethics, religious), organisations and provinces.  
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